Clinical Development
LEE011 (ribociclib)
Protocol CLEE011F2301 / [STUDY_ID_REMOVED] 
MON ALEESA -3: A randomized double -blind, placebo -
controlled study of ribociclib in combination w ith 
fulvestrant for the treatment of men and postmenopausal 
women w ith hormone receptor positiv e, HER2 -negativ e, 
advanced breast cancer w ho have recei ved no or o nly one 
line of prior endocrine treatment
Document type Amended Protocol Version ( Clean )
EUDRACT number 2015 -000617 -43
Version number 04 (Amended Protocol)
Development phase III
Document status Final
Release date 29-Jan-2020
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Template version (17-Nov-2014)

Novartis Confidential Page 2
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 6
List of tables ........................................................................................................................ 6
List of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 12
Amendment 4 (2 9-Jan-2020) ................................ ................................ ............................. 14
Amendment 3 (06 -Aug-2018) ........................................................................................... 18
Amendment 2 (28 -Jul-
2016) ............................................................................................. 21
Amendment 1 .................................................................................................................... 24
Protocol summary :
............................................................................................................. 29
1Background ................................ ................................ ................................ ........................ 34
1.1 Overview of disease pathogenesis and current treatment ...................................... 34
1.1.1 Epidemiology ........................................................................................ 34
1.1.2 Available therapeutic options in ER+, HER2
-negative breast 
cancer .................................................................................................... 34
1.1.3 Role of the CDK4/6 pathway  in breast cancer
...................................... 35
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. 36
1.2.1 Overview of ribociclib .......................................................................... 36
1.2.2 Overview of fulvestrant ......................................................................... 42
1.2.3
Overview of ribociclib in combination with fulvestrant....................... 44
2Rationale ............................................................................................................................ 45
2.1 Study  rationale and purpose ................................................................................... 45
2.2 Rationale for the stud y design ............................................................................... 46
2.3 Rationale for dose and regimen selection .............................................................. 46
2.4
Rationale for choice of combination drugs............................................................ 47
2.5 Rationale for choice of comparator drugs ............................................................. 47
2.6 Risks and benefits .................................................................................................. 48
2.6.1 Potential benefits to clinical trial partici pants ....................................... 48
2.6.2
Potential risks to clinical trial participants............................................ 48
3Objectives and endpoints ................................................................................................... 48
4Study  design ................................ ................................ ................................ ...................... 51
4.1 Description of stud y design ................................................................................... 51
4.1.1 Screening phase ..................................................................................... 53
4.1.2 Treatment phase .................................................................................... 53

Novartis Confidential Page 3
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
4.1.3 Safety  follow -up................................ ................................ .................... 54
4.1.4 Efficacy  follow -up ................................................................................ 54
4.1.5 Survival follow -
up ................................................................................ 54
4.2 Timing of interim anal yses and design adaptations ............................................... 54
4.3 Definition of end of the study ................................................................................ 55
4.4 Early study termination .......................................................................................... 55
5Population .......................................................................................................................... 56
5.1 Patient population .................................................................................................. 56
5.2 Inclusion criteria .................................................................................................... 56
5.3 Exclusion criteria ................................................................................................... 58
6Treatment ................................ ................................ ................................ ........................... 60
6.1 Study  treatment ...................................................................................................... 60
6.1.1 Dosing regimen ..................................................................................... 61
6.1.2 Guidelines for continuation of treatment .............................................. 63
6.1.3 Ancillary  treatments .............................................................................. 63
6.1.4
Rescue medication ................................................................................ 63
6.1.5 Treatment duration ................................................................................ 63
6.2 Dose escalation guidelines ..................................................................................... 63
6.3 Patient numbering, treatment assignment or randomization ................................. 64
6.3.1
Patient numbering ................................................................................. 64
6.3.2
Treatment assignment or randomization............................................... 64
6.3.3 Treatment blinding ................................................................................ 65
6.4 Study  drug preparation and dispensatio n
............................................................... 65
6.4.1 Study  drug packaging and labeling ....................................................... 66
6.4.2 Drug supply  and storage ........................................................................ 66
6.4.3 Study  drug compliance and accountabilit y
........................................... 66
6.4.4 Dispos al and destruction ....................................................................... 67
6.5 Dose modifications ................................................................................................ 67
6.5.1 Dose modification and dose delay ........................................................ 67
6.5.2 Follow -up for toxicities ......................................................................... 75
6.5.3 Anticipated risks and safety  concerns of the study drug ....................... 75
6.6
Concomitant medications ................................ ................................ ...................... 75
6.6.1 Permitted concomitant therap y ............................................................. 75
6.6.2 Concomitant therap y requiring caution ................................................. 76
6.6.3 Prohibited concomitant therap y
............................................................ 77
6.6.4 Drugs with QT prolongation ................................................................. 78

Novartis Confidential Page 4
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
7 Visit schedule and assessments ................................ ................................ ......................... 78
7.1 Study  flow and visit schedule ................................................................................ 78
7.1.1 Screening ............................................................................................... 91
7.1.2 Treatment period ................................................................................... 92
7.1.3 Discontinuation of Study Treatment ..................................................... 92
7.1.4 Withdrawal of Consent ......................................................................... 94
7.1.5 Follow up for Safet y Evaluations .......................................................... 95
7.1.6 Efficacy  follow -
up ................................................................................ 95
7.1.7 Survival follow -
up ................................................................................ 95
7.1.8 Lost to f ollow-up................................................................................... 95
7.1.9 End of post -treatment follow -
up ........................................................... 96
7.2 Assessment ty pes................................................................................................... 96
7.2.1 Efficacy  assessments ............................................................................. 96
7.2.2 Safety  and tolerability  assessments ..................................................... 101
7.2.3 Pharmacokinetics ................................................................................ 106
109
112
7.2.6 Patient reported outcomes ................................................................... 113
8Safety  monitoring and reporting ................................ ................................ ...................... 116
8.1 Adverse events ..................................................................................................... 116
8.1.1
Definitions and reporting .................................................................... 116
8.1.2 Laboratory  test abnormalities .............................................................. 117
8.2 Serious adverse events ......................................................................................... 118
8.2.1
Definitions........................................................................................... 118
8.2.2
Reporting............................................................................................. 118
8.3 Emergency  unblinding of treatment assignment ................................................. 119
8.4 Pregnancies .......................................................................................................... 119
8.5 Warnings and precautions .................................................................................... 120
8.6
Data monitoring committee ................................................................................. 120
8.7
Steering committee .............................................................................................. 120
9Data collection and management ..................................................................................... 120
9.1 Data confidentiality ............................................................................................. 120
9.2 Site monitoring .................................................................................................... 121
9.3
Data collection..................................................................................................... 121
9.4 Database management and quality  control ................................ .......................... 122
10Statistical methods and data anal ysis................................ ................................ .............. 123

Novartis Confidential Page 5
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.1 Analy sis sets ................................ ................................ ................................ ........ 123
10.1.1 Full anal ysis set................................................................................... 123
10.1.2 Safety  set............................................................................................. 123
10.1.3
Per-protocol set ................................................................................... 123
10.1.4 Pharmacokinetic anal ysis set
............................................................... 123
10.1.5 Cross -over analy sis set ........................................................................ 124
10.2 Patient demographics/other baseline characteristics ........................................... 124
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ..................... 124
10.4
Primary  objective ................................................................................................. 124
10.4.1 Variable ............................................................................................... 125
10.4.2 Statistical hy pothesis, model, and method of analysis ........................ 125
10.4.3 Handling of missing values/censoring/discontinuations ..................... 125
10.4.4 Supportive analy ses............................................................................. 125
10.5 Secondary  objectives ........................................................................................... 126
10.5.1 Overall Survival .................................................................................. 127
10.5.2 Other secondary  efficacy objectives ................................................... 128
10.5.3 Safety  objectives ................................................................................. 129
10.5.4 Pharmacokinetics ................................................................................ 131
10.5.5
Patient- reported outcomes ................................................................... 131
132
132
134
 
134
135
10.7 Interim anal ysis.................................................................................................... 135
10.7.1 Progression free survival ..................................................................... 135
10.7.2 Overall survival (OS) .......................................................................... 135
10.8
Sample size calculation........................................................................................ 136
11Ethical considerations and administrative procedures .................................................... 139
11.1 Regulatory
 and ethical compliance ...................................................................... 139
11.2 Responsibilities of t he investigator and IRB/
IEC/REB ....................................... 139
11.3 Informed consent procedures
............................................................................... 139
11.4 Discontinuation of the study ................................................................................ 139
11.5 Publication of study  protocol and results ............................................................. 140
11.6 Study  documentation, record keeping and retention of documents
..................... 140

Novartis Confidential Page 6
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
11.7 Confidentiality  of stud y documents and patient records ................................ .....141
11.8 Audits and inspections......................................................................................... 141
11.9 Financial disclosures ............................................................................................ 141
12Protocol adherence .......................................................................................................... 141
12.1 Amendments to the protocol ................................................................................ 141
13References (available upon request) ................................................................................ 142
14Appendices ...................................................................................................................... 148
14.1 Appendix 1 
- Concomitant medications .............................................................. 148
14.2 Appendix 2 - Guidelines for response, duration of overall response, TTF, 
TTP, progression- free survival and overall survival (based on RECIST 1.1) .....152
14.2.22 Time to treatment failure ..................................................................... 166
167
14.2.24 Duration of response ........................................................................... 167
14.3 Appendix 3 
-Bone Marrow Reserve in Adults ................................................... 178
14.4 Appendix 4 
-Patient reported outcomes ............................................................. 179
List of figures
Figure 1 -
1 Regulation of cell cy cle checkpoint control .......................................... 35
Figure 2 -
1 Ribociclib plus fulvestrant in ER+ breast cancer xenograft models .....46
Figure 4 -1 Study  Design ......................................................................................... 52
Figure 14 -
1 EORTC QL Q-C30 .............................................................................. 179
Figure 14 -
2 EQ-5D- 5L........................................................................................... 181
Figure 14 -
3 Brief Pain Inventory -Short Form ........................................................ 184
List of tables
Table 1
-1 Serious adverse events with a suspected causal relationship with 
ribociclib single agent ................................ ................................ ........... 40
Table 1-2 Adverse events suspected to be study  drug related in 
[CLEE011X2108] ................................ ................................ ................. 44
Table 3-1 Objectives and related endpoints .......................................................... 49
Table 6
-1 Dose and treatment schedule................................................................. 61
Table 
6-2 Packaging and labeling ................................ ................................ ......... 66
Table 6-3 Dose modification guidelines ................................................................ 68
Table 6
-4 Ribociclib/Placebo dose adjustment and management 
recommendations for hematological adverse reactions (CTC AE 
v4.03) ................................ ................................ ................................ ....68

Novartis Confidential Page 7
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Table 6-5 Ribociclib/placebo dose adjustment and management 
recommendation for hepatic toxicities (CTC AE v4.03) ...................... 69
Table 6-6 Ribociclib/placebo dose adjustment and management 
recommendation for QTcF prolongation (CTC AE v4.03) ................... 72
Table 6-7 Ribociclib/placebo dose adjustment and management 
recommendation for ILD/pneumonitis (CTCAE v4.03) ....................... 73
Table 6-8 Ribociclib/placebo dose adjustment and management 
recommendation for all other adverse reactions ................................... 74
Table 7
-1a Visit evaluation schedule -Patients that, after protocol amendment 
4, continue with their originall y randomized stud y treatment .............. 80
Table 7-1b Visit evaluation schedule – Cross over treatment phase for patients 
who cross over from placebo to L EE011 after protocol amendment 
4............................................................................................................. 87
Table 7
-2 Imaging collection plan ......................................................................... 98
Table 7
-3 ECOG performance status ................................................................... 101
Table 7
-4 Central clinical laboratory  parameters collection plan ........................ 102
Table 7-5a Local ECG collection plan.................................................................. 104
Table 7-5b Local ECG collection plan – for crossover patients............................ 105
Table 7-6 Sparse pharmacokinetic blood collection log ..................................... 108
Table 7
-7 Trough pharmacokinetic blood collection log .................................... 108
110
110
Table 7
-9 Patient reported outcomes collection plan .......................................... 114
Table 10
-1 Estimated timelines for interim and final analy ses............................. 136
Table 10-2 Probability  of Study  Outcomes under various true Hazard Ratios .....137
Table 14-1 List of prohibited medications during study  drug treatment ............... 148
Table 14-2 List of medications to be used with caution during study  drug 
treatment .............................................................................................. 150
Table 14
-3 Response criteria for target lesions ..................................................... 159
Table 14
-4 Response criteria for non -target lesions .............................................. 161
Table 14
-5 Overall lesion response at each assessment ........................................ 162
Table 14
-6 Overall lesion response at each assessment: patients with non -
target disease onl y............................................................................... 170
Table 14
-7 Options for event dates used in PFS, TTP, duration of response ........ 171

Novartis Confidential Page 8
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
List of abbreviations
AE Adverse Event
(e)PRO (electronic) Patient Reported Outcomes
AI Aromatase Inhibitors
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC Absolute Neutrophil Count
ASCO American Society of Clinical Oncology
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
AUC Area Under the Curve
AV Atrioventricular
BC Breast Cancer
BCRP Breast cancer resistance protein
BIRC Blinded independent review committee
BPI-SF Brief Pain Inventory –Short Form
BSEP Bile salt export pump
BUN Blood Urea Nitrogen
CABG Coronary artery bypass graft
CBR Clinical Benefit Ratio
CCND1 Cyclin D1
CDK4/6 Cyclin -Dependent Kinases 4 and 6
Cmax Peak blood concentration
Cmin Minimum concentration
CNS Central nervous system
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CSR Clinical study report
CSR addendum An addendum to Clinical Study Report (CSR) that captures all the additional information 
that is not included in the CSR
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrome P450
DBP Diastolic blood pressure
DDI Drug -Drug Interaction
DILI Drug -Induced Liver Injury
DLT Dose Limiting Toxicity
DMC Data Monitoring Committee
DNA Deoxyribonucleic Acid
DOR Duration of Response
DS&E Drug Safety and Epidemiology
E2F Group of transcription factors that plays a major role during the G1/S transition of the cell 
cycle
EBV Epstein Barr Virus
EC Ethics Committee
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group

Novartis Confidential Page 9
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
EDC Electronic Data Capture
EORTC QLQ -
C30European Organization for Research and Treatment of Cancer’s core quality of life 
questionnaire
EOT End of Treatment
EQ-5D EuroQol 5 Dimension questionnaire
ER Estrogen Receptor
ERT EResearch Technology
ET Endocrine therapy
EU European Union
FMO3 Flavin -containing monooxygenase 3
FAS Full Analysis Set
FFPE Formalin -Fixed, Paraffin -Embedded
FIH First-in-human
FISH Fluorescence in situ hybridization
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GGT Gamma -glutamyl transferase
GI Gastrointestinal
HDL High Density Lipoprotein
HER2 Human Epidermal Growth Factor Receptor 2
HIV Human Immunodeficiency Virus
HPV Human Papilloma Virus
HR Hazard ratio
HR+ Hormone Receptor Positive
HSV Herpes Simplex Virus
i.v. intravenous(ly)
IB Investigator Brochure
IC50 Inhibitory Concentration, where 50% inhibition is observed
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IHC Immunohistochemistry
IN Investigator Notification
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
IUD Intrauterine device
LDH Lactate Dehydrogenase
LDL Low Density Lipoprotein
LFT Liver Function Test
LKM Liver-kidney microsome antibodies
LLN Lower Limit of Normal
LLOQ Lower Limit of Quantification
LVEF Left Ventricular Ejection Fraction

Novartis Confidential Page 10
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
MAP Master Analysis Plan documents project standards in the statistical methods which will be 
used within the individual clinical trial RAP documentation
MATE1 Multidrug and toxin exclusion protein -1
MBC Metastatic Breast Cancer
MHC Major histocompatibility complex
MI Myocardial infarction
MTD Maximum Tolerated Dose
MUGA Multiple Gated Acquisition
NASH Non-alcoholic steato -hepatitis
NCCN National comprehensive cancer network
NCI National Cancer Institute
NSAI Nonsteroidal Aromatase Inhibitors
NSCLC Non-Small Cell Lung Cancer
OCT2 Organic cation transporter 2
ORR Overall Response Rate
OS Overall survival
p16 Product of the CDKN2A gene; a cyclin-dependent kinase inhibitor
PAS Pharmacokinetic Analysis Set
PD Pharmacodynamics
PFS Progression free survival
P-gP Permeability -glycoprotein
PgR Progesterone receptor
PHI Protected Health Information
PhRMA Pharmaceutical Research and Manufacturers of America
PK Pharmacokinetics
p.o. per os /by mouth/orally
PPS Per Protocol Set 
pRb Retinoblastoma Protein
PS Performance Status
PT Prothrombin time
QD Quaque Die (every day)
QTcF Q-T interval in the ECG (corrected according to the formula of Fridericia)
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analy ses
RBC Red Blood Cells
REB Research Ethics Board
RECIST Response Evaluation Criteria in Solid Tumors
RoW Rest of the World
R Value ALT/ALP in x ULN
SAE Serious Adverse Event
SBP Systolic Blood Pressure
SC Steering Committee
SD Stable disease
SEC Safety Event Categories
SERM Selective ER Modulators
S-ICF Study ICF
SISH Silver enhanced in situ hybridization

Novartis Confidential Page11
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
SLA Soluble liver antigen antibodies
SMA Smooth muscle antibodies solubleSMT Novartis Safety Management Team
SmPC Summary of Product Characteristics
SUSAR Suspected Unexpected Serious Adverse ReactionTmax The time at which the maximum observed concentration (Cmax) occursT1/2 The elimination half-life associated with the terminal slope (z) of a semi logarithmic 
concentration-time curve (time).
TBIL Total BilirubinTdP Torsades de PointeTTR Time to Response 
ULN Upper Limit of Normal
WBC White blood cell count
Novartis Confidential Page 12
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), saliva, tissue, urine, 
stool, etc. taken from a study subject or study patient
Control drug A study treatment used as a comparator to reduce assessment bias, preserve blinding of 
investigational drug , assess internal study validity, and/or evaluate comparative effects of 
the investigational drug
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. treatment 
group) at the same time
Cycles Number and timing or recomme nded repetitions of therapy are usually expressed as 
number of days (e.g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.)
Enrollment Point/time of patient entry into the study; the point at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational 
drugThe study treatment whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with “investigational new 
drug.”
Investigational 
treatmentDrug whose properties are being tested in the study as well as their associated placebo 
and active treatment controls (when applicable). This also includes approved drugs used 
outside of their in dication/approved dosage, or that are tested in a fixed combination. 
Investigational treatment generally does not include other study treatments administered 
as concomitant background therapy required or allowed by the protocol when used in 
within approved indication/dosage
Medication 
numberA unique identifier on the label of each study treatment package which is linked to one of 
the treatment groups of a study
Other study 
treatmentAny drug administered to the patient as part of the required study proce dures that was not 
included in the investigational treatment
Subject Number A unique identifying number assigned to each patient/subject/healthy volunteer who 
enrolls in the study
Personal Data Subject information collected by the Investigator that is transferred to Novartis for the 
purpose of the clinical trial. This data includes subject identifier information, study 
information and biological samples.
Premature 
patient 
withdrawalPoint/time when the patient exits from the study prior to the planned completion of all study 
treatment administration and/or assessments; at this time all study treatment 
administration is discontinued and no further assessments are planned, unless the patient 
will be followed for progression and/or survival
Randomization 
numberA unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Stage related to 
study timelineA major subdivision of the study timeline; begins and ends with major study milestones 
such as enrollment, randomization, completion of treatment, etc.
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the tumor, 
whether lymph nodes contain cancer, and whether the cancer has spread from the original
site to other parts of the body
Stop study 
participationPoint/time at which the patient came in for a final evaluation visit or when study treatment 
was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any st udy arm administered to the patient 
(subject) as part of the required study procedures, including placebo and active drug run -
ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatmen t combination; study treatment in this case refers to 
the investigational and non -investigational treatments in combination.

Novartis Confidential Page 13
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Study treatment 
discontinuationPoint/time when a patient permanently discontinues study treatment for any reason
Supportive 
treatmentRefers to any treatment required by the exposure to a study treatment, e.g. premedication 
of vitamin supplementation and corticosteroid for pemetrexed disodium.
Treatment group A treatment group defines the dose and regimen or the combination, a nd may consist of 1 
or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected using 
specified assessments at specified time points
Withdrawal of 
Study Consent Withdrawal of consent from the study occurs only when a subject does not want to 
participate in the study any longer, and does not allow any further collection of personal 
data

Novartis Confidential Page 14
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Amend ment 4 (2 9-Jan -2020 )
Amendment rationale
Study  CLEE011F2301 was initiated in June 2015 and completed enrollment on June 2016. 727
patients were randomized. 
The study  met its primary endpoint of progression- free survival (PFS) at the time of the primary 
analysis in January  2018, demonstrating a statistically  significant improvement in PFS in 
patients receiving ribociclib plus fulvestrant compared to patients receiving placebo plus 
fulvestrant with hazard ratio of 0.593 (95% CI: 0.480, 0.732) at one-sided 2.5 level of 
significance (p=4.10×10-7). Results of this trial led to the approval of KISQALI (Ribociclib, 
LEE011) for supplement indication and new indications in HR-positive, HER2- negative 
advanced or metastatic breast cancer in the United States in July 2018 and the positive opinion 
from CHMP in Nove mber 2018
.
The study  met its secondary  endpoint of overall survival (OS) at the time of the second OS 
interim analy sis in July 2019. As all the planned inferential analyses for this study  are now 
completed ,all stud y participants will be unblinded for knowledge of their treatment allocation . 
 In addition, patients who 
are still receiving study  treatment in the placebo arm, will be allowed to cross -over to the 
ribociclib arm, based on the Investigator’s judgement and an individualized benefit risk decision.
As of Jan8th, 2020, there are still 117 patients ongoing on study  treatment .
The purpose of this amendment is to:
i. Allow 
unblind ing ofall patients and investigators in order to know patient’s current 
treatment allocation .
ii. Allow for patients currently receiving 
placebo the opportunity  to transition to 
investigational treatment (LEE011) per investigator discretion.
iii. Specify  that central safety ECG assessments can cease and ECG assessments should be 
performed locall y and update the frequency  of safety  ECG assessments .
iv. Update the visit evaluation schedule for patients on placebo transitioning to 
investigational treatment (L EE011) .
v. Specify  that patient reported outcome (PRO) measures sh ould no longer be collected .
vii. Update of the protocol requirements for consistency with the most recent IB version 14 
information:
1. Update the dose adjustment and management recommendation table to include 
information on Interstitial L ung Disease (ILD)/pneumonitis .
2.Minor update to the Guidance for other A dverse Reactions to include Toxic 
Epidermal Necrol ysis (TEN) .
3. Update the adjustment of starting dose in special populations (hepatic impairment and 
renal impairment) .

Novartis Confidential Page 15
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
4. Update the list of prohibited medications during study  treatment and medications to 
be used with caution during stud y treatment .
viii. Minor editorial changes, typographical error corrections, and alignment to the most 
recent program standard language as describ ed in the list of changes below.
Following this protocol amendment and the unblinding of study  participants, the word “placebo” 
refers to the original treatment allocation in the study . Physical placebo capsules do no longer 
need to be administered but thewording has been kept in places in the protocol to avoid 
confusion.
Changes to the protocol:
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through font for deletions and underlined for ins ertions.
The changes made to the protocol due to this amendment are incorporated in the following 
sections:
Summary  section of the protocol has been updated to maintain consistency within the 
main body  of the protocol.
Section 4.3 End of Study and 6.1 Defi nition of Study  and Study  Treatment sections were 
updated to note that the study  will be unblinded and patients will have the opportunity  to 
transition from placebo to investigational treatment ( LEE011 )
.
Figure 4 -1 Study  Design has been updated to reflect the transition from placebo to 
investigational treatment (LEE011) . 
Section 6.3.2 Treatment assignment and randomization was updated to clarify  that the 
study  will be unblinded and patients will have the opportunity  to cross -
over from placebo 
to LEE011.
Section 6.3.3 Treatment unblinding was updated to clarify  that the study  will be 
unblinded.
Section 6.5.1.2.3 Added Toxic Epidermal Necrol ysis (TEN) to the guidance for all other 
Adverse Reactions
.
Section 6.5.1.2.4 Adjustment of starting dose in patients with hepatic impairment and 
renal impairment has been updated based on new information from pharmacokinetic 
analysis.
Table 6
-5 Dose adjustement recommendations for hepatic toxicities was updated as per 
latest Progr am Standard Language.
Table 6.6 Additional follow -up for QTcF prolongation: wording related to PK assessment 
was removed.
Table 6- 7 added to include dose adjustment and management recommendations on 
Interstitial L ung Disease (ILD)/pneumonitis. 
Section 7-1 Study  Flow and Assessments were updated for all patients and additional 
clarification and instruction was given for cross -over patients .
Table 7
-1awas updated to clarify  study  assessments .
Table 7
-1b was added t o clarify  assessments for cross -over patients.

Novartis Confidential Page 16
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Section 7.2.1.3 has been updated to clarify  that radiology  review from the blinded 
independent review committee has been completed.
Section 7.2.2.5.6 Hepatic Safety  Markers : was updated to clarify  hepatic safety  markers
willno longer be collected .
Section 7.2.2.6.1 Cardiac Assessments was updated to clarify  that allECGs will be 
performed locall y and the schedule of assessments was updated for all patients.
Section 7.2.3 PK was updated to clarify  that no additional PK shoul d be collected from 
any patient also including cross -over patients.
 
 
Section 7.2.6 updated to confirm no additional patient reported outcome assessments will 
be collected
.
Section 8.3 Emergency  unblinding was updated to reflect this section is not applicable 
now that the study  will be unblinded .
Section 9.3 and 9.4 D ata collection parameters have been udpated with latest changes.
Section 10.1.5 Added in information on the cross -over anal ysis set
Section 10.3 Updated to include treatment exposure summaries for cross- over patients
Section 10.4.4 Updated the supportive anal ysis to clarify  further anal ysis
Section 10.5.1 Confirm that since the secondary  objective (OS) was met,  
 and no fu rther formal anal yses of OS are planned
.
Section 10.5.3 I ncorporate safet y summaries for the cross -over analy sis set .
Section 10.7.2 was updated to clarify  that further anal ysis will be descriptive. 
Section 14 Appendices :
Appendix 1: C oncomitant medication tables for prohibited medications and 
medications to be used with caution updated
Table 14.1: List of prohibited concomitant medications during stud y drug 
treatment .
Table 14.2: L ist of medications to be used with caution during study  drug 
treatment .

Novartis Confidential Page 17
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Review requirements by  IRB/IEC and Health A uthorities
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
Some changes herein may affect the Informed Consent. Sites are required to update and submit 
for approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 18
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Amendment 3 (06- Aug-2018)
Amendment rationale
Study  CLEE011F2301 was initiated in June 2015 and completed enrollment on June 2016. 727
patients were randomized. The study  met its primary  endpoint of progression- free survival (PFS) 
at the time of the primary analysis in January  2018. Results of this trial led to the approval of 
KISQALI (Ribociclib, LEE011) for expanded and new indications in HR-positive, HER2-
negative advanced or metastatic breast cancer in the United States.
The purpose of this amendment is to:
(i)Update the dose adjustment and management recommendations for QTcF prolongation. 
Analy ses of preclinical and clinical data with ribociclib have demonstrated that ribociclib 
prolongs the QT interval in a concentration -
dependent manner. Moreover, based on the 
ribociclib exposure -ΔQTcF relationship and the clinical experience in studies 
CLEE011A2301 (MONALEESA -2), CLEE011F2301 (MONALE ESA -3) and 
CLEE011E2301 (MONAL EESA -7), ribociclib dose reduction is an effective strategy  for 
managing ribociclib therapy  in patients experiencing QTcF prolongation. Therefore, in 
order to reduce the risk of subsequent QTcF prolongation in patients experie ncing a QTcF 
between 481-500 msec, ribociclib dosing should be reduced by 1 dose level with the first 
occurrence of QTcF ≥ 481 msec. As a result, this amendment includes an update to the 
dosage management guidance for patients who experience QTc Fprolongat ion.
(ii)Update the prohibited concomitant medications based on drug-drug interaction and co-
medication considerations.
(iii)The study has met the primary endpoint. After all patients have gone through 36 months 
of follow -up from randomization, Tumor and other eff icacy  assessments will be 
performed as clinicall y indicated. In order to capture patients PRO data close to the tumor 
assessment dates, PRO assessment schedule will also follow the efficacy  assessment 
schedule . 
(iv)Imaging tumor assessments- As the radiology  review from the blinded independent review 
is completed, note added on stopping the transmission of images to CRO.
(v)Clarify  the timing of collection of patient reported outcomes (PRO) to provide flexibility  
for sites to collect PRO’s at any time during the patient visit but prior to any interaction with 
the investigator; paper PRO utilization, when ePRO technical issues occur.
(vi)Update the withdrawal of consent language to align with the new Global Data Protection 
Requirements. 
(vii) Minor additional updates, as su mmarized below.
Changes to the protocol: 
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
All the changes made to the protoc ol due to this amendment are incorporated in the following 
sections:

Novartis Confidential Page 19
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
List of abbreviations and glossary  of terms updated
Sections 6.1.1.1: General dosing guidelines information updated
Table 6- 6:  Potential risk of QT prolongation has been observed in pati ents treated with 
ribociclib. Therefore updates to dose adjustment have been added, dose reduction is 
recommended after the first event of QTc prolongation >480ms. 
Section 6.6.1: Permitted concomitant therap ysection updated.
Section 6.6.1.2: Hematopoietic growth factors information updated.
Section 6.6.1.4: Use of antiemetic medications: New section to explain use of antiemetic 
medications according to NCCN guidelines added.
Section 6.6.2: Concomitant therap y requiring caution: I nformation on concomitant therapy  
requiring caution updated.
Section 6.6.3: Prohibited concomitant therap y: Information on prohibited concomitant 
therap y updated.
Section 6.6.4: Drugs with QT prolongation- Co-administration of drugs with known risk 
of torsade’s pointes TdP further clarified.
Section 7.1.4: Withdrawal of consent wording revised to align with new Global Data 
Protection Requirements.
Section 7.2.1.1: I maging tumor assessments- As the radiology  review from the blinded 
independent review is completed, note added on stopp ing the transmission of images to 
CRO.
Section 7.2.6: Patient reported outcomes -updated text to explain the timing of PRO 
administration during patient visit and paper PRO implementation, when ePRO technical 
issues occur. 
Efficacy  Assessments Update: Section Efficacy  Assessments, Section 4.1.4, Section 
7.2.1.1, Section 7.16, Table 7 -1 updated for sections 7.2.1, 7.2.6.1, 7.2.6.2, 7.2.6.3, 
Updated  Table 7 -2, Updated Table 7 -9 for the timing of PRO assessments.. 
Table 7-2: Note added on stopping the transmission of images to CRO for patients’ 
radiological and photography .
Section 13: New References added.
Minor updates: Sections 6.4.2, Table 6 -4, Table 6-5, Section 7.1.3
Section 14 Appendices:
Appendix 1: Concomitant medications: L ist of prohibited conc omitant medications 
updated based on the Oncology  Clinical Pharmacology  guidance, drug -drug 
interaction and co -medication considerations (v07, release date: Jan2018). 
Table 14- 1: List of prohibited medications during study  drug treatment.
Table 14- 2: List of medications to be used with caution during study  drug 
treatment.
Review requirements by  IRB/IEC and Health A uthorities
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.

Novartis Confidential Page 20
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
Some changes herein may affect the Informed Consent. Sites are required to update and submit 
for approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 21
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Amendment 2 (28-Jul -2016)
Amendment rationale 
Study  CLEE011F2301 was initiated in June 2015 and enrollment has been completed on June 
14th.727 patients have been randomized in the study .
The purpose of this amendment is to:
(i). Eliminate the originally  planned futility  interim analy sis :
Since the start of Study CLEE011F2301, additional clinical data have been generated with 
LEE011 and other CDK 4/6 inhibitors that provide additional assurance of the activity  of this 
compound and class in patients with breast cancer. In addition, Study  CLEE011F2301 will be 
fully  enrolled prior to the time of the originally  planned futility  analysis, negating the need for 
the originall y planned interim futility  anal ysis. 
(ii) Eliminate the originally  planned efficacy  interim analy sis and add the requirement of 
minimum amount of information from 1st line patients in the primary  end point final analy sis:
The primary  objective of the study  is to compare investigator assessed PFS in the overall 
population (both 1st line and 2nd line). If the primary  analysis is statistically  significant, 
treatment effect will be evaluated in 1st line and 2nd line patients separately. Based on the 
estimated median PFS and proportion of patients in 1st line and 2nd line respectivel y, it is 
expected that the accumulation of events in 1st line will be slower than 2nd line patients . By 
the projected efficacy  interim analysis, there may not be enough events from 1st line patients 
to support the treatment effect in this sub population. Hence the originally  planned efficac y 
interim analy sis is eliminated. In addition, to ensure enough information coming from the 1st 
line patients, a requirement of minimum  amount of events coming from 1st line patients in the 
final anal ysis is added.
(iii). Change the approach for Blinded Independent Review Committee (BIRC) assessment of 
PFS from a full read to an audit (sample) based approach:
For studies with local PFS as the primary  endpoint, central PFS has generally  been used as a 
secondary  anal ysis in support of the treatment effect observed in the primary  efficacy  anal ysis. 
Although, 100% central review of scans has been performed in many  trials, there is a growing 
body  of evidence that an audit based approach for central evaluation is sufficient (Zhang et al, 
2012, FDA ODAC 2012). Therefore, the study is being amended to change the central 
assessment of PFS from a full read to an audit based approach. Consequently , blinded 
independent review committee (BIRC) based PFS will no longer be a secondary  endpoint but 
will be considered supportive of the pr imary  anal ysis.
Additional changes in the protocol amendment
(i). Clinical pharmacokinetic data has been updated as new data is available
(ii). Clarifications have been provided on the following stud y procedures:
Schedule of the EOT visit

Novartis Confidential Page 22
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Palliative radiotherap y, previo usly only allowed for bone pain relief, is permitted 
provided it is not delivered to a target lesion
The use of the randomization date as the reference for the tumor assessement schedule
(iii) To better evaluate treatment effect on ORR, a sensitivity  anal ysis of ORR is added for 
patients with measurable disease at baseline. 
(iv) The PK analy sis was updated to only summarize PK concentrations by  time point 
considering that PK parameters will not be estimable due to the sparse PK sampling 
schedule. PK data c ollected from this study  may  be used in population PK anal ysis of 
ribociclib using non -linear mixed effect modeling and would be reported in a separate 
report.
(v). The protocol appendix 2 has been updated to reflect the new Novartis guidance on the 
implem entation of RECIST 1.1
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Summary  section of the protocol has been updated to maintain consistency within the 
main body  of the protocol
Section 1.2.1.2.3 has been updated to add new pharmacokinetic data on ribociclib
Section 3, Table 3 -1 secondary   objectives and endpoints have been 
updated
 
to clarify the pharmacokinetic endpoint
Section 4.1.2 has been updated to clarify when an end of treatment (EOT) visit must be 
performed
Section 4.2 and Section 4.3 have been updat ed to remove the 1 stand 2 ndinterim anal yses 
(respectively  futility  and efficacy  anal ysis) for the primary  endpoint PFS
Section 6.5.1.3 has been updated to clarify
 that all QTcF grade values refer to the average 
of triplicate measurements 
Section 6.6.1.3 has been updated to remove the requirement of palliative radiation solely  
for bone pain
 
 
Section 7.2.1.1 has been updated 

Novartis Confidential Page 23
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
to reflect the change to the audit based stratefy  for the BIRC assessment
to clarify  that the randomization is the reference date for the planning of the tumor 
assessment schedule .
Section 7.2.1.3 has been added to describe the describe the audit -based central assessment
Section 8.6 has been updated to reflect the removal of the 1 stand 2 ndinterim analy ses 
(respectively  futility  and efficacy  anal ysis) for the primary  endpoint PFS
Section 10 , 10.5.1, 10.7.1 has been updated to reflect the removal of the 1 stand 2 nd
interim analy ses (respectively  futility and efficacy  anal ysis) for the primary  endpoint PFS
Section 10.4.4 has been updated to describe the supportive anal ysis of PFS using audit 
based BI RC assessment
Section 10.5 has been updated to remove reference to the BIRC based PFS as secondary  
endpoint
Section 10.5.2.1 has been removed to reflect the removal of the PFS as assess by  the BIRC 
as a secondary  endpoint
Section 10.5.2.2 has been updated to add a sensitivity  anal ysis for Overall Response Rate 
(ORR)
Section 10.5.4 has been updated to reflect the change in the anal ysis of PK data 
Section 10.7.2 to reflect the removal of one OS interim anal ysis at the originally  planned 
PFS efficacy  interim analy sis
Section 10.8 has been updated
to reflect the removal of one OS interim anal ysis at the originally  planned PFS 
efficacy  interim analy sis
to add the requirement of minimum amount of information coming from 1 stline 
patients in final anal ysis.
to add sample size calculation for audit size of sample -based BIRC assessment of 
PFS.
Section 13: new protocol references have been added
Appendix 2 has been updated to reflect the new Novartis guidance on the implementation 
of RECI ST 1.1
In addition to above, changes to t ypographical errors where applicable have been made.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

Novartis Confidential Page 24
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Amendment 1
Amendment rationale
Study  CLEE011F2301 was initiated in June 2015 and enrollmen t is currently  ongoing.
As of February  17th 2016, 351 patients have been randomized in the study .
The purpose of this amendment is to:
(i)Update and clarify the safety monitoring of patients to be consistent across ribociclib 
clinical trials, and better chara cterize the QTc and liver side effects, including:
Management of QTcF prolongation: 
Potential risk of QT prolongation has been observed in patients treated with ribociclib. 
Updates to inclusion and exclusion criteria, ECG monitoring (triplicates) and dose
modification guidelines for QTcF prolongation have been made. 
Management of hepatic toxicities:
Recent data suggests a potential risk of hepatic toxicity  (drug induced liver injury  [DILI ] 
indicated b y an increase of transaminases, in isolation or with bilirubin increase) in 
patients treated with ribociclib. Updates to monitoring and dose adjustment guidelines for 
hepatobiliary  toxicities including ALT, AST and total bilirubin have been added and 
separated from the dose modification guidance for other ad verse events.  
Management of dose modification based on l ocal laboratory results:
Clarification was provided that, in case of safet y emergency, local laboratories results can 
be used to evaluate the need for potential study
 treatment dose modifications.
(ii).Modification of the study population and eligibility criteria:
Following interaction with Health Authorities, men are eligible to be included in the 
study .
(iii)Additional changes
Revision of the screening visit window changed within 21 day s to within 28 day s of 
randomization
Whole body  bone scan window has been changed from within 28 day s to within 42 
days of randomization
Removal of the requirement for a central radiology  assessment by  medical oncologist: 
Medical oncologist review has been replaced b y a standard blinded independent 
review committee (BIRC) review assessment. 
List of prohibited concomitant medications has been updated based on recently  
released internal Oncology  Clinical Pharmacology  drug -drug interaction guidance 
(from 2015) and based on new data and recommendations from the latest version of 
LEE011 Investigator’s Brochure.

Novartis Confidential Page 25
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
 
 
In the initial rat ADME study  cited in previous IB version, thy roid had the highest 
exposure in albino animals only . As a precaution, thy roid function was monitored in 
all clinical study  protocols. A most recent study  (DMPK 1300792) using p.o. dos ing 
in partially  pigmented animals with a longer observation period showed the highest 
distribution to the melanin -containing structures and not to the thy roid gland. I n 
addition, no clinically  significant thy roid adverse events have been reported in clinical 
trials so far. Based on this information, the risk to thyroid gland is removed from the 
reference safet y information for the compound and thyroid laboratory monitoring in 
clinical protocols are no longer mandated.
Update of the protocol requirements fo r consistency  with the most recent IB
information:
New information is provided on the safety  pharmacology  and toxicology
Update clinical trial information with the most recent data
Minor editorial changes, ty pographical error corrections, additional clarifications to 
address investigators’ questions and alignment to the most recent program standard 
language as described in the list of changes below.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The changes being made to the protocol due to this amendment are incorporated in the following 
sections:
Summary  section of the protocol has been updated to maintain consistency within the 
main body  of the protocol
Section 1.1 Addition of disease information regarding the men population 
Section 1.1.2 Addition of most recent information on available therapeutic options
Section 1.2 Addition of language to refer to most recent version of the ribociclib 
investigator brochure
Section 2.3 and 2.5 have been updated to incorporated most updated trials information
 
Section 4 and Figure 4 -1 have been updated to incorporate men population and screening 
visit window of 28 day s into the study  design
Section 4.1 Advanced/ metastatic terms have been included to add clarit y to the pa tient 
population in the stratification criterion
Section 5.1 Patient population has been updated to reflect the inclusion of men in the 
study .
Section 5.2 I nclusion Criteria has been updated:

Novartis Confidential Page 26
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
#1) Addition of male population and male contraception informati on
#2) to clarify  that ovarian radiation or treatment with a luteinizing hormone -releasing 
hormone agonist (LH -RHa) are not allowed for induction of ovarian suppression in 
this study .
#3) and 4) to clarify  that diagnosis of breast cancer should be based on recent biopsy
#6) to clarify  the definition of curative therap y per protocol. Advanced/ metastatic 
terms have been included to add clarit y to the patient population. The terms relapse 
and progressed have been corrected accordingl y to the treatment setting .
#8) phosphorus assessment has been removed from screening visit.
Section 5.3 Exclusion Criteria have been updated:
#12) to clarify  that squamous cell carcinoma refers to squamous skin cancer. 
#17). and #18):
To clarify  the exclusion criteria for patients with clinically  significant, 
uncontrolled heart disease and/or cardiac repolarization abnormality  and for 
patients currentl y receiving prohibitied medications.
To clarify  that resting heart rate should be <90 bpm 
Section 6.1 has been updated with timing recommendation on dosing schedule and meal 
conditions
Section 6.5.1.2: 
To add clarit y on fulvestrant dosing interruption
To add clarit y on the use of local laboratories results for dose modifications.
To add clarit y on dose modification guidelines
Section 6.5: Table 6 -5 and Table 6-6
Section 6.5.1.2 wording has been modified to clarify to the dosing 
recommendations and requirements 
Dose m odifications ha vebeen updated to clarify  action sto be taken for 
hematologic toxicities, QTcF prolongation and all other toxicities, as well as 
providing new guidelines for hepatic toxicities . 
Renal toxicity  wording has been moved from section 6.5.1.3.2 to the safet y section 
6.5.1.3.1 for clarity .
“Placebo” has been added in the table wording and baseline value has been 
modified to baseline grade based on CTCAE.
Section 6.6.2.1 and 6.6.3: the use of corticosteroids therap y has been added to allow the 
topical and short term use per protocol. Chronic use remain prohibited due to the potential 
for drug -drug-interac tion.
Section 6.6.2 immunosuppressant therapies have been added in the medications to use 
with caution due to their higher risk of infections. 
Section 6.6.4 has been added to clarify  the use of medications with a known risk of QT 
prolongation 
Section 7, Table 7-1:

Novartis Confidential Page 27
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Modification to the screening window change within 21 day s to within 28 day s of 
randomization. 
Modification to the visit windows schedule to include a ±3 day s visit windows for all 
visits including PK visits
To add clarit y that ph ysical exam assessment will not be repeated at C ycle 1 Day 1 
when done in the timeframe - 7 to - 1 at the screening visit
 
Revision to the whole body  bone scan requirement window: change from 28 to  
within 42 day s or 6 weeks prior to randomization.
Section 7.1.1 screening: 
clarification that screening assessments to be performed at - 7 to -1 should be repeated 
in the case wher e randomization visit is delay ed more than 7 day s from cy cle 1 day  1. 
clarification on inform consent form process for patients who rescreen
Section 7.1.3 
Clarity  added by  the addition of the word “reasonable” 
update to the study  treatment discontinuation language in the case of AEs. 
Section 7.2.1.1 
Revision of window regarding whole bod y bone scan: change from within 28 days to 
within 42 day s of randomization
Updated to remove the medical oncologist review of central images.
Section 7.2.2: Thy roid monitoring has been removed as is not longer mandatory  based on 
recent stud y results.
Section 7.2.2.5: 
clarification on the use of local laboratories results 
Table 4 - addition of the hepatic safet y markers assessments 
Section 7.2.2.5.6: addition of the hepatic safet y markers section
Section 7.2.2.6.1 and Table 7- 5: 
Electrocardiogram (ECG) was updated with the use of triplicate for each collection 
time points 
Clarity  was added on the unscheduled ECG management
Section 7.2.3.1: clarification to PK sampl ing when no study  drug has been taken
 
 
. 
 
 
Section 7.2.6 Table 7 -9 has been updated to reflect the 28 day s screening visit window 
Section 8: implementation of new Serious Adverse Event (SAE) reporting instructions

Novartis Confidential Page 28
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Section 8.4: addition of pregnancies recommendations for female partner of any  male 
participants
Section 13: new protocol refer ences have been added
Section 14.1 Appendix 1 - Concomitant medications 
Table 14-1 and Table 14- 2 have been updated with the latest information available .
Modification to the table removing CYP2D6 since is it not applicable to the study  
treatment . 
In addition to above, changes to t ypographical errors where applicable have been made.
Review requirements by  IRB/IEC and Heath A uthorities
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 29
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Protocol summary :
Title A randomized double -blind, placebo -controlled study of ribociclib in combination 
with fulvestrant for the treatment of men and postmenopausal women with 
hormone receptor positive, HER2 -negative, advanced breast cancer who have 
received no or only one line of prior endocrine treatment
Brief title Study assessing the efficacy and safety of ribociclib plus fulvestrant in men and 
postmenopausal women with advanced br east cancer having been treated with no 
or only one prior endocrine therapy.
Sponsor and 
Clinical PhaseNovartis
Phase III
Investigation ty pe Drug
Study  type Interventional 
Purpose and rationale Treatment of hormone receptor (HR) positive, HER2 -negative breast cancer still 
represents an unmet medical need as a significant number of patients are 
expected to have, or to develop, resistance to endocrine therapies that have been 
given in the adjuvant or first line metastatic setting. CDK4/6 path way alterations 
appear to play a key role in the development of this resistance. The rationale for 
assessing the efficacy of ribociclib, a CDK4/6 inhibitor, in combination with the 
hormonal agent fulvestrant, in a randomized Phase III study is therefore based 
upon the role of the CDK4/6 pathway in HR+ breast cancer and the potential 
synergy when combined with hormonal agents such as fulvestrant.
The purpose of this study is to determine whether treatment with ribociclib plus 
fulvestrant will result in an i mproved progression free survival compared to 
fulvestrant and placebo in men and postmenopausal women with HR+, HER2 -
negative advanced breast cancer who have received no or only one prior 
endocrine treatment for advanced disease.
Primary  Objective(s) Theprimary objective is to compare progression free survival (PFS) between 
ribociclib in combination with fulvestrant to placebo in combination with fulvestrant 
among men and postmenopausal women with HR+, HER2 -negative advanced 
breast cancer who received n o or only one prior endocrine treatment for advanced 
disease.
Secondary  Objectives ● To compare the two treament arms with respect to overall survival
●To evaluate the two treatment arms with respect to overall response rate, 
clinical benefit rate, time to response and duration of response as assessed by 
tumor evaluation (RECIST 1.1) every 8 or 12 weeks.
●To evaluate the two treatment arms with respect to time to deterioration of 
ECOG performance status by assessing the performance status at each cycle.
● To evaluate the safety and tolerability of ribociclib in combination with 
fulvestrant by assessing the frequency/severity of adverse events (AEs) and of 
laboratory abnormalities on a continuous basis throughout the study.
●To evaluate patient reported o utcomes every 8 or 12 weeks for health -related 
quality of life (QOL) in the two treatment arms based on the global health 
status/QOL scale of the EORTC QLQ-C30 questionnaire.
●To characterize the pharmacokinetics (PK) of ribociclib (and relevant 
metabolit es such as LEQ803) at Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 2 Day 
15, when given in combination with fulvestrant by compiling summary statistics for 
PK parameters at steady state.

Novartis Confidential Page 30
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Study  design This is a randomized, phase III, double -blind, global trial comparing the 
combination of fulvestrant + ribociclib to fulvestrant + placebo in men and 
postmenopausal women with HR+, HER2-negative advanced breast cancer. The 
study will consist of a 28-day screening phase, of a treatment phase, and of a post -
treatment phase which includes safety, efficacy, and survival follow up.
Patients will be randomly assigned to either fulvestrant+ribociclib or 
fulvestrant+placebo in a 2:1 ratio. Randomization will be stratified by the following 
factors:
●Lung or liver metastases (yes versus no)
●Previous endocrine therapy
PopulationThe study will include 660 men and postmenopausal women with HR+ HER2 -
negative advanced breast cancer who received no or only one prior endocrine 
therapy. The investigator or designee must ensure th at only patients who meet all 
of the following inclusion and none of the exclusion criteria are offered treatment in 
the study.
Inclusion criteria Refer to Section 5.2 for details on and full listing of inclusion criteria.
●Patient is an adult ≥ 18 years old at the time of informed consent and has 
signed informed consent before any trial related activities and according to local 
guidelines
●Patient is a man or a postm enopausal woman
●Patient has a histologically and/or cytologically confirmed diagnosis of 
estrogen -receptor positive and/or progesterone receptor positive breast cancer
●Patient has HER2 -negative breast cancer
●Patient must have either:
● Measurable dis ease, i.e., at least one measurable lesion as per RECIST 
1.1.
OR
● If no measurable disease is present, then at least one predominantly lytic 
bone lesion must be present
● Patient has advanced (loco regionally recurrent not amenable to resection or 
radiati on therapy with curative intent or metastatic) breast cancer.
Patients may be :
● newly diagnosed advanced /metastatic breast cancer, treatment naïve
● relapsed with documented evidence of relapse more than 12 months from 
completion of (neo)adjuvant endocri ne therapy with no treatment for 
advanced/ metastatic disease
● relapsed with documented evidence of relapse on or within 12 months 
from completion of (neo)adjuvant endocrine therapy with no treatment for 
advanced/ metastatic disease
● relapsed with documented evidence of relapse more than 12 months from 
completion of (neo) adjuvant endocrine therapy and then subsequently 
progressed with documented evidence of progression after one line of 
endocrine therapy (with either an antiestrogen or an aromatase inhibitor) for 
advanced/ metastatic disease
● newly diagnosed advanced / metastatic breast cancer, thatprogressed 
with documented evidence of progression after one line of endocrine therapy 
(with either an antiestrogen or an aromatase inhibi tor)
●Patient has an Eastern Cooperative Oncology Group (ECOG) performance 
status 0 or 1
●Patient has adequate bone marrow and organ function

Novartis Confidential Page 31
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Exclusion criteria Refer to Section 5.3 for details on and full listing of exclusion criteria.
●Patient with symptomatic visceral disease
● Patient has received prior treatment with chemotherapy (except for 
neoadjuvant/ adjuvant chemotherapy), fulvestrant or any CDK4/6 inhibitor
●Patients wit h Child pugh score B or C
●Patient with inflammatory breast cancer at screening or concurrent malignancy 
or malignancy within 3 years of randomization
●Clinically significant, uncontrolled heart disease and/or cardiac repolarization 
abnormality including any of the following:
● History of angina pectoris, symptomatic pericarditis, coronary artery 
bypass graft (CABG) ormyocardial infarction within 6months prior to study 
entry
● Documented cardiomyopathy
● Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple 
Gated acquisition (MUGA) scan or echocardiogram (ECHO)
● L ong QT syndrome or family history of idiopathic sudden death or 
congenital long QT syndrome , or any of the following:
Risk factors for Torsades de Pointe (TdP) including un corrected 
hypokalemia or hypomagnesemia, history of cardiac failure, or history 
of clinically significant/symptomatic bradycardia
Concomitant medication(s) with a known risk to prolong the QT 
interval and/or known to cause Torsades de Pointe that cannot be
discontinued or replaced by safe alternative medication (e.g. within 5 
half-lives or 7 days prior to starting study drug) 
Inability to determine the QTcF interval
Clinically significant cardiac arrhythmias including but not limited to (e.g. 
ventricular t achycardia), complete left bundle branch block, high -grade AV 
block (e.g. bifascicular block, Mobitz type II and third degree AV block)
● Systolic Blood Pressure (SBP) >160 or <90 mmHg
● Bradycardia (heart rate < 50 bpm at rest), by ECG (mean of triplicate ) and
pulse.
Tachycardia (heart rate > 90 bpm at rest), by ECG (mean of triplicate) and 
pulse.
● On screening, inability to determine the QTcF interval on the ECG (ie: 
unreadable or not interpretable) or QTcF >450 msec (using Fridericia’s 
correction). All as determined by screening ECG (mean of triplicate ECGs).
● Patient has not recovered from all toxicities related to prior anticancer therapies 
to NCI CTCAE version 4.03 Grade ≤1
●Patient has received radiotherapy ≤ 4 weeks or limited field radiation for 
palliation ≤ 2 weeks prior to randomization
● Patients with central nervous system (CNS) involvement unless they meet ALL 
of the following criteria:
● At least 4 weeks from prior therapy completion (including radiation and/or 
surgery) to starting the study treatment
● Clinically stable CNS tumor at the time of screening and not receiving 
steroids and/or enzyme inducing anti-epileptic medications for brain metastases
●Patient has any other concurrent severe and/or uncontrolled medical condition 
that would, in the investigator’s judgment, cause unacceptable safety risks, 
contraindicate patient participation in the clinical study or compromise compliance 
with the protocol.
●Patient is currently receiving any of the following substances and cannot be 
discontin ued 7 days prior to start the treatment:
● Known strong inducers or inhibitors of CYP3A4/5.
● Medications thathave a narrow therapeutic window and are 
predominantly metabolized through CYP3A4/5.

Novartis Confidential Page 32
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
● Herbal preparations/medications, dietary supplements (exce pt vitamins)
Investigational and 
reference therapyFor this study, the term “investigational drug” refers to Novartis study drug 
ribociclib. Fulvestrant is also being used in this study. Study treatment in this study 
refers to the combination of drugs in each of the study arms and includes 
ribociclib/placebo and fulvestrant.
Patients will be randomly assigned to one of the below treatment arms in a 2:1 
ratio:
●Experimental arm (Arm A): fulvestrant + ribociclib
OR
●Control arm (Arm B): fulvestrant + place bo
Study  
treatmentPharmaceutical form 
and route of 
administrationFrequency  and/or Regimen
Fulvestrant Two 5ml injections for 
i.m. administrationDosed every 28 days (Cycle n Day 
1) with 1 additional dose on Day 
15 of Cycle 1
Ribociclib/ 
placeboCapsule for oral use Once daily; days 1 to 21 in a 28-
day Cycle
Efficacy  assessments ● CT/ MRI every 8 weeks for the first 18 months, then every 12 weeks until 36 
months, and thereafter as clinically indicated. until disease progression, death, 
withdrawal of consent, loss to follow -up, or subject/guardian decision
●Brain CT or MRI as clinically indicated if brain lesion at screening
●Whole body scan as clinically indicated
●Bone X -ray, CT or MRI (if bone lesion at screening) every 8 weeks for the first 
18 months , then every 12 weeks until 36 months, and thereafter as clinically 
indicated.
●Skin color photography (if skin lesions at screening) every 8 weeks during the 
first 18 months , then every 12 weeks until 36 months, and thereafter as clinically 
indicated.
●CT/ MRI for any disease outside of the chest, abdomen, pelvis (if lesion 
identified at screening) every 8 weeks for the first 18 months ,then every 12 weeks 
until 36 months, and thereafter as clinically indicated.
●Survival status every 12 weeks (or earlier if required) regardless of treatment 
discontinuation reason
Safety  assessments ●Physical examinations
●ECOG performance status
●Height, weight, and vital signs
●12 lead ECGs
●ECHO, MUGA scan
●Laboratory assessments including hematology, biochemistry, lipid panel, 
coagulation (via INR) , hepatic safety markers, and urinalysis
Other assessments Pharmacokinetic : PK blood samples will be collected for analysis of ribociclib (and 
metabolites) plasma concentrations 
Biomarkers : Tumor and blood samples will be collected for biomarker 
assessments. Tumor tissue will be used to assess molecular alterations of several 
genes shown to be associated with HR+ breast cancer and the CDK4/6 pathway. 
Collection of blood for circulating tumor DNA (ctDNA) analysis will allow additional 
serial monitoring of mutations in genes that are relevant to HR+ b reast cancer and 
CDK4/6.
In addition exploratory liver biomarkers (e.g. microRNA-122, HMGB1) will be 
evaluated to explore potential mechanisms underlying hepatic toxicity.
GWAS/HLA genotyping will be performed for potential association with safety 
endpoin ts.
Patient -reported outcomes : Patient questionnaires (EORTC -QLQ -C30, EQ -5D-
5L, BPI-SF) will be collected to assess health -related quality -of-life, health status, 

Novartis Confidential Page 33
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
functioning, disease symptoms, side effects, and cancer -related pain.
Following protocol amendment 4, no further ePRO, PK data , central ECG  
will be collected.
Data analy sis The primary objective for this study is to determine whether treatment with 
fulvestrant + ribociclib prolongs PFS compared to treatment with fulvestrant + 
placebo in men and postmenopausa l women with HR+, HER2 -negative advanced 
breast cancer. The primary efficacy endpoint, PFS, will be determined based on 
local tumor assessment following RECIST 1.1 guidelines. The primary efficacy 
analysis will be the comparison of the distribution of PFS between the two 
treatment groups using a stratified (randomization strata per IRT) log -rank test at 
one-sided 2.5% level of significance.
Distribution of PFS will be estimated using the Kaplan -Meier method. The median 
PFS along with 95% confidence intervals will be presented for each of the two 
treatment groups. The stratified Cox regression will be used to estimate the hazard 
ratio (HR) of OS, along with 95% confidence interval. Subgroup analyses will be 
performed on each level of stratification factors if the primary analysis is significant. 
The analysis will include Kaplan-Meier summaries and estimation of hazard ratios 
from un -stratified Cox regression models. Additional subgroup analyses to assess 
the homogeneity of treatment effect based on demographic and baseline disease 
characteristics may be performed .
The Full Analysis Set (FAS) will comprise all randomized patients. Following the 
intent to treat (ITT) principle, patients will be analyzed according to the treatment 
and strata they have been assigne d to at the time of randomization. The FAS will 
be the primary population for all efficacy analyses. The Safety Set includes all 
patients who received at least one dose of study medication defined as fulvestrant, 
or ribociclib/placebo and had at least one post-baseline safety assessment. 
Patients will be analyzed according to treatment actually received.
One of the secondary objective sof the study is to determine whether treatment 
with fulvestrant + ribociclib prolongs overall survival (OS) compared to tre atment 
with fulvestrant + placebo. OS will be hierarchically tested (provided the primary 
PFS analysis is statistically significant), in the following way .The first potential 
time point for OS analysis will be at the time of the primary PFS  analysis at which 
time approximately 161 deaths are expected. If OS is not statistically significant at 
this stage, the 2ndOS analysis is planned  after approximately 263deaths are 
expected. If OS is not statistically significant at this stage, the final  OS analy sis will 
be planned after approximately 351deaths .
Key words HR-positive, HER2 -negative, advanced breast cancer, ribociclib, fulvestrant, 
CDK4/6, Phase III, ER -positive, PR-positive, postmenopausal , men, metastatic 
breast cancer 

Novartis Confidential Page 34
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
1 Background
1.1 Overview of disease pathogenesis and current treatment
1.1.1 Epidemiology
An estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed among 
women in the US during 2015; excluding cancers of the skin, breast cancer is the most 
frequentl y diagnosed cancer in women. An estimated 40,730 breast cancer deaths (40,290 
women) are expected in 2015. Breast cancer ranks sec ond as a cause of cancer death in women 
after lung cancer ( Cancer facts & figures 2 015). Breast cancer in men is a less frequent disease 
than women and makes up < 1% of all cases of breast cancers; its treatment is based on the 
guidelines for female breast cancer (Foerster 2014 , Agrawal 2007, Patten 2013 ). Subty pes of 
BC are classified by the presence of estrogen receptor (ER), progesterone receptor (PgR), 
human epidermal growth factor receptor 2 (HER2) antigen as well as by distinct gene 
expression profiles (Perou et 
al 2000; Sotiriou and Pusztai 2009 ) and other features for 
prognostic and treatment purposes. Seventy  percent of invasive breast cancers in women > 45 
years of age, express ER and/or PgR, but not HER2, and are termed hormone receptor positive 
(HR+, HER2 -
negative) ( Huang 2005 ).
1.1.2 Available therapeutic options in ER+, HER2- negative breast cancer
Estrogen deprivation therapy  is the core treatment modality  in patients with HR+ advanced BC.
Endocrine therapy  options for postmenopausal women with ER+ advanced breast cancer 
(locally  advanced, recurrent, or metastatic breast cancer) include selective ER modulators 
(SERM; for example, tamoxifen), ER antagonists (for example fulvestrant), selective 
nonsteroidal aromatase inhibitors (NSAI ; anastrozole and letrozole) and steroidal aromatase 
inhibitors (exemestane). Blocking estrogen signaling with tamoxifen has been the main 
treatment approach for ER+ breast cancer for over 35 years. In postmenopausal women, 
aromatase inhibitors (AI) reduce peripheral estrogen synthesis by blocking the conversion of 
androgens to estrogens in non-ovarian tissues; synthesis in these tissues is the primary  source 
of estrogens in postmenopausal women. AIs are generall y used as the first line of therapy  for 
women with HR+ breast cancer (Beslija 2009; NCCN 2.2015). Fulvestrant is a pure ER 
antagonist approved at the dose of 500mg for the treatment of postmenopausal HR+ BC women 
previously  treated with antiestrogen ( Di Leo 2010 ; Di Leo 2014 ). Recently , the phase 2 FIRST 
trial (Robertson 2014) showed that the use of fulvestrant in first line setting significantl y 
prolonged PFS as compared to anastrozole (median TTP 23.4 months versus 13.1 months (HR 
0.66; 95% CI :0.47, 0.92; p=0.01)) and extends OS (54.1 months versus 48.4 months (HR 0.70; 
95% CI : 0.5, 0.98; p=0.04)) (Ellis 2015 ). The combination of targeted and endocrine therapies 
has also been evaluated: everolimus, an mTOR inhibitor, combined with exemestane showed 
synergistic inhibiti on of the tumor proliferation and is approved for postmenopausal women 
with advanced hormone receptor -positive, HER2- negative breast cancer (advanced HR+ BC) 
in combination with exemestane after failure of treatment with letrozole or anastrozole
(Baselga 
2012 ); recentl y, palbociclib, a CDK4/6i, has been approved in combination with letrozole for 
the treatment of postmenopausal women with estrogen receptor (ER) -positive, human 
epidermal growth factor receptor 2 (HER2) -negative advanced breast cancer as initial 

Novartis Confidential Page 35
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
endocrine -based therapy  for their metastatic disease based on the results of the phase 2 Paloma -
1 study .The addition of palbocicib to letrozole significantl y prolonged PFS as compared to 
letrozole alone (median PFS 20.2 months versus 10.2 months (HR 0.49; 95% CI:0.32, 0.75; 
p=0.0004)) (Finn 2015 ). Palbociclib in combination with fulvestrant for the treatment of 
patients with HR+ Her 2 advanced breast cancer who relapsed or progressed during prior 
endocrine therapy , resulted in prolonged progression free survival. (median PFS was 9.5 months 
for palbociclib plus fulvestrant  versus 4.6 months for the fulvestrant –placebo (HR 0.46; 95% 
CI: 0.36 
-0.59; P:<0.001)). In this stud y, women were eligible regardless of their menopausal 
status  and up to 1 line of prior chemotherapy  in the context of advanced disease was allowed. 
(Cristofanilli M 2015 , Turner 2015) 
1.1.3 Role of the CDK4/6 pathway  in breast cancer
Studies of ER+ breast cancer cell lines indicate that estrogens and antiestrogens act on sensitive 
populations of cells in early  to mid-G1 phase (Leung 1987 ). G1/S transition is under the control 
of cyclin dependent kinases (CDKs) which are activated by specific complex formation with 
regulatory  cyclins. CDK4 and CDK6 are activated by binding toD
-type cyclins and act early 
in G1 phase ( Sherr 1999 ; Musgrove et al 2011 ). A primary  target of CDK4/6 activation in G1 
phase is the retinoblastoma protein (pRb), which mediates G1 arrest through sequestration of 
transcriptional factors of the E2F-DP family . Phosphory lation of pRb and other members of the 
pocket protein family  (p107 and p130) by active cyclin-CDK complexes leads to release of E2F 
andDP and subsequent transcription of genes requisite for entry  into the S
-phase (Weinberg 
1995). D-type cyclins play an essential role in the recognition of extracellular growth stimuli 
and initiation of G1 to S transit ( Roussel 1995
; Sherr 1995 ).
Figure 1 -1 Regulatio n of cell cycle checkpoint control
Adapted from (Lange and Yee 2011 )Dysregulation of cell cycle checkpoints is common in 
cancer and aberrations in the cyclin/CDK/pRb pathway  are frequentl y observed in breast cancer. 

Novartis Confidential Page 36
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Such aberrations include amplification of cyclin D1 and CDK4 along with loss of CDKN2A 
which encodes p16INK4 a, an endogenous CDK inhibitor, all of which lead to activation of the 
cyclin/CDK/pRb pathway (Holm et al 2012; The Cancer Genome Atlas Network 2012; 
Beroukhim et 
al 2010). An upstream role for cyclin D1 has also been suggested by recent reports 
describing direct ph ysical interactions between cyclin D1 and the ER, leading to recruitment of 
steroid receptor coactivators and activation of ER-dependent transcription. This occurs in the 
absence of hormone and is independent of D cyclin association with CDK4 (Neuman 1997; 
Zwijsen 1997; Zwijsen 1998; McMahon 1999). Furthermore, recent preclinical data suggest 
that despite estrogen deprivation, ERα retains genomic activit y and drives a CDK4/E2F 
dependent transcriptional program ( Miller 2011).
Previously  published data have suggested that CDK4/6 inhibition may play a key role in the 
treatment of subsets of breast cancers. Loss of pRb has been observed in 10-30% of breast 
cancer patients (Knudsen and Knudsen 2008 ), however, this is more commonly  seen in ER-
negative patients, as evaluated using a gene signature of pRb loss (Ertel et al 2010). Patients 
with HR+ breast cancer exhibiting a gene expression signature of pRb loss had shorter 
recurrence -free survival follo
wing adjuvant tamoxifen (Bosco et al 2007 ). A tumor gene 
expression signature of E2F activation was associated with higher residual tumor cell 
proliferation following pre-surgical AI therap y. Therefore, activation of the CDK/pRb/E2F axis 
promotes endocrine resistance, and treatment with a CDK4/6 inhibitor or knockdown of CDK4 
expression would be expected to abrogate endocrine
-resistant cell proliferation (Caldon 2006).
In vitro data generated from 47 human breast cancer cell lines demonstrated preferential 
sensitivity  to CDK4/6 inhibitors in ER+ cell lines ( Finn et al 2009 ; O’Brien et al 2014 ). Tumor 
growth inhibition by CDK4/6 inhibitors has been demonstrated in vivo in preclinical models of 
endocrine -resistant breast cancer by  palbociclib (PD 0332991) ( Miller 2011 ; Thangavel 2011) 
and in mouse xenograft models of HR+ breast cancer by ribociclib in combination with letrozole 
or fulvestrant (O’Brien et al 2014). Clinically , palbociclib combined with letrozole showed a 
benefit prolonging the progression free survival (PFS) in postmenopausal women with 
ER+/HER2- negative advanced BC (Finn et al 2015) and has recentl y received accelerated 
approval based on PFS by the FDA.
In conclusion, targeting the CDK/pRb/E2F pathway  via a CDK4/6 inhibitor such as ribociclib 
in combination with endocrine treatment has the potential to have a positive infl
uence on breast 
cancer progression.
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
This study  includes ribociclib and fulvestrant as treatments.
1.2.1 Overview  of ribociclib
Ribociclib (L EE011) is an orally  bioavailable and highly  selective small molecule inhibitor of 
the CDK4/cy clin-D1 and CDK6/ cy clin-D3 enzyme complexes with IC50’s of 0.01 and 0.039 
μM in biochemical assays, respectivel y. Refer to LEE011 (ribociclib) [Investigator Brochure] 
for details.

Novartis Confidential Page 37
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
1.2.1.1 Nonclinical experience
1.2.1.1.1 Nonclin icalpharmacology of ribociclib
In Jeko-1 mantle cell lymphoma (MCL) cells that overexpress cyclin D1 as a result of the 
t(11;14) chromosomal translocation, ribociclib inhibits the phosphory lation of pRb at CDK4/6 -
specific sites with an average IC50of 60 nM. In nude rats bearing Jeko-1 subcutaneous 
xenografts, ribociclib demonstrates dose -dependent target inhibition in the tumors. Ribociclib 
doses that induce >75% inhibition of pRb phosphory lation in this model are associated with 
complete tumor regression (see LEE011 (ribociclib) [Investigator Brochure]). Ribociclib also 
inhibits the growth of many  other tumor cell ty pes in vitro and in vivo, including liposarcoma, 
melanoma, rhabdoid cancer, and carcinomas of the esophagus, breast, lung and pancreas. 
Regar dless of the various genetic aberrations that may be present in the cancer cells, the anti -
tumor activity  of ribociclib requires the presence of functional pRb. Refer to LEE011 (ribociclib) 
[Investigator Brochure] for more details.
A panel of human breast cancer cell lines was treated with increasing doses of ribociclib and 
dose-dependent inhibition of proliferation was observed across the panel with enhanced activit y 
against ER+ breast cancer cell lines with IC50 < 1µM being observed for most ER+ breast 
cancer lines (Novartis internal data, LEE011 (ribociclib) [Investigator Brochure Figure 4-3]). 
Ribociclib as a single agent has been shown to have activit y in 
preclinical models of ER+ breast 
cancer (Novartis internal data). In vivo studies of ribociclib in combination with endocrine 
therap y have demonstrated increased anti-tumor activity  of the combination for letrozole , 
fulvestrant and tamoxifen compared to single agent ribociclib activity([Investigator Brochure];
O’Brien et al. 2014 ;) which support the proposed combination.
1.2.1.1.2 Safety pharmacology and toxicology
In vivo cardiac safet y studies demonstrated a signal for QT prolongation with the potential to 
induce incidences of premature ventricular contractio ns (PVCs) at higher exposure levels. 
The effects of LEE011 on the bone marrow (hypocellularity), lymphoid system (lymphoid 
depletion), intestinal mucosa (atrophy ), skin (atrophy ), bone (decreased bone formation) and 
testes (atroph y) are consider ed to be related to the pharmacological inhibition of cell replication 
in these tissues due to CDK4/6 inhibition. 
An increased number of ovarian corpora lutea was observed in a single female dog in the 4-
week toxicity  study at the highest dose tested (20 mg/kg/day ) and this effect could also be 
related to the pharmacology  of LEE011 (arrest of estrous cy cle). 
The liver, bile system and gall bladder (proliferative changes, cholestasis, sand-like gallbladder 
calculi and inspissated bile) and the kidney  (concurrent degeneration and regeneration of 
tubular epithelial cells) were identified as additional target 
organs of toxicity  which are not 
likely  related to the primary  pharmacology  of LEE0 11.
Inflammatory  changes in the lungs of dogs were considered secondary  to aspiration of test 
article and are indicative of the irritant potential of the formulated test -article in the respiratory 
tract. Correlating hematological and/or biochemistry  change s were seen for the effects 
described in the bone marrow, l ymphoid s ystem and liver. 

Novartis Confidential Page 38
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Generally  all changes demonstrated either reversibility  or a clear tendency  towards reversibility .
In the rat, there was no evidence of teratogenicity  however ribociclib was embry ofetotoxic. 
Data from a rabbit embry ofetal development study , shows that ribociclib is teratogenic in the 
rabbit in the absence of maternal toxicity .
1.2.1.1.3 Nonclinical pharmacokinetics and metabolism of ribociclib
The pharmacokinetics (PK) of ribociclib was investigated in mouse, rat, dog and monkey . 
Ribociclib showed high clearance (CL) in the mouse, rat, dog and monkey . The volume of 
distribution was large across species and the terminal elimination half-life (T1/2) was moderate 
in rodents and monkey  (~2 to 5 h) and longer in dog (18 h). Bioavailability  was low to moderate 
in rat (37%) andcy nomolgus monkey  (17%); moderate in mouse (65%) and dog (64%). 
Following oral administration, time to reach maximal plasma concentrations (Tmax) occurred 
between 2 to4 h across species. Gender dependent toxicokinetics were observed in rats with 
higher exposure to ribociclib in males as compared to females and higher exposure to the 
metabolite, LEQ803. Plasma protein binding was moderate in all species (unbound fraction (fu) 
in human: 30%).
In a  r at ADME (absorption, distribution, metabolism and excretion) study , extensive 
distribution of [3H]L EE011 and its metabolites was observed. In pigmented rats, radioactivity  
was specificall y found in melanin -containing structures ; the highest exposure to total 
radiolabeled components was observed in ey e ciliary  body , eye choroid, meninges, tactile hair 
and hair follicles. Radioactivity  was not detected in the brain. LEQ803 (N -demethy lation) was 
a prominent metabolite found in mouse, rat, dog, monkey  and human hepatocy tes. This 
metabolite retains some pharmacologic activity  and interacts with human Ether -a-go-go Related 
Gene (hERG) channels in vitro. 
Results from the ADME (male rats) study  showed that 3H-components were predominant ly 
excreted with bile (61.4% of dose). Minor urinary  excretion was observed (5.9% of dose after 
p.o.). The majority  of the administered dose (87.3%) was excreted within 24 h via urine, feces 
(enteric secretion) and bile.
In vitro, ribociclib was a reversible inhibitor of cytochrome P450 (CYP) enzy mes CYP1A2, 
CYP2E1 and CYP3A4 and a time-dependent inhibitor of CYP3A4. Ribociclib may inhibit
CYP3A4 under therapeutic conditions. No induction of CYP1A2, CYP2B6 or CYP3A4 was 
observed. The in vitro inhibitory  potency  of ribociclib observed for the transporters OATP1B1 
(organic anion transporting pol ypeptide 1B1), BCRP (breast cancer resistance protein), OCT1 
(organic cation transporter 1), OCT2, MATE1 (multidrug and toxin extrusion protein 1), 
MATE2K and BSEP (bil e salt export pump) may  translate into clinically  relevant inhibition at 
therapeutic doses. Elimination of ribociclib is dominated by oxidative metabolism mainly  via 
CYP3A4 with a minor contribution by flavin -containing monooxy genase 3 (FMO3). The 
eliminat ion of ribociclib may be affected by co-administered drugs that inhibit or induce 
CYP3A4. Although ribociclib is a substrate of the P -glycoprotein (P-gp) efflux transporter, this 
process islikely  not clinically  relevant due to the high passive permeabilit y of ribociclib.
1.2.1.2 Clinical experience
Ribociclib is currentl y being investigated in patients as a single agent in 3phase I studies ,in 2 
phase II studies and in combination in 15studies: 12phase Ib/II studies and 3 randomized phase 

Novartis Confidential Page 39
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
III studies. Four studies, were closed for enrollment: a randomized phase II study ; a phase I 
dose finding study ; a phase I study  in malignant rhabdoid tumors and neuroblastomas; anda 
phase Ib/II stud y in BRAF mutant melanoma. Ribociclib is also being investigated in 4 clinical 
pharmacology  studies: 3 clinical pharmacology  studies in healthy  subjects have been completed.
Details on ongoing studies can be found in the LEE011 (ribociclib ) [Investigator Brochure ].
In single agent trials, a total of 199patients have been treated: 157in study  [CLEE011X2101]
as of 15-Jun- 2015 (in a Caucasian population, including 85 in the dose escalation), 17in 
[CLEE011X1101] as of 28-Jan- 2015 (in Japanese patients, all in the dose escalation) and 32in 
[CLEE011X2102] as of 9-Apr- 2015 (in patients under the age of 21 years, all in the dose 
escalation). Please refer to the L EE011 ( ribociclib) [I nvestigator Brochure] for more details.
Ribociclib is being evaluated in a combination with fulvestrant and BKM120 (buparlisib) in an 
ongoing stud y [CLEE011X2108] as detailed in Section 1.2.3.
The combination of ribociclib (600 mg) with letrozole (
2.5 mg once daily)is being evaluated 
in an ongoing stud y [CLEE011A2301] ; as of 12 -Feb-2015, the stud y has enrolled 668 patients.
The safety  of 664 patients was reviewed at themost recent DMC on 07- Oct-2015, with the 
recommendation to continue the study unchanged .
1.2.1.2.1 Clinical safety of ribociclib
Single agent therapy :
As of 15-Jun- 2015, 157 patients have been treated with single agent ribociclib in the first-in-
human (FIH) phase I study ; 85 patients have been treated in the initial dose escalation part for 
the 3 weeks on/1 week off regimen and 47 patients in the dose e xpansion part of the study ; 18 
patients were enrolled for the continuous dosing regimen with ribociclib and, 7 patients were 
enrolled in the liquid formulation cohort.
Patients with advanced solid tumors or lymphomas were treated with increasing doses of 
ribociclib orally, once daily  (qd) for 21 days followed by a 1-week rest (28-day cycle). Doses 
ranging from 50 mg to 1200 mg were evaluated on this schedule. Treatment has been 
discontinued in 120 (90%) patients; the primary reasons for treatment discontinuation were: 
disease progression (
106 [80 %] patients); adverse events (AEs) (7 [5%] patients); death (2 
[1.5%] patients); withdrawal of consent (3 [2%] patient); and loss to follow up (1 [1%] patient).
The most frequently  reported AEs (≥10%), regardless of grade, causality  and ribociclib dose 
were: nausea (52.3%); fatigue ( 40.9%); diarrhea (37.1%); vomiting (35.6 %); neutropenia 
(
34.1%); anemia (32.6 %); decreased appetite (23.5%) ,thrombocy topenia (23.5%);white blood 
cell count decrease (22.7%); leukopenia (
22%); constipation ( 21.2%); dyspnea (20.5 %); 
asthenia (19.7%); cough (18.2%); hypergly cemia ( 17.4%); headache, hypoalbuminemia 
(16.7% each);ECG QT prolonged (15.9%); abdominal pain , back pain, lymphocy te count 
decrease, pyrexia (15.2% each); AST increase , blood creatinine increased, dizziness, 
lymphopenia (14.4% each) , peripheral edema (13.6%) , neutrophil count decreased (12.9%); 
ALT increase; pain in extremity  (12.1% each) and hy pocalcemia ( 11.4%).
For either continuous or intermittent dosing, the onset of neutropenia (most frequently  Grade 
2) typ ically  occurs b y Da y 15, reaching a nadir in the third or fourth week with recover y during 
the week of drug holiday for the three weeks on/one week off schedule . Some patients require 

Novartis Confidential Page 40
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
additional time for recovery  (7 to 14 days). QT changes become evident in the first cycle by 
Day 8 and later (once stead y state is reached), are associated with the maximum drug levels 
between 1 to 8 h post -dose, and remain stable or improve in subsequent cycles.
As of 15-Jun- 2015 , asymptomatic Grade 2 QTcF prolongation was observed with increasing
frequency  when increasing the dose, starting at 600 mg: tenpatients (13.5%) in the 600 mg 
cohort, three patients (21%) in the 750 mg cohort, four patients (31%) in the 900 mg cohort, 
and two patients (67%) in the 1200 mg cohort. Fourpatients ( 5.4%) at 600 mg and two patients 
(15%) at 900 mg had as ymptomatic QTcF prolongation that resulted in a QTcF interval of 500 
ms or more. As compared to baseline value, QTcF prolongation was at least 30 msec in 2 
patients (50%) at 250mg, 2 (40% ) at 350 mg and 400 mg, 59
(79.7%) at 600 mg, 11 (78.6%) at 
750 mg, 11 (85%) at 900 mg and 2 (67%) at 1200 mg; and at least 60 msec in 23%, 0%, 39% 
and 67% of patients at 600 mg, 750 mg, 
900 mg and 1200 mg, respectively . One grade 1 
atrioventricular block of first degree was reported as related to ribociclib given at the dose of 
140 mg. No other cardiac abnormalities were observed as related adverse events in any  patient .
There have been no deaths related to study  drug reported on study  [CLEE011X2101] . The 
following serious adverse events shown in Table 1-1have been reported with a suspected causal 
relationship in study  [CLEE011X2101] as 
of 6 - Aug-2015. For a complete list of AEs, all grades 
and Grade 3/4that are suspected to be related to ribociclib refer to the LEE011 (ribociclib) 
[Investigator Brochure] .
Table 1
-1 Serious adverse events with a suspected causal relationship with 
ribociclib single agent
Serious suspected adverse events which have occurred with ribociclib (single agent)
System Organ Class Preferred Term Preferred Term
Blood and lymphatic system disorders Anaemia, Febrile neutropenia,
Neutropenia,Thrombocytopenia
Gastrointestinal disorders Diarrhoea, Nausea, Pancreatitis
General disorders and administration site conditions Generalized oedema
Infections and infestations Herpes simplex
Investigations Blood creatinine increased , Electrocardiogram QT 
prolonged
Events in italic fontindicate those events which are newly  included since the previous edition 
of the reference safet y information.
Refer toLEE011 (r ibociclib ) [Investigators Brochure] for more deta ils.
1.2.1.2.2 Clinical efficacy of ribociclib
Preliminary  anti-tumor activity  of ribociclib from an ongoing Phase I trial [CLEE011X2101]
was assessed across all dose levels (50 mg –1200 mg). Out of 114 evaluable subjects as of 24 -
Apr-2014, 3 partial responses were observed at the 600 mg dose level; one each in BRAF/NRAS 
wild type with CCND1 amplified melanoma, and head and neck acinar carcinoma with 
CDKN2A loss (both on the 3 weeks on/1 week off regimen), and ER+/HER2, PIK3CA mutant, 
CCND1 amplified breast cancer (on the continuous daily dosing regimen) LEE011 ( ribociclib) 
[Investigator Brochure]. Stable disease (SD) was the best overall response in 41 (37%) patients. 
Stable disease ≥4 cycles and ≥6 cycles was observed in 26 (24%) and 17 (15%) patients, 

Novartis Confidential Page 41
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
respectivel y. Six patients with SD ≥4 cy cles received treatment for >1 year, of these 2 patients 
were on study  for >2 years (Jeffrey  R Infante ASCO 2014 abstract 2528). Refer to ribociclib 
[Investigators Brochure] for more details.
1.2.1.2.3 Clinical pharmacokinetics of ribociclib
The pharmacokinetics of ribociclib 
have been evaluated following single and repeat daily  doses 
in the ongoing single agent, phase I study  in patients with advanced solid tumors or lymphomas 
[CLEE011X2101] . Following oral administration of ribociclib, peak plasma concentrations 
(Cmax) are achieved at approximately  1-4 hours post -dose. Ribociclib plasma exposure (Cmax  
and AUC0- 24h) demonstrates slightly  over -proportional increases across the dose range tested 
(50 to 1200 mg ).Stead y-state is generall y reached by  Day  8 and the mean effective T1/2 base d 
on accumulation ratio (i.e., T1/2,acc) ranged from 12.3 to 42.9 hours across the dose range 
tested. The mean accumulation ratio (Racc) calculated from AUC0 -24h at stead y-state and 
AUC0 -24h after a single dose across the studied doses ranged from 1.35 to 3.11. At the 
recommended dose for future development (600 mg), stead y
-state plasma Cmax (n=56) ranges 
from 606 -6170 ng/mL (geometric mean = 1790 ng/mL or 4.1 µM), median Tmax (n=72) is 2.1 
h, and AUC0 -24h (n=53) ranges from 6770- 90600 ng*h/mL (geometric mean = 23600 
ng
*h/mL). At this dose, inter-patient variability  in Cmax and AUC is 62% and 66%, 
respectivel y, as assessed by geometric coefficient of variation (CV% ). At the 600 mg dose level, 
LEQ803, an active metabolite of ribociclib, acco unted for approxi mately  8% (geometric mean) 
of ribociclib AUC0 -24h after single and multiple doses. Refer to the LEE011 (ribociclib ) 
[Investigators Brochure] for more details. In the human ADME study  [CLEE011A2102], a 
single oral dose of 600 mg [14C]LEE011 was administered to 6 health y male subjects. The 
majority  of the administered dose was excreted in feces (69.1%), with a minor amount excreted 
in urine (22.6%). Absorption was estimated to be approximately  58.8%. Ribociclib accounted 
for approximately  23% of the total radi oactivity  in plasma, based on AUCinf. Metabolites M1 
(glucuronidation of M15), M4 (LEQ803, N
-demeth ylation) and M13 (CCI 284, N-
hydroxylation) were the most abundant metabolites in plasma, representing an estimated 7.78%, 
8.60% and 9.39% of total [14C]AUC0- 48h, and 17.9%, 19.8% and 21.6% of ribociclib AUC0 -
48h, based on metabolite profiles. In a food effect study  [CLEE011A2111] in 24 health y 
subjects, a single dose of ribociclib (600 mg) was administered as drug-in-capsule (DiC) with 
a high-fat, high-calorie meal and under fasted conditions. Compared to the fasted state, oral 
administration of a single 600 mg dose of ribociclib DiC with a high-fat, high calorie meal 
decreased the rate of absorption resulting in a 23% decrease in Cmax (geometric mean ratio: 
0.775; 90% confidence interval [CI]: 0.700, 0.858) and a median difference in Tmax of 2 hours.
However, there was no effect o n the extent of absorption as the overall exposure (AUCinf) was 
unaffected under fed conditions (geometric mean ratio: 0.994; 90% CI: 0.925, 1.070). A similar 
trend was observed for LEQ803, an active metabolite of ribociclib, with a decrease in Cmax 
(32%), a delay  in median Tmax, and no substantial effect on overall exposure. Results from this 
study  indicate the DiC can be taken without regard to meals. Refer to the LEE011 (ribociclib ) 
[Investigators Brochure] for more details.
A DDI study  with ritonavir (astrong CYP3A4 inhibitor) and rifampicin (a strong CYP3A4 
inducer) was conducted in 48 healthy  subjects [CLEE011A2101] . Compared to ribociclib alone, 
ritonavir (100 mg bid for 14 days) increased ribociclib Cmax and AUCinf by  1.7-fold and 3.2-
fold, respecti vely, following a single oral dose of 400mg ribociclib . Cmax and AUClast for 

Novartis Confidential Page 42
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
LEQ803 decreased by  96% and 98%, respectivel y. These results demonstrated that concurrent 
use of strong CYP3A4 inhibitors may markedl y increase ribociclib exposure and are prohibited.
Compared to ribociclib alone, rifampicin (600 mg daily for 14 days) decreased ribociclib Cmax 
and AUCinf by  81% and 89%, respectivel y, following a single oral dose of 600 mg ribociclib . 
LEQ803 Cmax increased 1.7-fold and AUCinf decreased by 27%, respectively .These results 
demonstrated that concurrent use of strong CYP3A4 inhibitors or strong CYP3A4 inducers may 
markedl y decrease ribociclib exposure and are prohibited .
A DDI cocktail stud y wit h midazolam (a sensitive CYP3A4 substrate) and caffeine (a sensitive 
CYP1A2 substrate) conducted in 25 healthy subjects [CLEE011A2106] indicated that 
ribociclib (400 mg) is a moderate inhibitor of CYP3A4, but did not have a substantial effect on 
CYP1A2 substrates in humans . PK data indicate dthat compared to midaz
olam and caffeine 
alone, multiple doses of ribociclib (400 mg qd for 8 days) increased midazolam Cmax and 
AUCinf by 2.1-fold and 3.8-fold, respectivel y. The effect of multiple doses of ribociclib on 
caffeine was minimal, with Cmax decreased by approximatel y 10% and AUCinf increased 
slightly  by 20%. Based on these data, ribociclib (400 mg) is a moderate CYP3A4 inhibitor (≥ 
2-fold but < 5-fold increase in AUC) . Concurrent use of sensitive CYP3A4 substrates with a 
narrow therapeutic index is prohibited. Riboc iclib (400 mg) did not have a substantial effect on 
CYP1A2 in humans ; therefore concurrent use of CYP1A2 substrates is not expected to lead to 
clinically  significant DDIs. 
Refer to the LEE011 (r ibociclib ) [Investigators Brochure] for more details.
1.2.2 Overview  of fulvestrant
Fulvestrant is a unique estrogen receptor down regulator with no known agonist effects ( Addo 
et al 2002). Fulvestrant’s mechanism of action is distinct from other endocrine agent s (Wakeling 
et al 2000 ); it binds, blocks and, unlike tamoxifen or other SERMs, degrades the estrogen 
receptor, completel y inhibiting estrogen receptor signaling. As a result, there is less chance of 
the estrogen receptor being activated by alternative pathway s that are believed to cause 
resistance (e.g. growth factor
-mediated mechanisms) ( Nicholson et al 2005).
Fulvestrant (FASLODEX®) is a first in class endocrine agent that was approved at the dose of 
500mg for the treatment of postmenopausal women with HR+ advanced BC who have failed 
on prior anti-estrogen therap y. This approval was based on data from the CONFIRM study 
which demonstrated that 500 mgof fulvestrant showed better progression free survival 
compared to 250 mgfor postmenopausal women with estrogen receptor –positive advanced 
breast cancer who experienced progression after prior endocrine therap y (Di Leo 2010; Di Leo 
2014). More specificall y, in that trial, subgroup analysis showed that PFS was prolonged in 
patients who had recurred or relapsed during anti-estrogen therapy  (median PFS 8.6 vs. 5.8 
months; HR 0.76; 95% CI: 0.62- 0.94; p=0.013) or during AI therap y although not reaching 
statistical significance for the latter (median PFS 5.4 vs. 4.1 months; HR 0.85; 95% CI: 0.67 -
1.08; p=0.195) (FASLODEX®prescribing information ) . Median OS was 26.4 months for 
fulvestrant 500 mg and 22.3 months for 250 mg (HR 0.81; 95% CI 0.69 –0.96; p=0.02) ( DiLeo 
2014 ).
Fulvestrant has also been inves tigated as a first -line therap y in the phase II, randomized FI RST 
study (Fulvestrant First-Line Study  Comparing Endocrine Treatments) where fulvestrant 500 

Novartis Confidential Page 43
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
mg was compared to anastrozole in postmenopausal women with HR+ advanced breast cancer 
who received no prior endocrine therapy . When 79.5% of patients had discontinued study 
treatment, the median TTP for fulvestrant was 23.4 months versus 13.1 months for anastrozole 
(HR 0.66; 95% CI:0.47, 0.92; p=0.01). The best overall response to subsequent therapy  and
clinical benefit rate for subsequent endocrine therapy  were similar (Robertson 2012). Recent 
median OS data, with analy ses conducted at 66.8% maturity  showed 54.1 months for fulvestrant 
and 48.4 months for anastrozole (HR 0.70; 95% CI 0.5-0.98; p=0.041) (Ellis et al 2015, 
Robertson SABCS abstract 2014). Fulvestrant at the dose of 250 mg has also demonstrated 
efficacy  similar to tamoxifen in the first line setting of HR+ breast cancer tumors (78% of the 
study  population in a preplanned subset analysis) where median TTP was 8.2 months for 
fulvestrant and 8.3 months for tamoxifen (HR 1.10; 95% CI: 0.89- 1.36; p=0.39) (Howell 2004). 
The difference in 
these TTPs for fulvestrant may be attributed to the higher dose of 500 mg 
since findings from clinical, biological studies and PK modeling suggested that fulvestrant at 
an increased dose could further increase the clinical efficacy  (Robertson 2004). FALCON
(
Fulvestrant and Anastrozo Le COmpared in hormonal therap y Naïve advanced breast cancer ; 
clinicalt rials.gov identifier: [STUDY_ID_REMOVED]) is a randomized phase III study  comparing 
fulvestrant (500 mg) with anastrozole for postmenopausal women who have not previously 
been treated with any hormonal therap y in the metastatic setting. This study  has completed 
e
nrollment in September 2014 and results are still pending.
Clinical safety  of fulvestrant
The most common clinically significant adverse reactions occurring in ≥5% of patients
receiving fulvestrant 500 mg were: injection site pain, nausea, bone pain, arth ralgia, headache, 
back pain, fatigue, pain in extremity , hot flash, vomiting, anorexia, asthenia, musculoskeletal 
pain, cough, dyspnea and constipation. Please refer to the local SmPC for pooled safet y data for 
fulvestrant 500 mg data.
1.2.2.1 Clinical pharmacokin etics of fulvestrant
Fulvestrant is slowl y absorbed after administration of 500 mg intramuscularly  (long-acting 
formulation). Maximum plasma concentrations are reached after about 5 days. Steady -state is 
achieved within the first month of dosing, if an add itional dose is given 2 weeks after the initial 
dose. At steady -state there is more than a 2-fold difference between mean Cmax and Cmin. 
After intramuscular administration, the exposure is approximately  dose proportional in the dose 
range of 50 to 500 mg. Fulvestrant is subject to extensive and rapid distribution and is 
eliminated mainly  by metabolism. The major route of excretion is via 
the feces with less than 
1% being excreted in the urine. Fulvestrant has a high clearance, suggesting that it is a drug 
with high extraction ratio. The terminal half -life after intramuscular administration is governed 
by the absorption rate and was estimated to be 40 -50 day s.
Increased exposure to fulvestrant was observed in patients with moderate hepatic impairment 
(Child -Pugh class B). Fulvestrant has not been administered to patients with severe hepatic 
impairment (Child -Pugh class C) (FASLODEX®prescribing information ). Therefore, patients 
with Child -Pugh class B and Cwill not be enrolled. No dose reductions for fulvestrant will b
e 
allowed in study  CLEE011F2301.

Novartis Confidential Page 44
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
1.2.3 Overview  of ribociclib in combination with fulvestrant
Ribociclib and fulvestrant have the following toxicities in common: nausea, fatigue, vomiting, 
decreased appetite, constipation, dyspnea, cough, AST increase, headache, and back pain. 
These overlapping adverse events are expected to be tolerable and manageable.
In addition, there are no known drug interactions with fulvestrant. In vitro studies showed no 
relevant inhibition of the major CYP enzy mes, including CYP1A2, 2C9, 2C19, 2D6 or 3A4 by 
fulvestrant. The lack of inhibition of CYP3A4 was confirmed in an in vivo interaction study 
with midazolam. I n addition, interaction studies with rifampicin (strong CYP3A 4 inducer) and 
ketoconazole (strong CYP3A4 inhibitor) demonstrated no effect on fulvestrant 
pharmacokinetics (FASLODEX®prescribing information ) . Therefore, a drug-drug interaction 
(DDI) involving fulve strant and ribociclib is unlikely  to occur.
The combination of ribociclib and fulvestrant is currently  being explored in study 
[CLEE011X2108] . This is an open -label Phase Ib/II study  in postmenopausal women with 
locally  advanced or metastatic HR+/HER2
-BC. The phase Ib dose escalation includes triple 
combination arms of ribociclib + BKM120 (pan-PI3K) + fulvestrant and ribociclib + 
BYL719(PI3K -alpha) + fulvestrant and a dose confirmation arm with ribociclib + fulvestrant.
As of 05-Jun- 2015 , a total of 13 pa tients have been treated with the combination of ribociclib
(600 mg daily  on Day  1-21 of each 28 -day cycle)  andfulvestrant (500 mg every  28 day s with 
1 additional dose on Day 15 of Cycle 1)in study [CLEE011X2108] . Seven patients 
discontinued treatment, 1 adverse event was the reason for end of treatment and in the other 6 
patient due to progressive disease. All patients have completed the first 28 days cycle. Of these 
7 evaluable patients, there were no dose adjustments, interruptions or dose limiting toxicities. 
Grade 2/3 neutropenia was observed in 6 of the 7 patients. As of 04-Feb-2015, 5 patients are 
continuing to be treated with this combination, and 6 out of 7 patients have been exposed to the 
combination for more than 140 days.One patient met thedose limiting toxicity  criteria wih a 
Grade 3 pulmonary  embolism on Cycle 1. One patient discontinued after being hospitalized 
during Cycle 7 for Grade 4 atrial fibrillation, which was a serious adverse event and was 
suspected to be treatment related. Another patient discontinued at Cycle 5 due to progressive 
disease .
Table 1-2contains the adverse events presented in more than 2 patients treated with the 
combination of ribociclib plus fulvestrant in [CLEE011X2108] and suspected to be study  drug 
related.
Table 1
-2 Adverse events suspected to be study  drug related in 
[CLEE011X2108]
Table below is update with data including a cutoff incidence of more than 15%
All grades Grade 3/4
Preferred term n (% ) n (% )
-Total 13 (100) 11 (84.6)
NEUTROPENIA 9 (69.2) 8 (61.5)
FATIGUE 9 (69.2) 2 (15.4)
NAUSEA 6 (46.2) 0

Novartis Confidential Page 45
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
ANAEMIA 6 (46.2) 0
DECREASED APPETITE 5 (38.5) 0
WHITE BLOOD CELL COUNT 4 (30.8) 2 (15.4)
DIARRHOEA 4 (30.8) 0
VOMITING 3 (23.1) 0
THROMBOCYTOPENIA 3 (23.1) 0
ALANINE AMINOTRANSFERASE 2 (15.4) 1 (7.7)
ASPARTATE AMINOTRANSFERASE 2 (15.4) 1 (7.7)
PRURITUS 2 (15.4) 0
PLATELET COUNT DECREASED 3 (23.1) 0
DYSGEUSIA 2 (15.4) 0
ELECTROCARDIOGRAM QT 2 (15.4) 0
NEUTROPHIL COUNT DECREASED 2 (15.4) 2 (15.4)
BLOOD CREATININE INCREASED 2 (15.4) 0
LYMPHOCYTE COUNT DECREASED 2 (15.4) 0
ORAL PAIN 2 (15.4) 0
Preliminary  results of ribociclib in combination with fulvestrant suggest that this combination 
is safe and tolerable. Preliminary  PK anal ysis suggests that ribociclib (600 mg) and fulvestrant 
(500 mg) exposures were not affected in combination treatment. The best response for all 7 
(100%) patients has been stable disease thus far. 
Refer to the LEE011 (r ibociclib ) [Investigators Brochure] for more details.
2 Rationale
2.1 Stud y rationale and purpose
The rationale for combining ribociclib with fulvestrant is based onfindings that a significant 
number of HR+, HER2- negative breast cancer patients are expected to have, or develop, 
resistance to endocrine therapies that have been given in the adjuvant or first line metastatic 
setting, and CDK4/6 pathway  alterations appear to play a key role in the development of this 
resistance. Two related emerging mechanisms of endocrine resistance include the decoupling 
of cell cycle control from ER-signaling and the utilization of alternate growth signaling 
pathway s such as the P I3K pathway  (Miller et al 2011; Lange and Yee 2011 ). By  targeting two 
distinct pathway s (ER antagonism by  fulvestrant, CDK4/6 pathway  inhibition by  ribociclib), it 
is hypothesized that this combination will result in prolonged progression free survival. 
Preclinically , improved responses have 
been shown with the addition of ribociclib to fulvestrant 
in various cell lines. Clinical experience has helped characterizing ribociclib safet y profile and 
supported the initiation of phase III trials. A large number of patients have now been treated 
with ribociclib in phase I -III trials with an extensive number of patients having been exposed 
to doublet combina tion of ribociclib with endocrine therapy  ([CL EE011X2107] , 
[CLEE011X2108] , [CL EE011X2106] [CLEE011A2301] ).
Preclinical data (Novartis internal data, Figure 2 -
1), along with preliminary clinical safet y and 
tolerability  data from study [CLEE011X2108] (Section 1.2.3) for the combination of ribociclib 
and fulvestrant, support the conduct of this study .

Novartis Confidential Page 46
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Figure 2-1 Ribociclib plus fulvestrant in ER+ breast cancer xenograft models
The purpose of this study is to determine whether treatment with ribociclib plus fulvestrant will 
result in an improved clinical benefit compared to fulvestrant and placebo inmen and 
postmenopausal women with HR+, HER2 -negative advanced breast cancer who have received 
no or only  one prior endocrine treatment for advanced disease.
2.2 Rationale for the study  design
This is a randomized, placebo - control led two-arm study  with the objective to evaluate the 
efficacy  and safet y of adding ribociclib to fulvestrant in men and postmenopausal women with 
advanced breast cancer. The randomized, double -blind, placebo controlled, multicenter, parallel 
group design is the gold standard for phase III trials as it minimizes allocation bias, balancing 
both known and unknown prognostic factors in the assignment of treatments.
A randomization ratio (ribociclib+fulvestrant vs placebo+fulvestrant) of 2:1 is selected, since 
the efficacy  and safet y of fulvestrant is well characterized, a 2:1 randomization will allow a 
better evaluation of efficacy  and safety  of the ribociclib+fulvestrant combination. 
Randomization will be stratified b y the following factors (see Section 4.1 for further details):
1.Lung or liver metastases (yes versus no)
2.Previous endocrine therapy
The stratification factors are selected because of their well -recognized prognostic value.
2.3 Rationale for dose and regimen selection
The ribociclib dose and regimen selected for this study  is 600 mg daily  21 day s on/7 day s off. 
In the FIH study  of single agent ribociclib in adult patients with solid tumors [CLEE011X2101] , 
the MTD of ribociclib was 900 mg QD with a 3 weeks on/1 week off schedule. The 
recommended dose for future development was 600 mg QD with a 3 weeks on/1 week off 
schedule, which showed an acceptable safety profile, low risk for QTcF prolongation, adequat
e 
exposure, and preliminary evidence of disease stabilization as single agent. In the phase III 
study  of ribociclib/placebo (600 mg) combined with letrozole (2.5 mg once daily) in 
postmenopausal women with advanced breast cancer HR+ HER -2 negative [CLEE011A2301],

Novartis Confidential Page 47
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
the  DMC which took place on October 7, 2015 and reviewed safety of 664 patients  , 
recommended to continue the study  without changes.
Fulvestrant will be administered at the dose according to its approved label, 500 mg IM as two 
250 mg 5 ml inject ions (one in each buttock) on days 1, 15, 29 and then monthly  thereafter 
(FASLODEX®prescribing information ).
Based on available data from preliminary  results of patients treated with the combination of
ribociclib at 600 mg and fulvestrant at 500 mg in study  [CLEE011X2108] ,the combination is 
tolerable and a DDI between ribociclib and fulvestrant is unlikely . Therefore, these doses will 
also be used in this study.
2.4 Rationale for choice of combination drugs
Recent clinical data indicate that inhibitors of CDK4/6 are active in advanced ER+ breast cancer. 
Fulvestrant is acknowledged as an acceptable therapy  in the first-line metastatic setting (Cruz 
Jurado 2011) and is approved after failure to prior antiestrogen therap y. In this study , we 
propose to use ribociclib, which directl y targets pRb to interfere with the proliferation cycle, in 
combination with fulvestrant to prolong PFS in HR+, HER2
-negative postmenopausal women 
with advanced breast cancer who have received no prior therapy  or only one line of prior 
endocrine treatment for advanced disease.
The rationale to combine ribociclib with fulvestrant is based on the following:
Preclinical data demonst rating additional benefit of the combination of CDK4/6 inhibition 
by ribociclib and estrogen pathway  inhibition by fulvestrant compared to single agent 
activity  (Section 2.1 )
The efficacy  of fulvestrant in this patient population ( Section 1.2.2)
Preliminary  safety findings of the combination of ribociclib and fulvestrant in study  
[CLEE011X2108]
The low likelihood of a drug-drug interaction between rib
ociclib and fulvestrant and 
preliminary  PK data from [CLEE011X2108] suggesting no changes in exposures .
2.5 Rationale for choice of comparator drugs
Patients enrolled in the study  will either be in first line or in second line for the treatment of 
their metast atic disease.
In first line setting, currently  approved treatment options include tamoxifen, AI or letrozole in 
combination with palbociclib ( Section 1.1.2).
The recentl y presented data from the FIRST study, conducted in HR+ HER2
-negative advanced 
breast cancer patients with no prior endocrine therapy  or with long DFS after adjuvant endocrine 
therap y, showed superiority  of fulvestrant 500 mg compared to anastrozole ( Robertson 2014, 
Ellis 2015). Despite methodological limitations linked to indirect comparisons, the benefit 
brought by fulvestrant over anastrozole appears to be of the same extent than the one brought 
by the addition of palbociclib to letrozole -the results of both studies are being confirmed by 
phase 3 trials (Falcon and Paloma 2). Taken together, these data support fulvestrant 500 mg as 
an acceptable therap y in the first -line metastati
c setting.

Novartis Confidential Page 48
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
In second line setting, several acceptable options are available (NCCN 2.2015) and include 
Fulvestrant. In addition, Fulvestrant is currentl y approved for the treatment of HR+ 
MBC in 
postmenopausal women with disease progression following anti-estrogen therap y. Hence, 
fulvestrant is considered a standard therapy  for patients who have progressed on or after 
treatment with other endocrine agents and who require a well- tolerated alternative therap y 
(Ciruelos 2014).
In conclusion, fulvestrant at the selected dose of 500 mg given intramuscularly  at one month 
intervals, with an additional 500 mg dose given 2 weeks after the initial dose, is considered an 
appropriate comparator arm for this study .
2.6 Risks and benefits
2.6.1 Potential benefits to clinical trial participants
All patients enrolled in this trial will receive an active and valid endocrine therap y for first and 
second line treatment ofmen and post-menopausal women (see Section 2.5). They  will be 
randomized to receive in addition ribociclib or placebo. Based on preclinical and preliminary 
clinical data (see Section 1.2.3), treatment with ribociclib in combination with fulvestrant is 
expected to be well tolerated and it is hypothesized that it will result in delay ed disease 
progression b y inhibiting proliferation of endocrine -resistant breast cancer cells.
2.6.2 Potential risks to clinical trial participants
Patients in this study  will be carefull y monitored for key toxicities that have 
been observed with 
ribociclib (see Section 1.2.1.2.1), fulvestrant (see Section 1.2.2 ) or the combination of both (see 
Section 1.2.3) with the following assessments (see Section 7): periodic laboratory , renal and 
liver function, urinal ysis and ECG.
Risk will be further minimized by adherence to inclusion/excl usion selection criteria (see 
Section 
5), avoidance of prohibited medication (see Section 6.6.3), close safety  monitoring (see 
Section 8 ) and dose adjustment guidelines ( see Section 6.5 and current fulvestrant prescribing 
information (FASLODEX®prescribing information ). PK sampling will be conducted in 
patients to assess plasma concentration of the study  drug to evaluate any potential drug 
interaction. An independent data monitoring committee (IDMC )
(see Section 8.6 ) will be constituted and will monitor safet y, efficacy  and available PK data as 
outlined in the protocol. A Steering Committee (SC) (see Section 8.7) will be established 
comprising of investigators and Novartis personnel participating in the trial to ensure 
transparent management of the trial according to the protocol. A Novartis Safety  Management 
Team (SMT) periodicall y reviews and evaluates all emerging data across the ribociclib program 
for potential safety  signal assessment in a timely  manner.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3
-1below.

Novartis Confidential Page 49
Amended Protocol Version 03 (Clean) Protocol No. CLEE011F2301
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary Refer to Section 10.4
To compare PFS between ribociclib in combination 
with fulvestrant to placebo in combination with 
fulvestrant among men and postmenopausal women 
with HR+, HER2 -negative advanced breast cancer 
who received no or only one prior endocrine 
treatment for advanced diseaseThe primary end point is PFS based on local radiology assessments and 
using RECIST 1.1 criteria
Secondary Refer to Section 10.5
To compare the two treatment arms with respect to 
overall survival.Overall survival
To evaluate the two treatment arms with respect to 
overall response rate, clinical benefit rate, time to 
response and duration of response. ORR and as defined by RECIST 1.1. CBR, defined as percentage of 
patients with CR, PR or SD lasting 24 weeks or long er, TOR, DOR per 
RECIST 1.1
To evaluate the two treatment arms with respect to 
time to deterioration of ECOG performance status.Time to definitive deterioration of ECOG performance status from 
baseline
To evaluate the safety and tolerability of ribociclib in 
combination with fulvestrant.Frequency/severity of AEs, laboratory abnormalities
To evaluate patient reported outcomes for health -
related quality of life in the two treatment arms.Time to 10% deterioration in the global health status/QOL scale score of 
the EORTC QLQ -C30
Change from baseline in the global health status/QOL scale score of the 
EORTC QLQ -C30
To characterize the pharmacokinetics (PK) of 
ribociclib (and relevant metabolites such as LEQ803) 
when given in combination with fulvestrant.Concentration by time point for ribociclib (and relevant metabolites such 
as LEQ803)

Novartis Confidential Page 50
Amended Protocol Version 03 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 51
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
4 Study  design
4.1 Description of study  design
This is a randomized, phase III, double blind, placebo controlled, international study  to 
determine the efficacy  and safety  of treatment with fulvestrant with ribociclib versus fulvestrant 
with placebo inmen andpostmenopausal women with HR+, HER2- negative advanced breast 
cancer. This study  will consist of 4 phases: screening (up to 28days), randomized treatment, 
post-
treatment disease progression follow- up, and post -treatment survival f ollow -up.
Approximately  660 patients will be randomly  assigned to one of the below treatment arms in a 
2:1 ratio.
Experimental arm (Arm A): fulvestrant (500 mg intramuscular [as two 5 mLinjections] on 
Cycle 1 Days 1 and 15 (C1D1 and C1D15), and on CnD1 thereafter) + ribociclib (600 mg 
by mouth once daily  for three weeks followed by  one week break, in a 28 -day cycle).
OR
Control arm 
(Arm B): fulvestrant (500 mg intramuscular [as two 5 m L injections] on Cycle 
1 Days 1 and 15 (C1D1 and C1D15), and on CnD1 thereafter) + placebo (by mouth once 
daily  for three weeks followed by  one week break, in a 28 -day cy cle).
Randomization will be stratified b y the following factors:
1.Lung or liver metastases: (y es versus no)
2.Previ ous endocrine therapy  according t o the below definition:
A) Patients treatment naïve for metast atic/advanced disease include:
i. Patients whose disease relapsed >12 months after completion of (neo)adjuvant 
endocrine therap y with no subsequent treatment f or ad vanced/metastatic disease,
OR
ii. Patients with de novo advanced/ metastatic disease (no prior exposure to 
endocrine therap y).
B) Patients who received up to 1 line of treatment for metastatic/advanced disease 
include:
i. Patients whose disease relapsed on or with in 12 months from completion of (neo) 
adjuvant endocrine therapy , with no subsequent treatment for advanced/metastatic 
disease,
OR
ii. Patients whose disease relapsed > 12 months from completion of (neo) adjuvant 
endocrine therap
y, and progressed on or after s ubsequent endocrine treatment for 
advanced/metastatic disease,
OR
iii. Patients with advanced/metastatic disease at the time of diagnosis that progressed 
on or after endocrine therapy for advanced/metastatic disease with no prior (neo) 
adjuvant treatment for ea rly disease

Novartis Confidential Page 52
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Prior exposure to endocrine therap y subcategories included in groups A and B, were collated 
based on mPFS or TTP. Subcategory  A grouped patients with PFS or TTP above 10 months 
(Paridaens etal. 2008 ; Mouridsen 2001 ; Robertson 2014 ; Finn 2015 ); whereas subcategory  B 
grouped patients with shorter PFS or TTP around 4 -6.5 months ( Di Leo 2012
; Dombernowsk y 
1998; Buzdar 1998 ; Johnston 2012 ).
Patients will be treated until disease progression, unacceptable toxicity , or discontinuation from 
the study  treatment for any other reason (seeFigure 4-1).PFS, as assessed by the local 
radiologists/investigators and using RECI ST 1.1 criteria will be the primary  endpoint. PFS as 
assessed through blinded independent central review will be used for supportive evidence of
the primary  efficacy  endpoint.
Figure 4 -1 Study  Design
*Following Protocol Amendment 4, study  participants are unblinded, with an opportunity  for 
those patients still on study  treatmen t in the placebo combination to cross -over to the LEE011 
combination . Cross -over is optional and will be conducted onl y upon documented consent of 
the study  patient.
An Independent Data Monitoring Committee (IDMC) will be constituted and will monitor 
safet y and efficacy  as outlined in Section 8.6and Section 10.7. A Steering Committee (SC) will 
be established comprised of investigators and Novartis personel participating in the trial to 

Novartis Confidential Page 53
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
ensure transparent management of the study  according to the protocol as outlined in
Section 8.7.
If the study  proceeds after a positive effect on PFS is declared (at final analysis of PFS), 
crossover to the experimental arm from the control arm is not permitted and investigators and 
patients will remain blinded to study  treatment; all pat ients will continue to be followed for OS 
until the final OS analy sis.
4.1.1 Screening phase
Men and postmenopausal women with HR+, HER2 -negative advanced breast cancer will be 
screened for eligibility  during the period up to 28days immediately  prior to startin g the 
combination of fulvestrant + ribociclib or fulvestrant + placebo on study  Day 1. During this 
time, the inclusion and exclusion criteria will be assessed and all screening assessments, 
laboratory  tests, and procedures will be performed. Requested tumo r tissue will be retrieved. 
Results of all screening/baseline evaluations must be reviewed by the investigator or his/her 
designee prior to patient enrollment into the study  in 
order to assure that all inclusion and 
exclusio n criteria have been satisfied.
All study  patients must be thoroughly  informed about all aspects of the study , including the 
study  agents, visit schedule, required evaluations, and all regulatory requirements for informed 
consent. The signed informed consent must be obtained to participa te in this study  prior to the 
performance of an y study-related activities. If the patient is unable to read, an impartial witness 
should be present during the entire informed consent discussion. Eligibility  will be determined 
according to the inclusion/exc lusion criteria as described in Section 5. A list of procedures to 
be performed at the time of screening is summarized in Table 7-1a. Patients must meet all 
eligibi lity criteria to be considered for enrollment in the study .
4.1.2 Treatment phase
Patient eligibility  will be checked once all screening procedures are completed. An eligibility 
review and confirmation will be embedded to the Interactive Response Technology  (IRT) 
system. Please refer to and comply  with detailed guidelines in the IRT manual. The IRT system 
will confirm the inclusion of eligible patients and randomize them in a 2:1 ratio to one of the 
two treatment groups described in Section 4.1.
Patients may continue study  treatment until disease progression, occurrence of unacceptable 
toxicity , withdrawal of consent by the patient, patient is lost to follow -
up, or the sponsor 
terminates the study . Patients will be followed for survival regardless of treatment 
discontinuation for any reason, and regardless of achieving the primary  endpoint, until the 
planned number deaths for final OS analy sis have been documented (except if consent is 
withdrawn or patient is lost to follow -up). An end of treatment visit will be performed when 
patients permanentl y discontinue study  treatment.
All patients will have PK sampling; a subset (of approximately  150 patients) will have sparse 
PK collections on 3 occasions while the remainder will have a single trough PK sample on 3 
occasions as detailed in Section 7.2.3.

Novartis Confidential Page 54
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Following protocol amendment 4 , study  participants will be unblinded, with an opportunity  for 
those patients still in the study  in thearm of placebo + fulvestrant to transition tothetreatment of 
ribociclib + fulvestrant. 
Crossover is optional and will be conducted onl y upon documented consent of the study  patient
and protocol amendment 4 approval .A list of proce dures to be performed is summarized in 
Table 7
-1b.
4.1.3 Safety  follow -up
After discontinuation of study  treatment, all patients will be followed for safety , AEs and patient 
reported outcomes which will be col lected until 30 days after last stud y therapy  administration, 
except in case of death, loss to follow up or withdrawal of consent. For details please refer to 
Section 7.1.5.
4.1.4 Efficacy  follow -up
Patients who discontinue treatment for reasons other than disease progression or withdrawal of 
consent for efficacy  follow -
up, will continue to be followed every  8 weeks for efficacy  (i.e., 
tumor assessments and patient reported outcomes) during the first 18 months, then every 12 
weeks until 36 months and thereafter as clinically indicated until disease progression, death, 
withdrawal of consent, loss to follow -up, subject/guardian decision. All scans will be acquired 
and analy zed for primary endpoint locall y and will be sent to the CRO designated by  Novartis 
for central imaging interpretation. If a patient starts a new anti-neoplastic treatment without 
withdrawing consent, the patient will continue to be followed for efficacy  according to above 
specified protocol schedule until disease progression, death, withdrawal of consent, loss to 
follow -up, or subject/guardian decision. For further details please refer to Table 7-1a andTable 
7-1b and Section 7.1.6 .
4.1.5 Survival follow -up
All patients will be followed for survival once they discontinue study  treatment and tumor 
evaluations until the final number of OS events have been reached or the study  is stopped for 
other reasons. Survival follow- up will be done every  12 weeks ± 1 week or earlier if a survival 
update is required to meet safety  or regulatory  needs. Survival information can be obtained by 
clinical visits or telephone calls (Section 7.1.7) until death, the patient is lost to follow - up, or 
the patient withdraws consent for survival follow -up.
4.2 Timing of interim analy ses and design adaptations
There is no planned efficacy interim anal ysis for the primary PFS endpoint. I nterim anal ysis of
the secondar yendpoint of OS will be performed i f PFS is statistically  significant .as detailed in 
Section 10.5.1 and Section 10.7.2.

Novartis Confidential Page 55
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
4.3 Definition of end of t he stud y
The end of the study  for a given patient is defined as when the patient permanently  discontinues 
study  treatment with ribociclib + fulvestrant or placebo + fulvestrant and all the end of trial 
procedures are completed.
If the primar y endpoint, PFS , is statistically  significant at the final PFS analysis, data collection 
will continue during survival follow -up and End of Study  will be declared after the final number 
of OS events are reached (or earlier if OS reaches statistical significance at the interim anal ysis 
for OS) and after all patients have discontinued study therap y and completed the safet y follow -
up period (until 30 day s after treatment discontinuation).
If the primary  endpoint, PFS, is not statistically  significant at the final PFS analysis then End 
of Study  will be declared after all patients have discontinued study  therap y andcompleted the 
safet y follow- up period (until 30 day s after treatment discontinuation).
Patients continuing to derive benefit from study treatment at the end of the study  in the opinion 
of the investigator will be able to continue receiving trial therapy  on a separate protocol. 
Alternativel y Novartis will provide study treatment to the investigator as per local regulations.
Following with protocol amendment 4 and the statistically  significant OS benefit demonstrated 
at the 2ndOS analy sis, study  participants will beunblinded with an opportunity  for those patients 
still on study  in the arm of placebo + fulvestrant to transition to arm of ribociclib + fulvestrant. 
Cros sover is optional and will be conducted only upon documented consent of the study  patient. 
The study  will be closed when all study  patients have either discontinued study  treatment and 
completed the safet y follow -up period, withdrawn consent, are lost to follow -up, or as soon as 
arrangements are made for ongoing access to study  treatment for all patients still on study  
treatment, whichever happens first.
4.4 Early study  termination
The study  can be terminated at any time by Novartis. Should this be necessary , the patient 
should be seen as soon as possible and the assessments described in Section 7for a discontinued 
or withdrawn patient should be performed. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protection of the patient’s interests. The investigator will be responsible for informing IRBs 
and/or ECs of the earl y termination of the trial.
Reasons for earl y termina tion:
Unexpected, significant, or unacceptable safet y risk to subjects enrolled in the study
Decision based on recommendations from applicable board(s) after rev iew of safet y and 
efficacy  data
Discontinuation of study  drug development

Novartis Confidential Page 56
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
5 Population
5.1 Patient po pulation
The study  will include men and postmenopausal women with HR+, HER2 -negative advanced 
(loco regionall y recurrent not amenable to curative therap y or metastatic) breast cancer who 
received no or onl y one line of prior endocrine treatment for advanced breast cancer.
Patients with symptomatic visceral disease or any disease burden that makes the patient 
ineligible for endocrine therap y per the investigator’s best judgment will not be included in this 
study .
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered treatment in the study .
The patients are not permitted to participate in any additional parallel investigational drug or 
device studies.
5.2 Inclusion cri teria
Patients eligible for inclusion in this study  have to meet all of the following criteria:
Written informed consent must be obtained prior to any  screening procedures.
1.[Retired from protocol version 0.0]
1a.Patient is an adult male/female ≥ 18 y ears old 
at the time of informed consent and has 
signed informed consent before an y trial related activities and according to local 
guidelines.
Note: sexually  active males should use a condom during intercourse while taking drug and 
for 21 days after stopping medication and should not father a child in this period. A condom 
is required to be used also by vasectomized men as well as during intercourse with a male 
partner in order to prevent delivery  of the drug via seminal fluid.
2.Female patients must be postmenopausal. Postmenopausal status is defined either b y:
Prior surgical bilateral oophorectom y(with or without hy sterectom y)
Age ≥60
Age <60 and amenorrheic for 12 or more months in the absence of chemotherap y, 
tamoxifen, toremifene, or ovarian suppre ssion and FSH and estradiol in the 
postmenopausal range per local normal range
Note: For women with therap y
-induced amenorrhea, serial measurements of FSH and/or 
estradiol are needed to ensure postmenopausal status ( NCCN 2.2015 ). Ovarian radiation or 
treatment with a luteinizing hormone -releasing hormone agonist (LH -RHa) (goserelin 
acetate or leuprolide acetate) is not permitted for induction of ovarian suppression for the 
purpose of this trial.
3.Patient has a histologically  and/or cytologically  confirmed diagnosis of estrogen -receptor 
positive and/or progesterone receptor positive breast cancer by local laboratory (based on 
most recent analy zed biopsy ).

Novartis Confidential Page 57
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
4.Patient has HER2 -negative breast cancer (based on most recent analyzed biopsy )defined as 
a negative in situ h ybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative 
in situ hy bridization (FI SH, CI SH, or SISH) test is required by  local laboratory  testing.
5.Patient must have either:
Measurable disease, i.e., at least one measurable lesion as per RECI ST 1.1. (a lesion at 
apreviously  irradiated site may only be counted as a target lesion if there is a clear sign 
of progression since the irradiation).
OR
If no measurable disease is present, then at least one predominantl y lytic bone lesion 
must be present (patients with no measurable disease and only one predominantly l ytic 
bone lesion that has been previously  irradiated are eligible if there is documented 
evidence of disease progression of the bone lesion aft er irradiation).
6.Patient has advanced (loco regionall y recurrent not amenable to curative therap y(e.g. 
surgery  and/or radiotherapy )or metastatic) breast cancer.
Patients may  be :
newly  diagnosed advanced/ metastatic breast cancer, treatment naïve
relapsed with documented evidence of relapse more than 12 months from completion 
of (neo)adjuvant endocrine therap y with no treatment for advanced/ metastatic disease
relapsed with documented evidence of relapse on or within 12 months from completion 
of(neo)adjuvant endocrine therap y with no treatment for advanced/ metastatic disease
relapsed with documented evidence of relapse more than 12 months from completion 
of (neo) adjuvant endocrine therap y and then subsequently  progressed with documented 
evidence of progression after one line of endocrine therap y (with either an antiestrogen 
or an aromatase inhibitor) for advanced/ metastatic disease
advanced/metastatic breast cancer at diagnosis that progressed with documented 
evidence of progression after one line of endocrine therap y (with either an antiestrogen 
or an aromatase inhibitor)
Note: Patient who relapsed with documented evidence of relapse on/or within 12 months from 
completion of (neo)adjuvant endocrine therapy  and then subsequently  progressed with 
documented evidence of progression after one line of endocrine therapy  (with either an 
antiestrogen or an aromatase inhibitor) for metastatic /advanced disease will NOT be included 
in the study .
7.Patient has an Eastern Cooperative Oncology  Group (ECOG) performance status 0 or 1
8.[Retired from protocol version 0.0]
8a.Patient has adequate bone marrow and organ function as defined b y the following 
laboratory  values (as assessed by  central laboratory  for eligibility ):
Absolute neutrophil count ≥ 1.5 × 109/L
Platelets ≥ 100 × 109/L
Hemoglobin ≥ 9.0 g/dL
INR ≤1.5
Serum creatinine < 1.5 mg/dL

Novartis Confidential Page 58
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Total bilirubin < ULN except for patients with Gilbert’s syndrome who may only be 
included if the total bilirubin is ≤ 3.0 × UL N or direct bilirubin ≤ 1.5 × ULN.
Aspartate transaminase (AST) < 2.5 × ULN, except for patients with liver metastasis, 
who are onl y included if the AST is < 5 × ULN
Alanine transaminase (ALT) < 2.5 × ULN, except for patients with liver metastasis, 
who are onl y included if the ALT is < 5 × U LN
Patient must have the following laboratory  values within normal limits or corrected to 
within normal limits with supplements before the first dose of study  medication:
Sodium
Potassium
Magnesium 
Total Calcium (corrected for serum albumin)
5.3 Exclusion cri teria
Patients eligible for this study  must notmeet any of the following criteria:
1.Patient with symptomatic visceral disease or any disease burden that makes the patient 
ineligible for endocrine therap y per the investigator’s best judgment.
2.Patient has received prior treatment with chemotherap y (except for neoadjuvant/ adjuvant 
chemotherap y), fulvestrant or any  CDK4/6 inhibitor.
3.Patients has received prior neoadjuvant/adjuvant treatment with ant hracy clines at 
cumulative doses of 450mg/m² or more for doxorubicin or 900 mg/m² or more for 
epirubicin .
4.Patient with a known hy persensitivity  to an
y of the excipients of ribociclib or fulvestrant.
5. Patient with inflammatory  breast cancer at screening.
6.Patient is concurrentl y using other anti -cancer therapy .
7.Patient has had major surgery  within 14 days prior to starting study  drug or has not 
recovered from major side effects.
8.Patients with Child pugh score B or C.
9.Patient is currentl y receiving warfarin or other Couma din derived anti-coagulant, for 
treatment, proph ylaxis or otherwise. Therap y with heparin, low molecular weight heparin 
(LMWH), or fondaparinux is allowed.
10.Patient has not recovered from all toxicities related to prior anticancer therapies to NCI 
CTCAE version 4.03 Grade ≤1. Exception to this criterion: patients 
with any grade of 
alopecia are allowed to enter the study .
11.Patient has received radiotherap y ≤ 4 weeks or limited field radiation for palliation ≤ 2 
weeks prior to randomization, and who has not recovered to grade 1 or better from related 
side effec ts of such therapy  (with the exception of alopecia) and/or from whom ≥ 25% (Ellis 
1961) of the bone marrow was irradiated.
12.Patient has a concurrent malignancy  or malignancy  within 3 years of randomizati
on, with 
the exception of adequately  treated, basal or squamous cellskin carcinoma or curativel y 
resected cervical cancer.

Novartis Confidential Page 59
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
13.Patients with central nervous system (CNS) involvement unless they meet ALL of the 
following criteria:
At least 4 weeks from prior t herap y completion (including radiation and/or surgery ) to 
starting the study treatment.
Clinically  stable CNS tumor at the time of screening and not receiving steroids and/or 
enzy me inducing anti -epileptic medications for brain metastases.
14.Patient has impa irment of gastrointestinal (GI) function or GI disease that may significantly  
alter the absorption of the study  drugs (e.g., ulcerative diseases, uncontrolled nausea, 
vomiting, diarrhea, malabsorption sy ndrome, or small bowel resection).
15.Patient has a know n history  of HIV infection (testing not mandatory )
16.Patient has any other concurrent severe and/or uncontrolled medical condition that would, 
in the investigator’s judgment, cause unacceptable safety  risks, contraindicate patient 
participation in the clinic al study  or compromise compliance with the protocol: (e.g. chronic 
pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or 
viral infections, etc.)
17.[Retired from protocol version 0.0]
17a. Clinically  significant, uncontrolle d heart disease and/or cardiac repolarization 
abnormality  including any  of the following:
History  of angina pectoris, symptomatic pericarditis, or coronary  artery  bypass graft 
(CABG), myocardial infarction within 6months prior to study  entry
Documented ca rdiom yopathy
Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated 
acquisition (MUGA) scan or echocardiogram (ECHO)
LongQT s yndrome or family history of idiopathic sudden death or congenital long QT 
syndrome , or any  of the following:
Risk factors for Torsades de Pointe (TdP) including uncorrected h ypokalemia or 
hypomagnesemia, history  of cardiac failure, or history  of clinically  
significant/s ymptomatic brady cardia
Concomitant medication(s) with a known risk to prolong the QT interval and/or 
known to cause Torsades de Pointe that cannot be discontinued or replaced by  
safe alternative medication (e.g. within 5 half -lives or 7 day s prior to starting 
study  drug) 
Inability  to determine the QTcF interval 
Clinically  significant ca rdiac arrh ythmias including but not limited to (e.g., ventricular 
tachycardia), complete left bundle branch block, high-grade AV block (e.g., 
bifascicular block, Mobitz ty pe II and third degree AV block)
Systolic Blood Pressure (SBP) >160 mmHg or <90 mmHg
Brad ycardia (heart rate < 50 bpm at rest), b y ECG (mean of triplicate) andpulse.
Tach ycardia (heart rate > 90 bpm at rest), by  ECG (mean of triplicate) and pulse.
On screening, inability  to determine the QTcF interval on the ECG (ie: unreadable or 
not interpretable) or QTcF >450 msec (using 
Fridericia’s correction). All as determined 
by screening ECG (mean of triplicate ECGs).

Novartis Confidential Page 60
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
18.Patient is currentl y receiving an y of the following substances and cannot be discontinued 7 
days prior to Cy cle 1 Day  1:
Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit 
hybrids, pummelos, star -fruit, and Seville oranges.
Medications that have a narrow therapeutic window and are predominantl y metabolized 
through CYP3A4/5.
Herbal preparations/medication s, dietary  supplements (except vitamins) .
19.Patient is currently  receiving or has received systemic corticosteroids ≤ 2 weeks prior to 
starting stud y drug, or who have not fully recovered from side effects of such treatment.
Note: The following uses of corticosteroids are permitted: single doses, topical applications
(e.g., for rash), inhaled spray s (e.g., for obstructive airway s diseases), eye drops or local 
injections (e.g., intra -articular).
20.Participation in a prior investigational stud y within 30 days pri or to enrollment or within 5 -
half lives of the investigational product, whichever is longer.
21.Not able to understand and to comply  with study  instructions and requirements.
6 Treatment
6.1 Stud y treatment
For this study , the term “investigational drug” refers to Novartis study  drug ribociclib . 
Fulvestrant is also being used in this study . Study  treatment in this study  refers to the 
combination of drugs in each of the study arms and includes ribociclib/placebo and fulvestrant .
Ribociclib will be supplied by Novarti s or its designee as 200 mg hard gelatin capsules as 
individual patient supply  packaged in bottles.
Fulvestrant will be procured locall y according to local practice and regulation, or supplied by 
Novartis (or its designee). Storage conditions are described in the medication label. Medication 
labels will compl y with the legal requirements of each country  and be printed in the local 
language.
All dosages prescribed and dispensed to the patient and all dose changes during the study must 
be recorded on the Dosa ge Administration Record eCRF .
The study  met its primary  efficacy  endpoint (PFS) at the time of the primary  analysis. It also 
met the secondary  efficacy  endpoint of OS at the time of the pre-planned 2nd interim OS 
analysis. 
Given the demonstrated survival benefit, patients and investigators will be unblinded to the 
treatment allocation. Additionally , patients who remain on study  and are currentl y allocated to 
the placebo + Fulvestrant arm, will be given the opportunity  to transition to the ribociclib + 
Fulvestrant combination . 
Unblinded study treatment period will end once a patient discontinues from the study  treatment 
for an y reason or the end of study  (EOS) is declared, whichever occurs first.  

Novartis Confidential Page 61
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Following protocol amendment 4 and the unblinding of study  participants, the word “placebo” 
refers to the original treatment allocation in the study . Physical placebo capsules no longer need 
to be administered but the reference to placebo has been kept in places in the protocol to avoid
confusion.
6.1.1 Dosing regimen
All eligible patients will be randomized starting from Cy cle 1 Day  1 to receive either:
Fulvestrant + ribociclib
Fulvestrant + placebo
Ribociclib or placebo will be given orally  once daily  on day s 1
-21 of each 28 day  cycle. Days 
22-28 will be a “rest” period from dosing with ribociclib or placebo.
Fulvestrant will be administered intramuscularl y into the buttocks slowly (1-
2 minutes per 
injection) as two 5 mL injections, one in each buttock, on C ycle 1 Day 1 (C1D1), C ycle 1 Day 
15(C1D15), Cycle 2 Day  1 (C2D1) and every  28 day s thereafter (i.e., the first day of each 28 
day cycle) as per the (FASL ODEX®prescribing information ). There will be no “rest” in the 
fulvestrant schedule.
Table 6-1 Dose and treatment schedule
Study  treatmentsPharmaceutical form and 
route of administration Dose Frequency  and/or Regimen
fulvestrant
ribociclib /placeboTwo 5ml injections for i.m. 
administration
Capsule for oral use500mg
600 mgDosed every 28 days (Cycle n Day 1) with 1 
additional dose on Day 15 of Cycle 1
Once daily; days 1 to 21 in a 28-day Cycle
The study  drugs will be administered as a flat-fixed dose and not by body weight or body  surface 
area. There shall be no breaks between dosing cycles. A complete cycle of treatment is defined 
as 28 days. All study  treatment drugs should be administered as described below in Section 
6.1.1.1 and Section 6.1.1.2.
The investigator or responsible site personnel will instruct the patient to take the study dr ugs as 
per protocol (promote compliance). Patients will be instructed to return unused study  drugs to 
the site at discontinuation or completion of treatment. The site personnel will ensure that the 
appropriate dose of each study  drug is administered and that the drug accountabilit y is 
performed.
6.1.1.1 General dosing guidelines
The study  treatments should be taken as follows:
On scheduled visit day s, patients must take study  treatments in the clinic under the 
supervision of the Investigator or designee. On all oth
er day s patients will take 
ribociclib/placebo at home.
Patients should be instructed to take the stud y treatment of ribociclib/placebo capsules 
together with a large glass of water (~250 mL or ~8 oz) once a day  at the same time each 
day. For the first cy cle, patients must take ribociclib/placebo in the morning due to PK 
assessments. Once the PK assessments have been completed, patients can determine if 

Novartis Confidential Page 62
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
they prefer am or early afternoon dosing but should maintain a consistent time regardless 
of am or earl y afternoon dosing. Evening doses are strongl y not recommended . 
In general, study  treatment may  be taken without regard to meals. Please see
Section 6.1.1.2 below for additional guidelines for fasting lab assessments and for sparse 
PK collection.
Patients will be instructed to swallow the capsules whole and not to chew, crush or open 
them.
If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed 
before the next scheduled dose. The occurrence and frequency  of any vomiting during a 
treatment cycle must be noted in the adverse events section of the eCRF .Refer to Section 
6.6.1.4 for use of anti -emetic medications.
Any doses that are missed (not taken within 6 hours of the intended time) should be 
skipped and should not be replaced or made up on a subsequent day .
Patients must avoid consumption of grapefruit, grapefruit h ybrids, pomelos /pummelos
,
starfruit, Seville oranges or products containing the irjuice during the entire study  and 
preferabl y for an additional 7 day s before the first dose of study  medications .These foods 
are known as CYP3A4 inhibitors and have a potential to increase exposure to ribociclib.
Orange juice is allowed.
Herbal or dietary  supplements known as strong inhibitors or inducers of CYP3A4/5 or 
those with a known risk of QT prolongation are not permitted. 
Multivitamins are permitted.
6.1.1.2 Additional guidelines for fasting lab assessments and sparse PK
Fasting considerations for lab assessments ( e.g. glucose and lipid profile)
The patient should be fasting overnight (i.e., at least 8- 12 hours prior to the blood 
collection) for all visits with fasting glucose ,lipid profile sampling  
Water is allowed during all fasting periods; however coffee, tea and juice are not 
permitted during the fasting period.
Meal considerations for sparse PK collection
Only  for the sparse PK group, the meal condition (fasting, low fat, high fat) mu st be 
recorded on the eCRF within ± 30 minutes of the dose on C1D15 and C2D15. The meal 
condition is an estimate; however guidance is provided below.
On C1D15 and C2D15, when PK is paired with ECG assessments, patients may  consume 
breakfast only  after fast ed pre -dose blood samples (fasting glucose, fasting lipid profile) 
have been collected.
Pre-dose PK should be collected approximately  24hrs after the last dose (±2 hrs )and 
immediately  before the next dose .
A high-fat meal typically  contains 800-1000 calories with approximately  50% of the 
calories coming from fat (500-600 calories) ( FDA Guidance for Industry for Food -effect 
Bioavailability  and Fed Bioequivalence Studies, December 2002 ). An example of a high-

Novartis Confidential Page 63
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
fat meal could be two eggs, 2 slices of bread, 1 tablespon butter, 1 tablespoon jelly, 3 strips 
of bacon, 4 ounces of hash brown potato, and 8 ounces of whole milk. A low-fat meal could 
be approximately  300- 500 calories with approximately  25% of the calori es coming from fat 
(
75-125 calories) and could include 2 slices of bread, 1 tablespoon light fat margarine, 1 
tablespoon jelly, and 8 ounces of skim milk (USDA National Nutrient Database for Standard 
Reference, 2010 ).
6.1.1.3 Fulvestrant dosing
Fulvestrant 500 mg will be given after randomization at Cycle 1 Day 1, at Cycle 1 Day 15 (with 
a ± 3 day window) and then at Day 1
 of each subsequent cycle during the randomized treatment 
phase (with ± 3 day window). Fulvestrant is administered intramuscularly  into the buttocks 
slowly  as two 5mL  injections, one in each buttock. No dose modification of fulvestrant is 
planned in this study .
For information on fulvestrant and management of related adverse events, refer to the
FASLODEX®SmPC or local Prescribing Information.
6.1.2 Guidelines for continuation of treatment
For guidelines for continuation of treatment, refer to Section 6.5 Dosing modification.
Patients who permanently  discontinue fulvestrant for any reason must discontinue 
ribociclib/placebo, and move to End of Treatment phase, but will remain on study  for follow -
up evaluations (i.e. tumor follow -up and patient reported outcomes). Patients who permanentl y 
discontinue ribociclib/placebo may continue on the study  on fulvestrant per investigator’s 
discretion and will continue to be followed for safety  and/or efficacy .
6.1.3 Ancillary  treatments
Not applicable.
6.1.4 Rescue medication
Not applicable.
6.1.5 Treatment duration
Patients will be treated until disease progression (radiologicall y documented according to 
RECI ST 1.1) or until discontinuation of study  treatment due to any other reason 
(see Section 7.1.5).
6.2 Dose escal
ation guidelines
Not applicable

Novartis Confidential Page 64
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
6.3 Patient numbering, treatment assignment or randomization
6.3.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject No.) that is assigned when 
the patient is first enrolled for screening and is re tained as the primary  identifier for the patient 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential patient 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed consent form, the patient is assigned to the next sequential Subject 
No. available to the investigator through the Oracle Clinical RDC interface at that location.
The investigator or designated staff will contact the IRT and provide the requested identify ing 
information for the patient to register them into the IRT. Once assigned, the Subject No. must 
not be reused for an y other subject and the Subject No. for that individual must not be changed, 
even if the patient is re -screened. If the patient fails to be randomized or start treatment for an y 
reason, the reason will be entered into the Screening Disposition page.
IRT must be notified within 2 day s that t he patient was not randomized.
6.3.2 Treatment assignment or randomization
Patients will be randomized to one of the twotreatment arms (Section 4.1 and Section 6.1) in a 
ratio of 2:1.
Randomization will be stratified b y the following factors:
1.Lung or liver metastases: (y es versus no)
2.
Previous endocrine therapy
The randomization numbers will be generated using the following procedure to ensure that 
treatment assig nment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by the Interactive Response Technology  (IRT) provider 
using a validated system that automates the random assignment of patient numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, 
which in turn are linked to medication numbers. A separate medication randomization list 
will be produced by or under the responsibility  of Novartis Global Clinica l Supply  (GCS) using 
a validated system that automates the random assignment of medication numbers to medication 
packs containing each of the study  treatments.
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized vi a 
IRT to one of the treatment arms. The investigator or his/her delegate will call or log on to the 
IRT and confirm that the patient fulfills all the inclusion/exclusion criteria. The I RT will assign 
a randomization number to the patient, which will be use d to link the patient to a treatment arm 
and will specify  a unique medication number for the first package of study  treatment to be 
dispensed to the patient. The randomization number will not be communicated to the caller.
Following protocol amendment 4, p atients will be unblinded to their treatment allocation.
Additionally , patients who are currently  allocated to the placebo combination arm and still on 
study  treatment, will be given the opportunity  to transition to the L EE011 combination. 

Novartis Confidential Page 65
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Those patients on the placebo arm who do not wish to cross- over from placebo to LEE011 can 
remain on their current treatment allocation (i.e. fulvestrant alone) .
All of the study  treatment cross- over registration and dispending will be managed by  the study 
IRT system. After transition to the investigational treatment, placebo dispensing in IRT will 
stop. Comparator treatment (i.e. fulvestrant) will contin ue to be managed locally . 
6.3.3 Treatment blinding
This is a double blind study . In particular, patients, investigators, study  team, or anyone 
involved in the study conduct will remain blinded to the identity of the treatment from the time 
of randomization until database lock. The local (or Novartis -designated) radiologists will 
remain blinded to the identity  of the treatment from the time of randomization until final 
database lock.
Randomization data are kept strictly  confidential until the time of unblinding, and will not be 
accessible to anyone involved in the conduct of the study. The identity of the treatments will be 
concealed by the use of investigational drugs (ribociclib or ribociclib matching placebo) that 
are identical in packaging, labeling, schedule of adminis
tration and in appearance. 
Confidentiality  of randomization data is required to limit the occurrence of potential bias arising 
from the influence that the knowledge of treatment may have on the recruitment and allocation 
of patients.
Unblinding of study  drug assignment will only occur in the case of patient emergencies (Section 
8.3), for regulatory  reporting purposes and at the conclusion of the study .
In rare cases when unblinding occurs because of emerg ency  patient management, the actual 
treatment arm will not be communicated to any of the Novartis employees involved in running 
the trial in order to remain blinded.
An independent statistical group (external to Novartis), not involved in the trial conduct , will 
prepare data reports for the DMC. An independent clinical pharmacologist will analyze the data 
from patients with PK sampling if the data were to be presented at the DMC meetings . Details 
will be presented in the DMC charter.
Prior to the release of protocol amendment 4, the study  met both its primary  and secondary 
endpoints. Given the demonstrated survival benefit from LEE011 treatment, patients will be 
unblinded to their treatment allocation. 
6.4 Stud y drug preparation and dispe
nsation
Patients will be provided with an adequate supply  of study  drug for self-administration at home, 
including instructions for administration, until at least their next scheduled study  visit. Patients 
will receive ribociclib/placebo on an outpatient basis. The investigator shall provide the patient 
with instructions for ribociclib/placebo administration according to the protocol.
Fulvestrant should be dispensed according to local prescribing information and practice.
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study  treatment as per protocol. Study  treatment will be dispensed to the patient by  authorized 

Novartis Confidential Page 66
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
site personnel only . All dosages prescribed to the patient and all dose changes during the stud y 
must be recorded on the Dosage Administration Record CRF.
6.4.1 Study drug packaging and labeling
The study  medication packaging has a 2 -part label. A unique medication number is printed on 
each part of this label which corresponds to one of the treatment arms and a [specific visit or 
dose/dose level]. Responsible site personnel will identify  the study  treatment package(s) to 
dispense to the patient by using the IRT and obtaining the medication number(s). Site personnel 
will add the patient number on the label. Immediately  before dispensing the package to the 
patient, site personnel will detach the outer part of the label from the packaging and affix it to 
the source document (Drug Label Form) for that patient’s unique patient number.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the drug and the medication number but no 
information about the patient.
Table 6-2 Packaging and labeling
Study  treatments Packaging Labeling (and dosing frequency )
ribociclib or placebo Capsules in bottles Labeled as ‘LEE011/placebo’
Study treatment packaging has a 2 -part 
label.
A unique medication number is printed on 
each part of this label which corresponds to 
one of the two treatment arms.
fulvestrant Refer to local product information Refer to local product information
6.4.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, the study treatment should be stored according to the 
instruction s specified on the drug labels and in the [ribociclib Investigators Brochure] .
Study  treatments will be procured locall y according to local practice and regulation, or supplied 
by Novartis (or its designee).
6.4.3 Study drug compliance and accountability
6.4.3.1 Study drug compliance
Compliance will be assessed by the investigator and/or study  personnel at each patient visit and 
information provided by the patient and/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each patient 
visit.
Compliance will be assured by  administrations of the study  treatment under the supervision of 
investigator or his/her designee, and will be verified by  determinations of ri bociclib in plasma.

Novartis Confidential Page 67
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
6.4.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by the field 
monitor during site visits and at the completion of the study. Patients will be asked to return all 
unused study  treatment and packaging on a regular basis, at the end of the study  or at the time 
of study  treatment discontinuation.
At study  close-out, and, as appropriate durin g the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  logto the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
6.4.3.3 Handling of other study  treatment
Not applicable.
6.4.4 Disposal and destruction
The study  drug suppl y can be destro yed at the local Novartis facility , Drug Supply  group or 
third party, as appropriate. Study  drug destruction at the investigational site will only be 
permitted if authorized by Novartis in a prior agreement and if permitted by local regulations.
6.5 Dose modifications
6.5.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose adjustments are 
permitted in order to allow the patient to continue the study  treatment. These changes must be 
recorded on the Dosage Administration Record CRF.
6.5.1.1 Fulvestrant
The established clinical dose of fulvestrant (500 mg) will be used in each arm and no dose 
modi fication of fulvestrant is planned in this study  (Table 6 - 3). For information on fulvestrant 
and management of related adverse events, refer to the FASLODEX®SmPC or local 
Prescribing Information.
6.5.1.2 Riboci clib/placebo
Recommendations for dose reduction, interruption or discontinuation of ribociclib in the 
management of study  drug related adverse reactions are summarized in Table 6-4, Table 6-5, 
Table 6
-6,Table 6 -7andTable 6-8. No dose modification for fulvestrant is permitted.

Novartis Confidential Page 68
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Table 6-3 Dose modification guidelines
Ribociclib/placebo ( 3 weeks on/1 
week off schedule) Fulvestrant 
DoseNumber of capsules
& strength DoseNumber of injections & 
strength
Starting dose 600 mg 3 x 200 mg capsules 500 mg 2 x 250mg (5 mL) injection s
First dose reduction 400 mg 2 x 200 mg capsules No dose modification allowed
Second dose reduction 200 mg 1 x 200 mg capsules No dose modification allowed
Clinical judgment of the treating physician should guide the management plan of each patient 
based on individual benefit/risk assessment. However, for events requiring a discontinuation in
Table 6-4, Table 6-5, Table 6-6,Table 6-7and Table 6-8or listed in Section 7.1.3 , treatment 
must be 
discontinued.
Unscheduled local laboratory  assessments may  be performed if medicall y indicated to 
document a (potential) adverse event or when the treating ph ysician cannot wait for central 
laboratory  results for decision making (e.g. dose modifications). In this particular situation, if 
possible, the blood sample obtained at the same time point shou ld be submitted to the central 
laboratory  for anal ysis in parallel with local anal ysis. 
The results of the local laboratory  will be recorded in the eCRF if any  of the following criteria 
are met:
A treatment decision was made based on the local results, or
Local lab results document an adverse event not reported b y the central lab, or
Local lab results document an adverse event severity  is worse than the one reported b y the 
central lab, or
There are no concomitant central results available.
For assessment of patients’ eligibility to the study, only laboratory results from the central 
laboratory will be used.
Table 6-4 Ribociclib /Placebo dose adjustment and management 
recommendations for hematological adverse reactions (CTC A E v4.03)
The results of the local laboratory  will be recorded in the eCRF if any  of the 
follow ing criteria are met:
Toxicity /Grade Dose Adjustment and Management 
Reco mmendations
Thrombocy topenia
Grade 1( ≥75 x 109/L) No dose adjustment required.
Grade 2 ( ≥50 x 109/L –<75 x 109/L) Dose interruption until recovery to grade 1.
Re-initiate ribociclib/placebo at the same dose.
Grade 3 ( ≥25 x 109/L -<50 x 109/L) Dose interruption until recovery to grade 1.
Re-initiate ribociclib/placebo at the same dose level.
If toxicity recurs at grade 3: temporary dose interruption 
until recovery to grade 1 and reduce ribociclib/placebo to 
the next lower dose level.

Novartis Confidential Page 69
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Toxicity /Grade Dose Adjustment and Management 
Reco mmendations
Grade 4( <25 x 109/L) Dose interruption until recovery to grade 1.
Re-initiate ribociclib/placebo at the next lower dose level.
If toxicity recurs at grade 4: discontinue ribociclib/placebo.
Absolute neutrophil count (ANC)
Grade 1 ( ≥1.5 x 109/L) No dose adjustment required.
Grade 2 ( ≥1.0 -<1.5 x 109/L) No dose adjustment required.
Grade 3 ( ≥0.5 -<1.0 x 109/L) Dose interruption until recovery to ≥1.0 x 109/L.
Re-initiate ribociclib/placebo at the same dose level.
If toxicity recurs at grade 3: temporary dose interruption 
until recovery to ≥ 1.0 x 109/L.
If resolved in ≤7 days, then maintain dose level.
If resolved in >7 days, then reduce ribociclib/placebo dose 
to the next lower dose level.
Grade 4 (<0.5 x 109/L) Dose interruption until recover y to ≥ 1.0 x 109/L.
Re-initiate ribociclib/placebo at the next lower dose level.
If toxicity recurs at grade 4: temporary dose interruption 
until recovery to ≥1.0 x 109/L and reduce 
ribociclib/placebo at the next lower dose level.
Febrile neutropenia
Grade 3
ANC <1.0 x 109/L with a single temperature 
of >38.3 ºC (101 ºF) or a sustained temperature 
of ≥38 ºC (100.4 ºF) for more than one hourDose interruption until improvement of ANC ≥ 1.0 x 109/L 
and no fever. Restart at the next lower dose level.
If febr ile neutropenia recurs, discontinue 
ribociclib/placebo.
Grade 4
Life-threatening consequences;
urgent intervention indicatedDiscontinue ribociclib/placebo.
Anemia
(Hemoglobin)
Grade 1 ( ≥10.0 –LLN g/dL) No dose adjustment required.
Grade 2 ( ≥8.0 –<10.0 g/dL) No dose adjustment required.
Grade 3 (<8.0 g/dL) Dose interruption until recovery to grade 2.
Re-initiate ribociclib/placebo at the same dose.
Grade 4
Life-threatening consequences;
urgent intervention indicatedDiscontinue ribociclib/placebo.
Table 6-5 Ribociclib/placebo dose adjustment and management 
recommendation for hepatic toxicities (CTC AE v4.03)
Please refer to Section 6.5.1.2.1 for additional information.
HEPATOTOXICITY (BILIRUBIN, SGPT/ALT, SGOT/AST)
TOTAL BILIRUBIN without ALT/AST increase above baseline value
Grade 1 (> ULN –1.5 x ULN)
(confirmed 48 -72h later)Maintain dose level with LFTs monitored bi -weekly .
Grade 2 (> 1.5 –3.0 x ULN) Dose interruption of ribociclib/placebo
If resolved to ≤ grade 1 in ≤ 21 days, then maintain 
dose level
If resolved to ≤ grade 1 in > 21 -28days or toxicity 
recurs, the n reduce 1 dose level
Repeat liver enzyme and bilirubin tests twice weekly for 
2 weeks after dose resumption 

Novartis Confidential Page 70
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
If toxicity recurs after two dose reductions, or recovery 
to ≤ grade 1 is > 28 days, discontinue ribociclib /placebo
Grade 3 (> 3.0 –10.0 x ULN) Dose interruption of ribociclib/placebo , until  resolved to 
≤ grade 1 , then lower 1 dose level of ribociclib /placebo
Repeat liver enzyme and bilirubin tests twice weekly for 
2 weeks after dose resumption 
If resolved to ≤ grade 1 in > 28 days or toxicity recurs, 
discontinue ribociclib /placebo
Grade 4 (> 10.0 x ULN) Discontinue ribociclib /placebo
Confounding factors and/or alternative causes for increase of total bilirubin should be excluded before dose 
interruption/reduction. They include but are not limited to: evidence of liver metastases, evidence of 
obstruction, such as elevated ALP and GGT ty pical of gall bladder or bile duct disease, hyperbilirubinemia due 
to the indirect component only (i.e. direct bilirubin component ≤ 1 x ULN) due to hemolysis or Gilbert 
Syndrome, other pharmacologic treatment, viral hepatitis, alcoholic or autoimmune hepa titis, other hepatotoxic 
drugs.
For patients with Gilbert Syndrome, these dose modifications apply to changes in direct bilirubin only.
Bilirubin will be fractionated if elevated.
AST or ALT
AST or ALT without bilirubin elevation > 2 x ULN
Same grade as baseline or increase from baseline 
grade 0 to grade 1
(confirmed 48 –72 h later)No dose adjustment required with LFTs monitored per 
protocol if same grade as baseline or bi -weekly in case 
of increase from baseline grade 0 to 1
Increase from baseline gr ade 0 or 1 to grade 2 (> 
3.0 –5.0 x ULN)Dose interruption of ribociclib/placebo
If resolved to ≤ baseline grade in ≤ 21 days, then 
maintain dose level
If resolved to ≤ baseline grade in > 21 days or toxicity 
recurs, then reduce 1 dose level
Repeat live r enzyme and bilirubin tests twice weekly for 
2 weeks after dose resumption 
If toxicity recurs after two dose reductions or recovery 
to ≤ baseline grade is > 28 days, discontinue 
ribociclib /placebo 
Increase from baseline grade 0 or 1 to grade 3 (> 
5.0 –20.0 x ULN)Dose interruption of ribociclib/placebo until resolved to 
≤ baseline grade , then lower 1 dose level of 
ribociclib /placebo
Repeat liver enzyme and bilirubin tests twice weekly for 
2 weeks after dose resumption 
If recovery to ≤ baseline grade is > 28 days, discontinue 
ribociclib /placebo
If toxicity recurs, discontinue ribociclib /placebo
Increase from baseline grade 2 to grade 3 (> 5.0 –
20.0 x ULN)Dose interruption of ribociclib until resolved to ≤ 
baseline grade, then lower 1 dose level of 
ribociclib/placebo 
Repeat liver enzyme and bilirubin tests twice weekly for 
2 weeks after dose resumption 
If toxicity recurs after two dose reductions or recovery 
to ≤ baseline grade is > 28 days, discontinue 
ribociclib./placebo
Grade 4 (> 20.0 x ULN) Discontinue ribociclib /placebo
AST or ALT and concurrent Bilirubin

Novartis Confidential Page 71
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
For patients with normal ALT and AST and total 
bilirubin at baseline: AST or ALT > 3 x ULN 
combined with  total bilirubin > 2 x ULN without 
evidence of cholestasis
or
For patient with elevated AST or ALT or total 
bilirubin at baseline: baseline : [AST or ALT >2 x 
baseline AND >3.0x ULN] OR [AST or ALT 8.0 x 
ULN] -whichever is lower -combined with [total 
bilirubin >2 x baseline AND >2.0 x ULN]Discontinue ribociclib/placebo
Confounding factors and/or alternative causes for increased transaminases should be excluded before dose 
interruption/reduction. They include but are not limited to: concomitant medications, herbal preparations or 
dietary supplements, infection, hepato -biliary disorder or obstruction, new or progressive liver metastasis, and 
alcohol intake.
6.5.1.2.1 Additional follow -up for hepatic toxicities
Increase in transaminases combined with total bilirubin (TBIL) increase may be indicative of
drug-induced liver injury (DILI), and shoul d be considered as clinically  important events. The 
threshold for potential DILI may depend on the patient’s baseline AST/ALT and TBIL value; 
patients meeting an y of the following criteria will require further follow -up as outlined below:
For patients with normal ALT and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N 
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or AL T > 8.0 x ULN] , whichever is lower, 
combined with [TBIL > 2 x baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as: ALP elevation > 2.0 x ULN with R value < 2 in patients without bone metastasis, or elevation 
of AL P liver fraction in patients with bone metastasis.
Note: The R value is calculated by  dividing the ALT by  the AL P, using multiples of the ULN 
for both values. It denotes the relative pattern of ALT and/or ALP elevation is due to cholestat ic 
or hepatocellular liver injury  or mixed ty pe injury .
In the absence of cholestasis, these patients must be immediately discontinued from study drug 
treatment, and repeat LFT testing as soon as possible, preferabl y within 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory tests, detailed 
history , physical assessment and thepossibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
Hepatic toxicity  monitoring includes the following LFTs: albumin, ALT, AST, total bilirubin , 
direct and indirect bilirubin , alkaline phosphatase (fractionated if alkaline phosphatase is grade 
2 or higher) , creatine kinase, prothrombin time (PT)/INR and 
GGT. For patients with Gilbert 
Syndrome: total and direct bilirubin must be monitored, intensified monitoring applies to 
changes in direct bilirubin only .
Close observation is recommended in case of AST, ALT, and/or bilirubin increase requirin g 
dose interruption, which involves:
Repeating liver enz yme and serum bilirubin tests two or three times weekly . After dose 
resumption repeat liver enzy me a nd bilirubin tests t wice weekly  during the first 2 weeks, 

Novartis Confidential Page 72
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
afterwards the f requency  of re -testing can decrease to once a week or less if abnormalities 
stabilize or return to normal values.
Obtaining a more detailed history  of current sy mptoms.
Obtaining a more detailed history of prior and/or concurrent diseases , including history  of 
any pre-existing liver conditions or risk factors.
Obtaining a history  of concomitant drug use (including non -prescription medications, 
herbal and dietary  supplements), alcohol use, recreational dr ug use, and special diets.
Ruling out acute viral hepatitis ty pes A, B, C, D, and E; hepatotropic virus infections 
(CMV, EBV or HSV); autoimmune or alcoholic hepatitis; NASH; hy poxic/ischemic 
hepatopath y; and biliary  tract disease.
Obtaining a history  of exposure to environmental chemical agents.
Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR, direct 
bilirubin).
Considering gastroenterology  or hepatology  consultations.
Assessing cardiovascular dy sfunction or impaired liver oxy genation, including 
hypotension or right heart failure as possible etiologies for liver dy sfunction.
Obtaining a PK sample, as close as possible to last dose of study  drug .
Obtaining a l iver biopsy ,as clinically indicated ,to assess pathological change and degree 
of potential liver injury .
All cases confirmed on repeat testing, meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant”, thus met the definition of SAE (Section 8.2.1), and reported as SAE using the term 
“potential drug-induced liver injury ”. All events should be followed up with the outcome clearl y 
documented. Results of tests as well as other clinically  important information will be recorded 
in the eCRF.
6.5.1.2.2 Additional follow -up for QTc Fprolongation
Table 6-6 Ribociclib/placebo dose adjustment and management 
recommendation for QTcF prolongation (CTC AE v4.03)
Grade Dose Modification
For All Grades 1 Check the quality of the ECG and the QT value and repeat if needed .
2 Perform analysis of serum electrolytes (K+, Ca++, Phos, Mg++). If
outside of the normal range , interrupt ribociclib/placebo administration, 
correct with supplements or appropriate therapy as soon as possible, 
and repeat electrolytes until documented as normal.
3 Review concomitant medication usage forthe potential to i nhibit 
CYP3A4 and/or to prolong the QT interval.
4 Check compliance with correct dose and administration of 
ribociclib/placebo.
1*
QTcF450-480 msPerform steps 1 -4 as directed in “For All Grades.” No dose adjustment 
required.

Novartis Confidential Page 73
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
2*
QTcF481-500 msInterrupt ribociclib/placebo. Perform steps 1 -4 as directed in “For All 
Grades.”
Perform a repeat ECG within one hour of the first QTcF of ≥ 481 ms.
Repeat ECG as clinically indicated until the QTcF returns to < 481 ms . 
Restart ribociclib/placebo with dose reduced by 1 dose level. Refer to Table 
6-31for dosing schedule. . 
If QTcF ≥ 481 ms recurs , ribociclib should be reduced again by 1 dose level. 
Repeat ECGs 7 days and 14 days after dose resumption (t hen as clinically 
indicated) for any patients who had therapy interrupted due to QTcF ≥ 481 
ms.
3
QTcF≥ 501 ms on at least two 
separate ECGsInterrupt ribociclib/placebo. Perform steps 1 -4 as directed in “For All 
Grades.” 
Perform a repeat ECG within one hour ofthe first QTcF of ≥ 501 ms.
If QTcF remains ≥ 501 ms, consult with a cardiologist (or qualified specialist) 
and repeat cardiac monitoring as indicated until the QTcF returns to < 481 
ms.
If QTcF returns to < 481 ms, ribociclib/placebo will be r educed by 1 
dose level. Refer to Table 6 -3for dosing schedule.
If QTcF remains ≥ 481 ms after performing steps 1-4 as directed in 
“For All Grades” discontinue ribociclib/placebo.
Repeat ECGs 7 days and 14 days after dose resumption (then as clinically 
indicated) for any patients who had therapy interrupted due to QTcF ≥ 501 
ms.
If QTcF of ≥ 501 ms recurs, discontinue ribociclib /placebo
4*
[QT/QTc F≥ 501 or > 60 ms 
change from baseline]
and
[Torsades de pointes or 
polymorphic ventricular 
tachycardia, or signs/symptoms 
of serious arrhythmia]Discontinue ribociclib/placebo. Perform steps 1 -4 as directed in “For All 
Grades.”
Obtain local cardiologist (or qualified specialist) consultation and repeat 
cardiac monitoring as indicated until the QTcF returns to <481 ms.
*All values refer to the average of triplicate measurements 
Table 6-7 Ribociclib /placebo dose adjustment and management 
recommendation for ILD/pneumonitis (CTCA E v4.03)
Grade Dose Adjustment and Management Recommendations
1
(asymptomatic)No dose adjustment required. Initiate appropriate medical therapy and monitor as clinically 
indicated.
2
(symptomatic)Interrupt ribociclib dose until recovery to Grade ≤1, then resume ribociclib at the next lower 
dose level*. 
3 and 4
(severe)Discontinue ribociclib
*An individualized benefit -risk assessment should be performed before resuming ribociclib
6.5.1.2.3 Guidance for a ll other adverse reactions
Consider performing an analysis of serum potassium, calcium, phosphorus, and magnesium for 
all adverse reactions, if indicated. If electrol yte values are outside of the normal range, , 
interrupt ribociclib/placebo administration, correct electrol ytes with supplements or appropriate 

Novartis Confidential Page 74
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
therap yas soon as possible, and repeat electrol yte testing until documented normalization of 
the electrol ytes.
Patients who experience non-acute renal impa irment of grade 2 or higher during the treatment 
period should discontinue 
ribociclib/ placebo treatment and should be followed for safet y 
assessments.For all other adverse events, including Toxic Epidermal Necrolysis (TEN), which 
is a grade 4 event b y CTC AE,please follow recommendations in Table 6-8.
Table 6-8 Ribociclib/placebo dose adjustment and management 
recommendation for all other adverse reactions 
Grade Dose Adjustment and Management Recommendations
1 No dose adjustment recommended. Initiate appropriate medical therapy and monitor.
2 Dose interruption until recovery to grade 1. Initiate appropriate medical therapy and monitor.
Re-initiate ribociclib/placebo at the same dose.
If the same toxicity recurs at grade 2, interrupt ribociclib/placebo until recovery to grade 1. Re -
initiate ribociclib/placebo at the next lower dose level.
3 Dose interruption until recovery to grade 1. Initiate appropriate medical t herapy and monitor.
Re-initiate ribociclib/placebo at the next lower dose level.
If toxicity recurs at grade 2: temporary dose interruption until recovery to grade 1 and reduce 
ribociclib/placebo dose the next lower dose level.
If toxicity recurs at grade 3, discontinue ribociclib/placebo.
4 Discontinue ribociclib/placebo and treat with appropriate medical therapy.
6.5.1.2.4 Adjustment of starting dose in special populations
Renal Impairment
Based on rat ADME data, ribociclib was predominantly  excreted in the in the bile as metabolites, 
with limited excretion of unchanged drug in urine. Based on a population pharmacokinetic 
analysis [CL EE011A2116], mild and moderate renal impairment had no ef fect on the exposure 
of ribociclib, therefore requiring no dose adjustment. For patients with severe renal impairment, 
a lower dose adjustment is recommended.
For fulvestrant, no dose adjustments are recommended for patients with mild to moderate renal 
impairment (creatinine clearance ≥30 ml/min). Safety  and efficacy  for fulvestrant have not been 
evaluated in patients with severe renal impairment (creatinine clearance <30 ml/min), and, 
therefore, caution is recommended in these patients ( FASLODEX®prescribing information ).
Hepatic Impairment
Based on a pharmacokinetic study  [CLEE011A2109] in healthy  subjects and non-cancer 
subjects with impaired hepatic function, no dose adjustment is necessary  in subject
s with mild 
hepatic impairment (Child -Pugh class A). Subjects with moderate (Child -Pugh class B) and 
severe hepatic impairment (Child -Pugh class C) can have increased exposure to ribociclib and
therefore a starting dose of 400 mg once daily  is recommended. For fulvestrant, increased 
exposure to fulvestrant was observed in patients with moderate hepatic impairment (Child -Pugh 
class B). Fulvestrant has not been administered to patients with severe hepatic impairment 
(Child -Pugh class C) (FASL ODEX®prescribing information ). Therefore, patients with Child -
Pugh class B and C will not be enrolled. No dose reductions for fulvestrant will be allowed in 

Novartis Confidential Page 75
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
study  CLEE011F2301 therefore patients with baseline hepatic impairment are excluded from 
the study .
Elderly
Physicians should exercise caution in monitoring the effects of ribociclib in the elderl y. 
Insufficient data are available to provide a dosage recommendation.
6.5.2 Follow -up for toxicities
Patients who complete treatment or whose treatment is interrupted or permanently  discontinued 
due to an adverse event or abnormal laboratory value must be followed at least once a week for 
4 weeks, and subsequently at 4 -week intervals, until resolution or stabilization of the e vent. All 
patients will be followed for safety  at least 30 days following the last dose of study  treatment 
(fulvestrant and/or ribociclib/placebo).
6.5.3 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility criteria, as well as specifi c dose modification and stopping 
recommendations are included in this protocol. Refer to Section 6.5 for details.
6.6 Concomitant medications
6.6.1 Permitted concomitant therapy
Medications required to treat AEs, manage cancer symptoms, concurrent diseases and 
supportive care agents, such as pain medications, anti-emetics and anti-diarrheal sare allowed.
Please consult the list of prohibited medications and the list of use with caution medications for 
further guidanc e.  
The patient must be told 
to notify  the investigational site about any new medications he/she 
takes after the start of the study  treatment. All medications (other than study  drugs) and 
significant non-drug therapies (including vitamins, herbal medicine s, physical therapy  and 
blood transfusions) administered within 30 days of study  entry and during the study  must be 
listed on the Concomitant medications/Significant non-drug therapies eCRF.
6.6.1.1 Bisphosphonates and denosumab
Bisphosphonates and denosumab are g enerally  allowed with the following comments:
Chronic concomitant bisphosphonate/denosumab therap y for the prevention of bone 
metastasis is not permitted.
Bisphosphonate/denosumab therap y for the treatment of osteoporosis is permitted.
Bisphosphonate/denosumab therapy  for the prevention of skeletal related events for 
patients with bone metastases is permitted.
If bisphosphonate/denosumab therap y is to be started after the first dose of study  drug, 
prior consultation and approval by Novartis is required and the reason for its use must be 
clearl y documented.

Novartis Confidential Page 76
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Patients taking concomitant medication chronically should be maintained on the same dose and 
dose schedule throughout the study  period, as medically  feasible. The days of PK blood 
sampling should be repres entative of the other study  days with regard to the use of the 
chronicall y administered concomitant medications. However, if a concomitant medication is 
used intermittently  during the study , this medication should be avoided on the days of PK 
sampling, if medically  feasible.
6.6.1.2 Hematopoietic growth factors
Prophy lactic use of WBC growth factors with ribociclib/placebo is not recommended.
6.6.1.3 Palliative radiotherapy
Palliative radiation is permitted. It should not be delivered to a target lesion . Cumulative courses
of RT should not encompass more than 25% of irradiated bone marrow 
(see Appendix 3 ).
If palliative radiotherap y is initiated after the start of study  treatment, the reason for its use must 
be clearly  documented and progression as per RECI ST 1.1 must be ruled out.
No dose modification of study  treatment is needed during palliative radiotherap y.
.
6.6.1.4 Use of antiemetic medications
Ribociclib has low to minimal emetogenic potential according to 
thedefinition of antineoplastic 
agent emetogenicit y (Grunberg et al, 2010). Antiemetic therap y can be used according to 
clinical guidelines for antineoplastic medications with low to 
minimal emetogenic potential fo r
treatment and/or prevention of nausea and vomiting as a result of study  treatment (NCCN 
Clinical Practice Guidelines in Oncology . Antiemesis, 2016; Roila F et al, 2016 ). 
Potential drug interaction between ribociclib/placebo and antiemetic medications should alway s 
be taken into consideration. For example the combination of the prohibited antiemetic 
medication ondansetron with ribociclib may precipitate TdP. Refer to Table 14-1and Table 14-
2for the 
list of medications that are prohibited or allowed to be used with ribociclib/placebo.  
6.6.2 Concomitant therapy requiring caution
Medications to be used with caution during combined ribociclib/placebo and fulvestrant 
treatment in this study  are listed below (see Table 14-2 in Appendix 1, this list is not
comprehensive and is only meant to be used as a guide. Please contact the medical monitor with 
any questions). These medications should be excluded from patient use if possible. If they must 
be given based on the investigator’s judgment, then use with caution and consider a 
ribociclib/placebo interruption if the concomitant medication is only  needed for a short time.
Moderate inhibitors or inducers of CYP3A4/5 (may increase or decrease ribociclib exposure, 
respectively )
Sensitive substrates of CYP3A4/5 tha t do not have narrow therapeutic index (ribociclib 
may increase exposure to these medications)

Novartis Confidential Page 77
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Strong inhibitors of BSEP (based on in vitro data, the co-administration with ribociclib 
may lead to intrahepatic cholestasis)
Medications that carry  a possible risk for QT prolongation (may  precipitate QT 
prolongation and TdP)
Sensitive substrates of the renal transporters, MATE1 and OCT2 (ribociclib hasthe
potential to increase exposure to substrates of these transporters although no animal or 
clinical data ar e available to support these statements)
Sensitive substrates of transporter BCRP ( ribociclib has thepotential to increase 
exposure to substrates of these transporters, although no animal or clinical data are 
available to support these statements)
6.6.2.1 Cortico steroids
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to lead to 
induction of CYP3A enzymes, thereb y potentially  reducing ribociclib drug exposure to 
subtherapeutic levels. Systemic corticosteroid treatment should not be given during the study , 
except for:
Topical applications (e.g., for rash), inhaled spray s (e.g., 
for obstructive airway s diseases), 
eye drops or local injections (e.g., intra -articular);
A short duration (< 5 days) of sy stemic corticosteroids ≤ to the anti-inflammatory  potency  
of 4 mg dexamethasone (e.g. for chronic obstructive pulmonary  disease, or as an 
antiemetic)
6.6.3 Prohibited concomitant therapy
The following medications are prohibited during combined ribociclib/placebo and fulvestrant 
treatment in this study  (see Table 14-1 in Appendix 1, this list is not comprehensive and is only 
meant to be used as a guide. Please contact the medical monitor
 with any  questions):
Strong inhibitors or inducers of CYP3A4/5 (may  significantl y increase or decrease 
ribociclib exposure, respectivel y)
Substrates of CYP3A4/5 with a narrow therapeutic index (ribociclib may  increase 
exposure to these medications resulting in toxicity  to these medications)
Medications with a known risk for QT prolongation and/or Torsades de Pointes (TdP) 
(may  precipitate QT prolongation and TdP in combination with ribociclib)
Other investigational and antineoplastic therapies
Herbal prepara tions/medications or dietary  supplements that are strong inhibitors or 
inducers of CYP3A4/5 or those with a known risk of QT prolongation.  These include, but 
are not limited to: St. John’s wort, Kava, ephedra (ma huang), gingko biloba, 
dehy droepiandroster one (DHEA), yohimbe, saw palmetto, black cohosh and ginseng. 
Patients should stop using these preparations/medications at least 7 day s prior to first dose 
of study  treatment.

Novartis Confidential Page 78
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
6.6.4 Drugs with QT prolongation
As far as possible, avoid co-administr ering medications with a “Known”, “Possible” or 
“Conditional” risk of TdP (www.qtdrugs.org ) or any other medication with the potential to 
increase the risk of drug-
related QT prolongation (e.g., via a potential DDI increas ingthe 
exposure of ribociclib or the exposure of the QT prolonging drug). If concomitant 
administration of drugs with a known risk of TdP is required and cannot be avoided, 
ribociclib/placebo must be interrupted (see Table 6-6). If during the course of the study , 
concomitant administration of a drug with “Possible risk” or “Conditional risk” of TdP is 
required, based on the investigator assessment and clinical need, study treatment may be 
resumed under close clinical and ECG monitoring to ensure patient safety . A list of drugs 
associated with QT prolongation and/or TdP is available online 
(www.qtdrugs.org). Medication 
with a known risk for QT prolongation are prohibited during stud y treatment.
Refer to the ribociclib Investigators Brochure and other drug package insert and Appendix 1for 
information on possible interactions with other drugs .
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7
-1aand Table 7 -1blist all of the assessments and indicates with an “X” the visits when 
they are performed. All data obtained from these assessments must be supported in the patient’s 
source documentation. The table indicates which assessments produce data to be entered into 
the database (D) or remain in source documents only  (S) (“Category ” column).
The following CRF(s) will be used as sou rce document(s): local lab results.
Allowed visit windows are specified as follows:
Screening assessments, apart from those listed below, must occur within 2 8days of the 
randomization as per Table 7 -
1a.
Vital signs, physical exam, ECOG performance status, required labs, ph ysical exam 
should be performed within 7 day s of randomization.
Note: If the ph ysical examination w asperformed ≤ 7 day s prior to the first dose of 
ribociclib /placebo, then they  do not need to be repeated on C ycle 1 Day 1 .
In order for an accurate evaluation of baseline QTc, a total of three 12 -lead ECGs will be 
performed at screening between -7and -1 day .
Randomization and Cycle 1 Day  1 should preferably  occur on the same day . A maximu m 
of a 3 day s window between randomization and Cy cle 1 Day  1 visit is permitted
.
For all visits (including PK visits C1D15, C2D1 and C2D15) , a general ±3 day s visit 
window is permitted on assessments to take into account scheduling over public holiday s, 
ifnot explicitly  specified otherwise.
For PK sampling, the samples may  be obtained within the time window specified in 
Table 7-6 and Table 7 -7.

Novartis Confidential Page 79
Amended Protocol Version 0 4(Clean) Protocol No. CLEE011F2301
Radiological and patient reported outcome assessments must be performed as outlined in 
Table 7-1a . A visit window of ± 7 day s is allowed. (The whole bod y bone scan should be 
performed within 42 days or 6 weeks prior to randomization).
Any screening assessments required within - 7 to -1 day s must be repeated if Cy cle 1 Day  
1 visit is delayed more than 7 day s after randomization visit. Every  effort should be made 
to follow the schedule outlined in Table 7-1a .
Patients on placebo+fulvestrant that elect to transition to LEE011+fulvestrant arm or patient 
who continue with their current treatment (i.e. fulvestrant alone), should have safet y 
assessments as per Table 7-1a and Table 7-1b. Tumor assessments will continue as clinicall y 
indicated as described in Section 7 (see Table 7 -
1b). 
The assessment schedule for patients who will cross -over is presented in Table 7-1b. Consult 
Table 6-4, Table 6-5and Table 6-6for monitoring frequency  in cases of hematologic toxicity , 
liver
function abnormalities or QT prolongation respectively .  
Instructions for patients electing to cross -over from placebo to LEE011 at the next scheduled 
visit: 
All patients commencing LEE011 after cross -over from placebo will need to have 
hematology , electrolytesand biochemistry  tests performed on cross over Cycle 1 Day 1, 
Cycle 1 Day 15, Cycle 2 Day 1, at the beginning of cycles 3 to 6, then as clinically  indicated, 
but not less frequentl y than every 12 weeks. 
Patients must have ECG for QT assessment on the first day before the administration of 
LEE011. LEE011 should be initiated only in patients with QTcF values <450 msec .
ECGs shoul d be repeated on cross -over C ycle 1 Day 15, C ycle 2 Da y 1, Day 15 and then as 
clinically  indicated. 

Novartis Confidential Page 80
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301
Table 7-1a Visit evaluation schedule -Patients that, after protocol amendment 4, continue with their originally  randomized 
study  treatment Category
Reference to 
protocol 
sectionScreening 
phaseTreatment phase Post treatment follow -up phase
Survival 
phase
Visit name Screening Cycle 1 Cycle 2 Cycle 
3
Subsequent 
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days -28 to
-1-7 to -1 1 15 115 1 1 Within 15 
days from 
last doseLast dose + 
30 day sEvery  8 
weeks (if 
applicable) Every  12 
weeks
Screening
Study Informed 
ConsentD7.1.1 x
IRT Screening (after 
ICF signature)S7.1.1 x
Disposition Assessment
End of Phase 
DispositionD x x x
Patient history
Demography D7.1.1.3 x
Inclusion/exclusion 
criteriaD7.1.1.3 x
Medical history and 
current medical 
conditionsD7.1.1.3 x
ER and PgR status D7.1.1.3 x

Novartis Confidential Page 81
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301Category
Reference to 
protocol 
sectionScreening 
phaseTreatment phase Post treatment follow -up phase
Survival 
phase
Visit name Screening Cycle 1 Cycle 2 Cycle 
3
Subsequent 
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days -28 to
-1-7 to -1 1 15 115 1 1 Within 15 
days from 
last doseLast dose + 
30 day sEvery  8 
weeks (if 
applicable) Every  12 
weeks
HER2 status D7.1.1.3 x
Diagnosis and extent of 
cancerD7.1.1.3 x
Prior antineoplastic 
therapyD7.1.1.3 x
Prior / concomitant 
medicationsD7.1.1.3 Continuous –up to 30 days after last dose
Randomization
Eligibility checklist 
(within IRT)S7.1.1 x
IRT -Randomization D7.1.1 x
IRT -study drug 
administrationS7.1.1 x x x x x
Physical examination
Physical examinationS7.2.2.1 x x x Every third 
cyclex
Performance statusD7.2.2.4 x x x x Every third 
cyclex
Height D7.2.2.3 x
Weight D7.2.2.3 x x x x x x

Novartis Confidential Page 82
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301Category
Reference to 
protocol 
sectionScreening 
phaseTreatment phase Post treatment follow -up phase
Survival 
phase
Visit name Screening Cycle 1 Cycle 2 Cycle 
3
Subsequent 
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days -28 to
-1-7 to -1 1 15 115 1 1 Within 15 
days from 
last doseLast dose + 
30 day sEvery  8 
weeks (if 
applicable) Every  12 
weeks
Vital signsD7.2.2.2 x x x x x Every third 
cyclex
Laboratory  assessments
HematologyD7.2.2.5.1 x x x x Every third 
cyclex
Chemistry with fasting 
glucoseD7.2.2.5.2 x x x x Every third 
cyclex
Fasting Lipid PanelD7.2.2.5.3 x x x
Coagulation D7.2.2.5.4 x As clinically indicated x
Urinalysis D7.2.2.5.5 x x x x

Novartis Confidential Page 83
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301Category
Reference to 
protocol 
sectionScreening 
phaseTreatment phase Post treatment follow -up phase
Survival 
phase
Visit name Screening Cycle 1 Cycle 2 Cycle 
3
Subsequent 
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days -28 to
-1-7 to -1 1 15 115 1 1 Within 15 
days from 
last doseLast dose + 
30 day sEvery  8 
weeks (if 
applicable) Every  12 
weeks
Tumor assessment
Tumor evaluation 
(RECIST 1.1)D7.2.1 x Every 8 weeks during the first 18 months , then every 12 weeks until 36 months and 
thereafter as clinically indicated until disease progression, death, withdrawal of 
consent, loss to follow -up, subject/guardian decision, and at EOT (If PR/CR is 
reported, confirmation of response is required; confi rmatory assessment should be 
performed ≥ 4 weeks after response is first documented)
Fluid/Tissue collection 
results (if available)D7.2.1 As clinically indicated until disease progression
Whole body bone scanD7.2.1 x (within 42 
days prior to
randomization)As clinically indicated
Cardiac assessment
Triplicate ECG 
(standard 12 -lead)D7.2.2.6.1 x x x x x x x
For all 
cycles up to 
Cycle 6 ,
then as 
clinically 
indicated
As clinically indicated

Novartis Confidential Page 84
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301Category
Reference to 
protocol 
sectionScreening 
phaseTreatment phase Post treatment follow -up phase
Survival 
phase
Visit name Screening Cycle 1 Cycle 2 Cycle 
3
Subsequent 
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days -28 to
-1-7 to -1 1 15 115 1 1 Within 15 
days from 
last doseLast dose + 
30 day sEvery  8 
weeks (if 
applicable) Every  12 
weeks
ECHO or MUGA with 
EFD7.2.2.6.2 x As clinically indicated

Novartis Confidential Page 85
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301Category
Reference to 
protocol 
sectionScreening 
phaseTreatment phase Post treatment follow -up phase
Survival 
phase
Visit name Screening Cycle 1 Cycle 2 Cycle 
3
Subsequent 
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days -28 to
-1-7 to -1 1 15 115 1 1 Within 15 
days from 
last doseLast dose + 
30 day sEvery  8 
weeks (if 
applicable) Every  12 
weeks
Safety
Adverse events D8.1 Continuous –up to 30 days after last dose
Pharmacokinetics
Sparse PK D7.2.3 x x x
Meal record (high 
fat/low fat/fasting for 
sparse PK)D6.1.1.2 x x
Trough PK D7.2.3 x x x

Novartis Confidential Page 86
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301Category
Reference to 
protocol 
sectionScreening 
phaseTreatment phase Post treatment follow -up phase
Survival 
phase
Visit name Screening Cycle 1 Cycle 2 Cycle 
3
Subsequent 
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days -28 to
-1-7 to -1 1 15 115 1 1 Within 15 
days from 
last doseLast dose + 
30 day sEvery  8 
weeks (if 
applicable) Every  12 
weeks
Patient Quality  of life questionnaires
EORTC QLQ -C30 D7.2.6.1 x NA after protocol amendment 4.
EQ-5D-5L D7.2.6.2 x NA after protocol amendment 4.
BPI-SF D7.2.6.3 x NA after protocol amendment 4.
Study  Drug administration
fulvestrant D x x x x x
ribociclib (LEE011) / 
placeboD Day 1 to Day 21 daily,
Day 22 to Day 28 off
Discontinuation
IRT –Discontinuation S7.1.3 x
Antineoplastic 
therapies since 
discontinuation of study 
treatment D7.1.6 x x x
x
Survival follow -up D7.1.7 x

Novartis Confidential Page 87
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301
Table 7- 1b Visit evaluation schedule –Cross over treatment phase for patients who cross over from placebo to LEE011 after 
protocol amendment 4 . CategoryReference 
to 
Protocol 
SectionTreatment Phase -
only applies to cross -over patients for cross over 
treatment cy cles Post treatment follow -up phase
Survival 
phase
Visit name Cross 
over    
Cycle 1Cross 
over
Cycle 
2Cross 
over 
Cycles 3 
to 6All 
subsequent 
Cross over
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -
up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days 1 15 115 1 1 Within 15 
days from 
last doseLast 
dose + 
30 
daysEvery  8 
weeks (if 
applicable) Every  12 
weeks
Dispensing
IRT –cross over 
registrationx
IRT –study drug 
administrationx x x x x
Physical Examination
Physical examination S7.2.2.1 x x x Every 3rd
cyclex
Performance status 
(ECOG)D7.2.2.4 x x x Every 3rd
cyclex
Weight D7.2.2.3 X x x As clinically 
indicatedx
Vital signs D7.2.2.2 x x x Every 3rd
cyclex
Laboratory  assessments

Novartis Confidential Page 88
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301CategoryReference 
to 
Protocol 
SectionTreatment Phase -
only applies to cross -over patients for cross over 
treatment cy cles Post treatment follow -up phase
Survival 
phase
Visit name Cross 
over    
Cycle 1Cross 
over
Cycle 
2Cross 
over 
Cycles 3 
to 6All 
subsequent 
Cross over
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -
up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days 1 15 115 1 1 Within 15 
days from 
last doseLast 
dose + 
30 
daysEvery  8 
weeks (if 
applicable) Every  12 
weeks
Hematology D7.2.2.5.1 x x x x Every 3rd
cyclex
Bioche mistry (including 
fasting glucose)D7.2.2.5.2 x x x x Every 3rd
cyclex
Fasting Lipid Panel D7.2.2.5.3 x x
Coagulation D7.2.2.5.4 As clinically indicated x
Urinalysis D7.2.2.5.5 As clinically indicated x
Tumor Assessments
Tumor Evaluation 
(RECIST 1.1)D7.2.1As clinically indicated
Fluid/Tissue collection 
results (if available)D7.2.1 As clinically indicated until disease progression
Whole body bone scanD7.2.1 As clinically indicated
Safety
Triplicate ECG (standard 
12-lead)D7.2.2.6.1 x x x x As clinically indicated  x
ECHO or MUGA with EF D 7.2.2.6.2 As clinically indicated

Novartis Confidential Page 89
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301CategoryReference 
to 
Protocol 
SectionTreatment Phase -
only applies to cross -over patients for cross over 
treatment cy cles Post treatment follow -up phase
Survival 
phase
Visit name Cross 
over    
Cycle 1Cross 
over
Cycle 
2Cross 
over 
Cycles 3 
to 6All 
subsequent 
Cross over
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -
up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days 1 15 115 1 1 Within 15 
days from 
last doseLast 
dose + 
30 
daysEvery  8 
weeks (if 
applicable) Every  12 
weeks
Concomitant 
medications/proceduresD6.6 Continuous -up to 30 days after last dose
Adverse events D8.1 Continuous  –up to 30 days after last dose
Study  Drug administration
Fulvestrant D6.1.1 x x xDay 1 of 
each cycle
Ribociclib (LEE011) D6.1.1Day 1 to Day 21 daily,
Day 22 to Day 28 off
Disposition Assessment
End of Phase Disposition x x
Discontinuation
IRT –DiscontinuationS7.1.3 x

Novartis Confidential Page 90
Amended Protocol Version 04(Clean) Protocol No. C LEE011F2301CategoryReference 
to 
Protocol 
SectionTreatment Phase -
only applies to cross -over patients for cross over 
treatment cy cles Post treatment follow -up phase
Survival 
phase
Visit name Cross 
over    
Cycle 1Cross 
over
Cycle 
2Cross 
over 
Cycles 3 
to 6All 
subsequent 
Cross over
cyclesEnd of 
study  
treatment 
(EOT)Safety  
follow -
up Efficacy  
follow -upEnd of 
post -
treatment 
follow -upSurvival 
follow -up 
Study  days 1 15 115 1 1 Within 15 
days from 
last doseLast 
dose + 
30 
daysEvery  8 
weeks (if 
applicable) Every  12 
weeks
Survival follow -upD7.1.7 x

Novartis Confidential Page 91
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
7.1.1 Screening
After signing the study  ICF, the screening assessments will be done within 1 to 28days prior 
to randomization or within 1 to 7 days prior to randomization for selected assessments (see 
Table 7-1a for the list of assessments to be performed).
Note: Any screening assessment that is don e outside the screening window (Day -28 to Day  -1 
or Day  -7 to Day  -1 as applicable) must be repeated prior to randomization.
Re-screening of patients is only allowed once per patient if the patient was not registered as 
entering the treatment phase before (i.e. IRT randomization). In this case the Subject No. 
assigned to the patient initially  will be used and the patient will be identified with this number 
throughout her entire participation to the study .
Any screening assessments required within -7 to -1 days must be repeated if Cycle 1 Day 1 visit 
is delay ed more than 7 days after randomization visit. For laboratory  evaluations used to 
determine eligibility , a repeated evaluation within the screening window is permitted for 
screening results out of the defined range. If the repeated laboratory  result meets the criteria, 
that result may  be used to determine eligibility . If the repeated laboratory  result does not meet 
the criteria, the patient will be considered a screening failure. In case rescreening occurs, all 
evaluations re -assessed should meet the eligibility criteria . A new informed consent form must 
be signed only if there is an interruption in the patient’s eligibility  evaluation and the 
investigator chooses to re -screen the patient  following screen failure; the 28 day  screen period 
does not apply  to the informed consent process.  If a new informed consent form is signed, 
adverse events and medical history  will be assessed relative to the new informed consent date.
Assessments of patient reported outcomes should be collected prior to any clinical assessments, 
drug dosing or diagnostic testing.
Any imaging assessments alread y completed during the regular work -up of the patient within 
28days prior to randomization, including before signing the main stud y ICF can be considered 
as the baseline images for this study .
7.1.1.1 Eligibility  screening
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibility check will be embedded in the IRT system. 
Please refer and compl y with detailed guidelines in the I RT manual.
7.1.1.2 Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatment for an y reason will be 
considered a screen failu re. The reason for not being started on treatment will be entered on the 
Screening Phase Disposition Page. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for Screen Failure patients. No other data 
will b e entered into the clinical database for patients who are screen failures, unless the patient 
experienced a Serious Adverse Event during the Screening Phase (see Section 
8.2for SAE 
reporting details).

Novartis Confidential Page 92
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
7.1.1.3 Patient demographics and other baseline characteristics
The data that will be collected on patient characteristics at screening includes:
Demograph y (Date of birth and initials (where permitted), sex, race, ethnicity , source of 
patient referral)
Diagnosis and extent of cancer (including staging at study  entry  and histology /cytology )
Medical history  (e.g., important medical, surgical, and allergic conditions from the patient’s 
medical history  which could have an impact on the patient’s evaluation) / current medical 
conditions (e.g., all relevant current medical conditions which are present at the time of 
signing informed consent). Ongoing medical conditions, symptoms and disease which are 
recorded on the Medical History  eCRF should include the toxicity  grade.
ER, PgR and HER2 status
All prior antineoplastic therapies including surgical interventions and chemo -, biologic -, 
immunologic- and radiation -therapies provided as treatment for cancer prior to the 
administration of study  drug.
All medications and signifi cant non-drug therapies taken within 30 days before the first dose 
is administered. They  must be recorded on the Prior and Concomitant medication or 
Surgical and medical procedures eCRF page and updated on a continual basis if there are 
any new changes to the medications.
Patient
-reported outcome questionnaires (EORTC QLQ -C30, EQ -5D- 5L, and BPI -SF (See 
Section 7.2.6).
Furthermore the following assessments will be performed:
Vital signs
Height, weight
Physical examination
Performance status (ECOG)
Laboratory  evaluations (hematology , PT, INR, chemistry
, lipid panel, urinaly sis)
ECG
ECHO/MUGA
Radiological assessments (e.g. CT Scan)
7.1.2 Treatment period
Patients will be treated with fulvestrant + ribociclib orfulvestrant + placebo until disease 
progression, unacceptable toxicity , withdrawal of consent by the patient, patient is lost to follow 
up, death, discontinuation from the study  treatment due to any other reason or the sponsor 
terminates the study . For de tails of assessments, refer to Table 7 -1aandTable 7 -1b.
7.1.3 Discontinuation of Study Treatment
Patients may voluntarily  discontinue from the study  treatment for any reason at any time. If a 
patient decides to discontinue from the study  treatment, the investigator must make areasonable
effort (e.g. telephone, e-mail, letter) to understand the primary  reason for this decision and 
record this information inthe patient’s chart and on the appropriate CRF pages. They  may be 

Novartis Confidential Page 93
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
considered withdrawn if they  state an intention to withdraw, fail to return for visits, or become 
lost to follow -up for an y other reason.
The investigator should discontinue study  treatment for a given patient if,he/she 
believes that 
continuation would be detriment al to the patient’s well-being.Patients may voluntarily 
withdraw from the stud y or be dropped from it at the discretion of the investigator at an y time.
Patient may  be withdrawn f rom the study  treatment under the following circumstance s:
Emergence of adverse events where the recommendation as per Section 6.5.1.2 is 
discontinuation of ribociclib therap y (including, but not limited to QTcF ≥ 501 msec, confirmed 
at repeated ECG measurements and recurrent after dose adjustment was performed; 
documented episode of ventricular tach ycardia, or ventricular fibrillation; complete heart block 
(Grade III AV block) or Second degree AV block Mobitz type II as well as any relevant 
hepatotoxicity  events).
Lost to follow up
Physician decision
Progression of disease
Study  terminated by  the sponsor
Protocol deviation
Technical problems.
Patient must be withdrawn from the study  treatment if any  of the following occur:
Pregnancy
Death
Subject/guardian decision
In addition to the general withdrawal criteria, the following study  specific criteria will also 
require stud y treatment discontinuation:
Adjustments to study  treatment due to toxicity  that result in discontinuation. Please refer 
to Section 6.5
Use of prohibited medication. Please refer to Section 6.6.3
Any other prot ocol deviation that results in a significant risk to the patient’s safet y.
The appropriate personnel from the site and Novartis will assess whether study treatment 
should 
be discontinued for any patient whose treatment code has been broken inadvert ently for any 
reason.
Patients who discontinue study  treatment should NOT be considered withdrawn from the study . 
They  should return for the assessments indicated in Section 7.1.5 and Section 7.1.6. If they  fail 
to return for these assessments for unknown reasons, every  effort (e.g. telephone, email, letter) 
should be made to contact them as specified in Section 7.1.7 . The patient remains on study  until 
such time as he/she completes protocol criteria for ending study  assessments. At that time, the 
reason for study  completion should be recorded on the End of Post Treatment Phase Disposition 
CRF page.
Patie nts who discontinue study  treatment should be scheduled for an End of Treatment (EOT) 
visit within 15 days following the date study  treatment 
is permanently  discontinued, at which 

Novartis Confidential Page 94
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
time all of the assessments listed for the EOT visit will be performed. For details of assessments, 
refer to Table 7-1. If the decision to discontinue the patient occurs at a regularly  scheduled visit, 
that visit may become the EOT visit rather than having the patient return fo r an additional visit.
An End of phase disposition eCRF page should be completed, giving the date and reason for 
stopping the study  treatment. If a withdrawal occurs, or if the patient fails to return for visits, 
the investigator must determine the primary reason for a patient’s 
premature withdrawal from 
the study  and record this information on the EOT eCRF page. The EOT visit is not considered 
the end of the stud y.
At a minimum, all patients who discontinue study  treatment, including those who refuse to 
return for a final visit, will be contacted for safet y evaluations during the 30 days following the 
last dose of study  treatment.
The investigator must also contact the IRT to register the patient’s discontinuation from study  
treatment.
7.1.3.1 Replacement policy
Not applicable.
7.1.4 Withdrawal of Consent
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a subject :
Does not want to participate in the study  anymore, and 
Does not allow further collection of personal data. 
-In this situation, the investigator should make a reasonable effort (e.g. telephone, e-mail, 
letter) to understand the primary  reason for the subject’s decision to withdraw his/her 
consent and record this information. Study  treatment must be discontinued and no 
further assessments conducted, and the data that would have been collected at 
subsequent visits will be considered missing. Further attempts to c ontact the subject are 
not allowed unless safet y findings require further communicat ionor follow -up.
-All efforts should be made to complete the assessments prior to study  withdrawal. A 
final evaluation at the time of the subject’s study  withdrawal should be made as detailed 
in the assessment table. 
Novartis will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicable 
law.
For US and Japan: Allbiological sa mplesnot y et anal yzed at the time of withdrawal maystill 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and RoW: All biological samples not yet analyzedat the time of withdrawal will no 
longer be used, unless permitted by  applicable law. They will be stored according to applicable 
legal requirements.

Novartis Confidential Page 95
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
7.1.5 Follow up for Safety  Evaluations
All patients will be followed up for safet y up to 30 days after last dose of study  treatment 
(fulvestrant + ribociclib/placebo). Patients whose treatment is interrupted or discontinued due 
to an AE, including abnormal laboratory  value, must be followed until resolution or stabilization 
of the event, whichever comes first. This could include all study  assessments appropriate to 
monitor the event.
Data collected should be added to the Adverse Events CRF and the Concomitant Medications 
CRF.
7.1.6 Efficacy  follow -up
For patients who discontinue treatment for reasons other than disease progression, death, lost 
to follow -up, or withdrawal of consent, tumor assessments (see Section 7.2.1.1) and patient 
reported outcomes (see Section 
7.2.6) must continue to be performed every 8 weeks during the 
first 18 months
,then every 12 weeks until 36 months and thereafter clinically  indicated until 
disease progression, death, lost to follow -
up, or any other reasons listed in Section 7.1.9. At that 
time, the reason for study  completion should be recorded on the End of Post treatment phase 
Disposition eCRF page. If a patient starts a new anti -cancer therap y prior to progression, tumor 
evaluations should continue with the same above schedule (Table 7-1a and Table 7 -1b) until 
disease progression is documented. 
7.1.7 Survival follow -up
All patients will be followed for survival status every  12 weeks (see Section 4.1.5) regardless 
of start of new antineoplastic therap y or any other treatment discontinuation reason, until death, 
lost to follow -up, or withdrawal of consent. Additional survival assessments may be performed 
outside the 12 weeks follow up schedules if a survival update is required for an interim 
assessment to meet safety or regulatory  needs.
Survival information can be obtained via phone, and information will be documented in the 
source documents and relevant eCRFs .
 
 
7.1.8 Lost to f
ollow- up
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw consent, the investigator should show "due diligence" by contacting 
the patient, family  or family  physician as agreed in the informed consent and by documenting 
in the source documents steps taken to contact the patient, e.g. dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow up should be recorded as such on the appropriate 
Disposition CRF.

Novartis Confidential Page 96
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
7.1.9 End of post -treatment follow -up
Prior to collecting survival follow -up information, the end of post treatment phase disposition 
eCRF page will be completed once a patient has discontinued study  treatment, completed safet y 
follow -up, and can no longe r perform efficacy  assessment.
End of post -treatment follow -up may  occur one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Progressive disease
Protocol deviation
Study  terminated by  the sponsor
Technical problems
Subject/guardian decision
Death
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
7.2.1.1 Imaging tumor assessments
Tumor response will be assessed locall y and centrally  according to the Novartis guideline 
version 3.1 (Appendix 2) based on RECI ST Version 1.1 (Eisenhauer et al 2009 ). Further details 
regarding blinded independent review committee (BIRC) assessment will be provided in the 
BIRC charter. The central review ofthe scans will be carried out in a blinded fashion. The 
decision regarding patient management will remain with the local investigator.
Patients 
should have at least one documented measurable lesion (per RECIST v1.1) or in the 
absence of measurable disease , have at least one predominantly  lytic bone lesion at study  entry.
Imaging assessments will be performed at screening within 2 8days prior to randomization and 
subsequently  every 8 weeks during the first 18 months, every 12 weeks until 36 months, then 
change to as clinicall y indicated See Table 7 -2for details of assessments. The interval (8 week, 
12 week , or as clinically  indicated) should be respected regardless of whether study  treatment 
is temporarily  withheld
or unscheduled assessments performed.
After baseline, all assessments should be performed within ±7 days of the scheduled day of 
assessment. The same method of assessment and the same technique should be used to 
characterize each indiv idual and reported lesion at baseline and during follow up.
If a patient discontinues treatment for reasons other than radiological documentation of 
progression of disease, an efficacy  assessment should be performed at the time of End of 
Treatment unless 
aCT/MRI  for tumor measurement was performed within 21 days. Efficacy  
assessments should continue as per the scheduled visit per Table 7-1a andTable 7-1band Table 
7-2.

Novartis Confidential Page 97
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
To the extent possible, each lesion should be assessed using the same imaging method 
throughout the stud y.
All patients will undergo CT or MRI  of the chest, abdomen and pelvis at baseline and 
subsequent scheduled visits per Table 7-1a and Table 7 -1band Table 7-2. The preferred 
imaging methodology  is CT with intravenous (i.v.) contrast. However, if at baseline, a patient 
is known to have a contraindication to CT i.v. contrast media or develops a contraindication 
during the trial, a non-contrast CT of chest (MRI  is not recommended due to respiratory  artifacts) 
plus contrast -enhanced MRI  (if possible) of abdomen and pelvis should be performed.
A whole body  bone scan according to institutional guidelines (e.g. Tc-
99 bone scan, whole body 
bone MRI, FDG -PET or sodium fluoride positron emission tomograph y (NaF PET)) should be 
acquired at baseline for all patients if not collected previously  within 42 days ( 6 weeks) prior 
to randomization. Skeletal lesions identified on the whole body  bone scan at baseline, which 
are not visible on the chest, abdomen and pelvis CT (or MRI ) scan should be imaged at baseline 
and followed at scheduled visits using localized CT, MRI or x-ray. Whole body  bone scans 
need not be repeated after screening unless clinically  indicated.
Color photograph y, including a metric ruler to estimate the size of the lesion, must be acquired 
for all skin lesions present at baseline per instructions provided in the manual from the 
designated vendor. These should be followed throughout the study  according to the schedule 
outlined in Table 7-2.
Other metastatic di sease sites will be followed by  CT or MRI , as clinical ly indicated.
Chest X -ray or ultrasound should not be used to assess tumor lesions.
Partial Response (PR) and Complete Response (CR) must be confirmed by  repeat assessments 
performed not less than 4 weeks and after the criteria for objective response are first met. In 
case tumor assessment is performed <8 weeks from the first assessment of an objective response 
to confirm PR/CR, subsequent tumor assessments should revert back to the protocol schedule 
outlined in Table 7-1.
Positron Emission Tomograph y(PET)/CT may  be used only  if the CT component is of similar 
diagnostic quality  as a CT performed without PET, including the utilization of oral and i.v. 
contrast media. At the discretion of the Investigators, FDG -PET scans may be performed to 
document progressive disease per RECI ST 1.1 ( Appendix 2 ).
If possible, a single radiologist should perform all tumor response evaluations for an individual 
patient. Any lesions in previously  irradiated areas 
should not be considered measurable unless 
they have experienced progression since the radiotherap y. Any pre-existing radiographic 
findings which may mimic metastatic disease and any prior radiotherap y should be recorded in 
the eCRF.
Any imaging assessments alread y completed during the regular work -up of the patient within 
28days prior to randomization (and 42 days for the whole body  bone scan) , including before 
signing the main study  ICF can be considered as the baseline images for this study .
Results from tissue or body fluid collection should be recorded in the eCRF to complement 
radiographic findings
.

Novartis Confidential Page 98
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
All study  imaging performed, including any intercurrent or off-schedule imaging studies 
acquired (e.g., to fulfill a progression or response criterion), should be submitted to the 
designated imaging CRO for quality  control promptly  after acquisition. If an off-schedule 
imaging assessment is performed to confirm response or if progression is suspected, subsequent 
imaging assessments should be performed in accordance with the original imaging schedule.
Physical exam tumor assessments, photograph y, pathology /histo logy and cytology  results, as 
well as, information regarding prior interventions, pre-existing radiographic findings that mimic 
metastatic disease at baseline/screening and on-study  interventions should be captured in the 
appropriate eCRFs and may be trans mitted to the imaging CRO for additional review if 
appropriate .
Note: Radiology  review from the blinded independent revie w committee has been completed. 
Therefore, patients
’radiological and photograph y data images should no longer be transmi tted 
to the imaging CRO.
Table 7
-2 Imaging collection plan
ProcedureScreening: Day  
−28 to Day  -1 Treatment phase*End of 
treatment* Post -Treatment Phase
CT or MRI 
(Chest, 
Abdomen, 
Pelvis)Mandated Every 8 weeks during 
the first 18 months ,
then every 12 weeks 
(± 7 days) until 36 
months and thereafter 
as clinically indicated
until disease 
progression, death, 
withdrawal of consent, 
loss to follow -up, or 
subject/guardian 
decision (±7 d ays).Mandated Every 8 weeks during the first 
18 months , every 12 weeks 
(±7 days) until 36 months, 
and thereafter as clinically 
indicated until disease 
progression, death, 
withdrawal of consent, loss to 
follow -up, or subject/guardian 
decision (±7 days). In the 
absence of disease 
progression, continue the 
assessment even if a new 
anti-neoplastic therapy is 
started until disease 
progression, only in this case 
a ±14 days window is 
allowed.
Brain CT or 
MRIMandated at 
screening if history 
of, existing or 
suspe cted brain 
metastasesIf brain lesion at 
screening: every 8 
weeks during the first 
18 months then every 
12 weeks (± 7 days)
until 36 months and 
thereafter as clinically 
indicated until disease 
progression, death, 
withdrawal of consent, 
loss to follow -up, o r 
subject/guardian 
decision (±7 days).Mandated 
only if 
brain 
lesion at 
screeningIf brain lesion at screening: 
Every 8 weeks during the first 
18 months then every 12 
weeks (±7 days) until 36 
months and thereafter as 
clinically indicated until 
disease prog ression, death, 
withdrawal of consent, loss to 
follow -up, or subject/guardian 
decision (±7 days). In the 
absence of disease 
progression, continue the 
assessment even if a new 
anti-neoplastic therapy is 
started until disease 
progression, only in this case 
a±14 days window is 
allowed.

Novartis Confidential Page 99
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
ProcedureScreening: Day  
−28 to Day  -1 Treatment phase*End of 
treatment* Post -Treatment Phase
Whole body 
bone scan**Mandated , within 
42 days ( 6 weeks) 
prior to 
randomization. As clinically indicated
Bone X -ray, CT 
or MRIOnly if skeletal 
abnormalities 
identified by whole 
body bone scan ** 
at screening, which 
are not visible in 
the chest, 
abdomen, pelvis 
CT/MRI.If bone lesion at 
screening, every 8 
weeks during the first 
18 months then every 
12 weeks (± 7 days)
until 36 months and 
thereafter as clinically 
indicated until disease 
progression, death, 
withdrawal of co nsent, 
loss to follow -up, or 
subject/guardian 
decision (±7 days).Mandated 
only if 
bone 
lesion at 
screeningIf bone lesion at screening, 
every 8 weeks during the first 
18 months then every 12 
weeks (±7 days) until 36 
months and thereafter as 
clinically ind icated until 
disease progression, death, 
withdrawal of consent, loss to 
follow -up, or subject/guardian 
decision (±7 days). In the 
absence of disease 
progression, continue the 
assessment even if a new 
anti-neoplastic therapy is 
started until disease 
progres sion, only in this case 
a ±14 days window is 
allowed.
Skin color 
PhotographyOnly if skin lesions 
at screeningIf skin lesions at 
screening, every 8 
weeks during the first 
18 months then every 
12 weeks (± 7 days)
until 36 months and 
thereafter as clinically 
indicated until disease 
progression, death, 
withdrawal of consent, 
loss to follow -up, or 
subject/guardian 
decision (±7 days).Mandated 
if skin 
lesions at 
screeningIf skin lesions at screening, 
every 8 weeks during the first 
18 months then every 12 
weeks (±7 days) until 36 
months and thereafter as 
clinically indicated until 
disease progression, death, 
withdrawal of consent, loss to 
follow -up, or subject/guardian 
decision (±7 days). In the 
absence of disease 
progression, continue the 
assessment ev en if a new 
anti-neoplastic therapy is 
started until disease 
progression, only in this case 
a ±14 days window is 
allowed.

Novartis Confidential Page 100
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
ProcedureScreening: Day  
−28 to Day  -1 Treatment phase*End of 
treatment* Post -Treatment Phase
CT or MRI of 
any disease 
outside of 
chest, 
abdomen and 
pelvis (e.g., 
neck)Only if suspected 
lesion at screeningIf lesion identified at 
screening, every 8 
weeks during the first 
18 months then every 
12 weeks (± 7 days)
until 36 months and 
thereafter as clinically 
indicated until disease 
progression, death, 
withdrawal of consent, 
loss to follow -up, or 
subject/guardian 
decision (±7 days) .Mandated 
if lesion at 
screeningIf lesion identified at 
screening, every 8 weeks 
during the first 18 months 
then every 12 weeks (±7 
days) until 36 months and 
thereafter as clinically 
indicated until disease 
progression, death, 
withdrawal of consent, loss to 
follow -up, or subject/guardian 
decision (±7 days). In the 
absence of disease 
progression, continue the 
assessment even if a new 
anti-neoplastic therapy is 
started until disease 
progression, only in this case 
a ±14 days window is 
allowed.
*Tumor evaluation at EOT is required for patients who discontinue study treatment before the first scheduled 
post-baseline tumor assessment (week 8) and for patients whose previous tumor assessment did not 
demonstrate PD and was done more than 21 days prior to en d of treatment visit.
** Whole body bone scan according to institutional guidelines (e.g. Tc -99 bone scan, whole body bone MRI, 
sodium fluoride positron emission tomography (NaF PET) or fluorodeoxyglucose (FDG) PET).
Note: All scans will be acquired and an alyzed for primary endpoint locally and sent to the CRO designated by 
Novartis for central imaging interpretation . Central collection should continue until the primary PFS analysis has 
been conducted .
7.2.1.3 Blinded independent review  committee (BIRC) assessment
The primary  end point of the study  is the local investigator assessed PFS. The BIRC assessed 
PFS will serve as a supportive evidence of the primary  end point. The BIRC will perform an 
assessment of PFS data for a randoml y selected subgroup of patients. An independent random 
sampling process will select all scans (and relevant information) from approximately  40% of 
rando mized patients, whose BIRC randomization identity  will be unknown to the investigators. 
The central review of the scans will be carried out in a blinded fashion. The decision regarding 
patient management will remain with the investigators. If consistency o f treatment effect is not 
established, the BIRC may perform an assessment of PFS data for all patients.  Further details 
regarding BIRC assessment will be provided in the BIRC charter.
At present, radiology  review from the blinded independent review commi ttee has been 
completed.

Novartis Confidential Page 101
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by assessing physical examinations, ECOG performance status, height 
and weight, vital signs, ECG, patient reported outcomes, laboratory  assessments (including 
hematology ,chemistry , lipid panel, hepatic safety  markers and INR )as well as collecting of the 
adverse events at every  visit. For details on AE collection and reporting, refer to Section 8.1.
7.2.2.1 Physical examination
The physical examination comprises a total body examination that should include: general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, 
lymph-nodes, extremities, vascular and neurological review. If indicated, rectal, external 
genitalia, breast and pelvis exams will be performed. 
Information about the physical 
examination must be present in the source documentation at the study  site. Physical examination 
is to be performed according to the visit schedule as outlined in Table 7 -1aand Table 7-1b.
Significant findings that were present prior to the signing of informed consent must be included 
in the Medical History  page on the patient’s CRF. Significant new findings that begin or worsen 
after informed consent must be recorded on the Adverse E vent page of the patient’s CRF.
7.2.2.2 Vital signs
Vital signs (body temperature, pulse rate, blood pressure) will be monitored as per the visit 
schedule (see Table 7-1aand Table 7 -1b). Blood pressur e (systolic and diastolic) and pulse 
should be measured after the patient has been sitting for approximately  five minutes.
7.2.2.3 Height and weight
Height and bod y weight will be measured as outlined in the visit schedule (see Table 7
-1aand
Table 7-1b).
7.2.2.4 Performance status
The performance status will be assessed according to the ECOG performance status scale (Table 
7-3) ( Oken 1982 ) following the schedule given in Table 7-1a andTable 7 -1b.
Table 7-3 ECOG performance status
Grade ECOG status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature e.g., light house work, office work
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead
7.2.2.5 Laboratory  evaluations
Clinical laboratory  analyses (Hematology , Chemistry , Coag ulation, Urinal ysis, Lipid Panel) are 
performed by the central laboratory as per schedule in the Table 7-1a and Table 7-1b. Details 

Novartis Confidential Page 102
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
on the collection, shipment of samples and reporting of results by the central laboratory  are 
provided to investigators in the laboratory  manual. Visit windows of ± 3 days are allowed for 
all visits.
Novartis must be provided with a copy  of the central laboratory ’s certific ation (if applicable), 
and a tabulation of the normal ranges and units of each parameter collected in the eCRF. Any 
changes regarding normal ranges and units for laboratory  values assessed during the study  must 
be reported via an updated tabulation indicat ing the new effective date. Additionally , if at any 
time a patient has laboratory  parameters obtained from a different (outside) laboratory , Novartis 
must be provided with a copy  of the certification and a tabulation of the normal ranges and units 
for thislaboratory  as well. The investigator is responsible for reviewing all laboratory  reports 
for patients in the study  and evaluating any  abnormalities for clinical significance.
Unscheduled local laboratory  assessments may be performed if medically  indicated to 
document a (potential) adverse event or when the treating physician cannot wait for central 
laboratory  results for decision making (e.g. dose modifications). In this particular situation, if 
possible, the blood sample obtained at the same time point should be submitted to the central 
laboratory  for anal ysis in parallel with local anal ysis. 
The results of the local laboratory  will be recorded in the eCRF if any  of the following criteria 
are met:
A treatment decision was made based on the local results, or
Local lab results document an adverse event not reported b y the central lab, or
Local lab results document an adverse event severity  is worse than the one reported b y the 
central lab, or
There are no concomitant central results available
For assessment of patients’ eligibility to the study, only laboratory results from the central 
laboratory will be used.
At an y time during the study, abnormal laboratory parameters which are clinically relevant and 
require an action to be taken with study  treatment (e.g., require dose modification and/or 
interruption of study  treatment, lead to clinical symptoms or signs, or require therapeutic 
intervention), whether specificall y requested in the protocol or not, will be recorded on the AE 
eCRF page. Laboratory  data willbe summarized using the Common Terminology  Criteria for 
Adverse events (CTCAE) version 4.0.3. Additional analyses are left to the discretion of the 
investigator.
Table 7-4 Central clinical laboratory  parameters collection plan
Test Category Test Name
Hematology White blood cell count ( WBC) with differential (neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils), hemog lobin (Hgb) and platelet count.
Biochemistry with 
fasting glucoseSodium, potassium, urea or BUN, creatinine, fasting glucose, calcium, corrected 
calcium, magnesium,phosphorous total protein and albumin.
AST (SGOT), ALT (SGPT), total bilirubin, direct bilirubin, GGT and alkaline 
phosphatase, amylase , lipase and LDH.
Fasting Lipid Panel Total cholesterol, LDL -cholesterol, HDL -cholesterol and triglycerides
Coagulation PT, International normalized ratio [INR]

Novartis Confidential Page 103
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Test Category Test Name
Urinalysis Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, Ketones, Leukocyt es 
esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)
If there are any significant findings on the dipstick then a microscopic evaluation should 
be measured: Microscopic Panel ( WBC and RBC sediments, Casts, Crystals, Bacteria, 
Epithelial cell s)
7.2.2.5.1 Hematology
Hematology  tests are to be performed according to the Visit Schedules outlined in Table 7 -1a
and Table 7-1b. For details of the Hematology  panel refer to Table 7 - 4.
7.2.2.5.2 Biochemistry
Biochemistry  tests are to be performed according to the Visit Schedules outlined in
Table 7-1a andTable 7 -1b. For details of the biochemistry  panel refer to Table 7 - 4.
7.2.2.5.3 Lipid panel
Lipid panel tests are to be performed according to the Visit Schedules outlined in Table 7-1a
andTable 7
-1b. For details of the lipid panel refer to Table 7-4.
7.2.2.5.4 Coagulation
Coagulation tests are to be performed according to the Visit Schedules outlined in Table 7-1a
and Table 7 -
1b. For details of the coagulation panel refer to Table 7 - 4. If the coagulation blood 
sample collected at screening is clotted when received by central laboratory  for testing or the 
central laboratory results of only the coagulation are delayed, the patient is still eligible to enter 
the study  with a local INR tes t ≤
1.5.
7.2.2.5.5 Urinalysis
Urinaly sis is to be performed according to the Visit Schedules outlined in Table 7-1aandTable 
7-1b. For details of the urinaly sis panel refer to Table 7 -4.
7.2.2.5.6 Hepatic Safety Markers
Following protocol amendment 4, hepatic safety marker collection will stop.
 
 
 
 
 
 
Blood samples will be colle cted from all patients at Day 1of Cycles 1 through 6. Patients should 
be fasted overn
ight for at least 8 hours.
An additional blood sample is requested from patients in response to rise in ALT/AST or in 
total bilirubin (as described below) if this rise occurs outside of the scheduled collection dates:

Novartis Confidential Page 104
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
In patients with normal AST and ALT a ndtotal bilirubin at baseline that present a rise of 
AST or ALT ≥ grade 2 with total bilirubin > 2 x ULN without evidence of cholestasis 
(defined as: AL P elevation > 2.0 x UL N with R value [AL T/ALP in x ULN] < 2 in 
patients without bone metastasis, or ele vation of ALP liver fraction in patients with bone 
metastasis). 
OR
For patients with elevated baseline AST or ALT or total bilirubin that present [AST or 
ALT >2 x baseline AND >3.0x UL N] OR [AST or AL T 8.0x ULN] -whichever is lower -
combined with [total b ilirubin 2xbaseline AND >2.0 x ULN] 
OR
ALT or AST > 8 x ULN without bilirubin increase
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
Following protocol amendment 4, central ECG collection ceases and all ECGs should be 
read locally. No timematched PK samples should be collected with ECG assessments .
Standard triplicate 12 lead ECG assessment swill be performed after the patient has been resting 
for 5-10 min prior to each time point indicated in Table 7- 5aand Table 7 -5bbelow. Triplicate 
ECGs should be taken approximately  2 minutes apart. Thecombined QTcF values from these 
triplicate ECGs will be averaged to provide a single value for each time point . Eligibility  will 
be based on the average of the triplicate ECGs conducted at screening.
Timing of study  procedures:
*ECG assessments are to be done prior to PK sampling (if applicable).
Table 7 -5a Local ECG collection plan
Cycle Patients Day Time ECG T ype
Screening All -7 to -1 Anytime Triplicate 12 Lead
1 All Day 152Pre-dose1Triplicate 12 Lead

Novartis Confidential Page 105
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Cycle Patients Day Time ECG T ype
All 2h post -dose (± 15 min) Triplicate 12 Lead
All 4 h post -dose (± 15 min) Triplicate 12 Lead
2 All Day 12Pre-dose1Triplicate 12 Lead
All Day 152Pre-dose1Triplicate 12 Lead
2h post -dose (± 15 min) Triplicate 12 Lead
3 All Day 1 Pre-dose1Triplicate 12 Lead
2h post -dose (± 15 min) Triplicate 12 Lead
4 All Day 1 Pre-dose1Triplicate 12 Lead
5 All Day 1 Pre-dose1Triplicate 12 Lead
6 All Day 1 Pre-dose1Triplicate 12 Lead
2h post -dose (± 15 min) Triplicate 12 Lead
All other cycles All As clinically 
indicatedAnytime Triplicate 12 Lead
EOT Anytime Triplicate 12 Lead
Unscheduled ECG Anytime Triplicate 12 Lead
1The exact date and time of dosing must be recorded on the appropriate eCRF
Table 7-5b Local ECG collection plan –for crossover patients
Patients Cross Over Cycle Day / time ECG type 
All 1 Day 1 / Pre-dose1Triplicate 12 Lead
All 1 Day 15/anytime Triplicate 12 Lead
All 2 Day 1 /anytime Triplicate 12 Lead
All 2 Day 15 / anytime Triplicate 12 Lead
All All other cycles As clinically indicated Triplicate 12 Lead
All EOT Anytime Triplicate 12 Lead
All Unscheduled ECG Anytime Triplicate 12 Lead
1The exact date and time of dosing must be recorded on the appropriate eCRF
Patients in the placebo arm who elect to transition from placebo to LEE011 must have ECG for 
QT assessment on the first day before the administration of LEE011. LEE011 should be 
initiated only in patients with QTcF values <450 msec.ECGs should be repeated on cross -
over Cycle 1 Day 15, C ycle 2 Da y 1, Day  15and then as clinicall y indicated as per Table 7-5b.
In order for an accurate evaluation of baseline QTcF, a total of three 12-lead ECGs will be 
performed within 7 day s prior to randomization (at screening between Day  -7 and Day  -1).
Note: In order to ensure ECG evaluation is received from the central laboratory  for eligibilit y 
assessment, it is advisabl e to perform the ECG at least 24 hours prior the scheduled 
randomization date.
If a QTcF value of ≥ 481 ms is observed in a single ECG or as the average (when collected as 
a triplicate) at any time after randomization, study  treatment must be interrupted, repeat ECG (s)
and follow management guidelines detailed in Table 6 -6.
An unscheduled ECG may be repeated at the discretion of the investigator at any time during 
the study  and as clinically  indicated. Unscheduled ECGs with clinically  significant findings 

Novartis Confidential Page 106
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
should be collected in triplicate. Additionally , a local cardiologist may be consulted at any time 
during the stud y at the discretion of the investigator. If an unscheduled ECG is performed at an 
external medical facility , a copy  of the ECG should be obtained and forwarded to the ECG 
central laboratory , and a copy  kept in the source documents at the study  site. Centrally  reviewed 
ECG findings should be documented on the ECG CRF page.
In the event that a QTcF value of ≥501ms is observed or if an unscheduled ECG is performed 
for safet y reasons, it is recommended to collect a time -matched PK sample and record the time 
and date of the last study  drug intake to determine the drug exposure . If PK sampling is possible, 
refer to the section PK sampling and detail approp riate procedures to be followed (Section 7.2.3).
All ECGs including unscheduled triplicate ECGs with clinically  relevant findings, collected 
during the study  should be transmitted to the central laboratory  and will be centrall y reviewed 
by an independent reviewer. The results of the centrall y assessed ECGs are electronically 
transferred into the clinical database.
Any original ECG not transmitted to a central laboratory  should be forwarded for central review . 
Interpretation of the tracing must be made by a
 qualified physician and documented on the ECG 
CRF page. Each ECG tracing should be labeled with the study  number, patient initials (where 
regulatio ns permit), patient number, date, and kept in the source documents at the study  site. 
Clinically  significant ECG abnormalities present at screening when the patient signed informed 
consent should be reported on the Medical History  CRF page. New or worsened clinicall y 
significant findings occurring after informed consent must be recorded on the Adverse Events 
CRF page.
7.2.2.6.2 Cardiac imaging - MUGA (multiple gated acquisition) scan or 
echocardiogram
Cardiac imaging will be performed by MUGA scan or ECHO in order to assess the left 
ventricular ejection fraction. This assessment will be performed according to the schedule given 
in Table 7
-1aand Table 7 -1b.
The same technique 
(MUGA or ECHO) must be used during the course of the trial, and the 
method used will be recorded in the eCRF. Only  clinically  significant abnormalities should be 
reported in the Adverse Events eCRF .
In case a patient develops left ventricular systolic dysfunction while on study  treatment dose 
adjustment guidelines described in Table 6 -7must be followed.
7.2.3 Pharmacokinetics
Follow ing protocol amendment 4, there will be no more PK blood collection, including 
patients that cross -over to the LEE011 combination arm. 
Pharmacokinetic blood samples will be obtained from all patients for the analy sis of ribociclib 
(and any relevant metabo lites such as LEQ803). Patients will be assigned to the sparse PK 
collection group or the trough PK collection group.
Sparse PK collection group: I n the sparse PK group, approximately  the first 150 patients 
enrolled will have PK collections as described in Table 7-6.

Novartis Confidential Page 107
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Trough PK collection group: I n all remaining patients, PK collections will be collected as 
described in Table 7 -7.
Meal conditions (fasting, low fat, high fat) will be recorded within ± 30 minutes of a dose on 
the meal record eCRF page for patients assigned to the sparse PK collection group on Cy cle 1 
Day 15 and C ycle 2 Day 15
; the impact of meal conditions on PK in patients may  be explore d.
Refer to Section 6.1.1.2 and Section 10.6.3 for details.
An unscheduled PK blood sample may be collected at any time for measurement of plasma drug 
concentrations if clinically indicated or at the Investigator’s discretion. I f a patient discontinues 
from the study  treatment due to toxicities related to study  treatment, an unscheduled PK blood 
sample may be obtained as soon as possible after the last dose and the date and time of last dose 
recorded. In addition, an unscheduled blood sample may be collected if additional ECG 
measurements are conducted.
The date and exact time of dosing on PK collection days, as well as the date and actual time of 
blood sampling must be recorded on the appropriate eCRF pages. In addition, the exact time of 
dosing o n the previous day  must be precisel y recorded.
If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed, and 
medication should resume on the next day. The occurrence and frequency  of any vomiting must 
be noted in the adverse events section of the eCRF. In addition, thedate and exact time of 
vomiting should only be recorded if it occurs within 4hours of dosing on the days of PK 
sampling. If a vomiting episode occurs within the first 4 hours post-dosing during the day of 
the last dose prior to trough PK samples the exact time (whenever possible) must be noted on 
the eCRF. Adetailed description of the planned analy ses for PK isgiven in Section 10.5.4.
7.2.3.1 Pharmacokinetic blood sample collection and handling
Blood samples will be obtained from all patients either by direct venipuncture or through an 
indwelling cannula (e.g., inserted in a forearm vein, or central venous line) for the analy sis of 
plasma concentrations of ribociclib (and any relevant metabolites such as LEQ803), when 
feasible. At the specified time points described in Table 7-6and Table 7-7, one single 3mL 
blood draw will be collected into a tube containing EDTA and gently  inverted several times to 
thoroughl y mix the anticoagulant. The blood tube will be centrifuged to separate the plasma.
Plasma will immediately be split and transferred into separate pre -labeled tubes for ribociclib . 
Plasm a samples will be stored frozen in an upright position until shipment.
Any sampling problems (e.g., patient took study  drug before blood sample, scheduled sampling 
time is missed, sample is not drawn according to the schedule) should be noted as a comment 
on the eCRF
.
Refer to the [Central Laboratory  documents] for detailed instructions for the collection, 
handling, and shipment of PK samples.

Novartis Confidential Page 108
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Table 7-6 Sparse pharmacokinetic blood collection log
Note: Sparse PK sampling will be performed on approximately the first 150 patients in this study. Blood for 
Sparse PK profiling will be collected on C1D15 and C2D15 at Pre -dose (0), 2, 4, 6hr, and C2D1 Pre-dose (0hr) 
for ribociclib/placebo. Only for the sparse PK group, the meal c ondition (fasting, low fat, high fat) will be 
collected within ± 30 minutes of the dose on the eCRF on days C1D15 and C2D15.
Cycle DayScheduled Time Point 
Relative to DosingDRID No. for 
ribociclib/ 
placeboPK Sample No. 
for ribociclib/ 
placeboBlood Vol ume 
(mL)
1 15 Pre-dosea 101/1001d101 3
2h post -dose (± 15 min) 101 102 3
4h post -dose (± 15 min) 101 103 3
6h post -dose (± 15 min) 101 104 3
2 1 Pre-dosea102 105 3
15 Pre-dosea103/1003d106 3
2h post -dose (± 15 min) 103 107 3
4h post-dose (± 15 min) 103 108 3
6h post -dose (± 15 min) 103 109 3
Unscheduled AnytimebNA 1001+ 3
PK samples related to a QTcF 
≥ 501 mscNA 1051+ 3
a.Collect Pre -dose PK sample immediately before drug administration (approximately 24 -hrs after the last 
dose and immediately before the next dose)
b.Unscheduled PK blood samples may be collected at any time for measurement of plasma drug 
concentrations if clinically indicated or at the Investigator’s discretion and will be uniquely, sequentially 
numbered 1001, 1002, etc., for ribociclib/placebo
c.Unscheduled PK samples related to a QTcF ≥ 501 ms will be uniquely, sequentially numbered 1051, 1052, 
etc., ribociclib/placebo
d.The first dose reference ID (DRID) No. is for the current dose, while the second DRID No . is for the last 
dose the subject received prior to the collection of the PK sample
Table 7-7 Trough pharmacokinetic blood collection log
Note: Trough PK sampling will be performed in all remaining patients Pre -dose on C1D15, C2D1 and C2D15.
Cycle DayScheduled Time Point Relative 
to DosingDRID No. for 
ribociclib/ 
placeboPK Sample 
No. for 
ribociclib/ 
placebo Blood Volume (mL)
1 15 Pre-dosea201/2001d201 3
2 1 Pre-dosea202 202 3
15 Pre-dosea203/2003d203 3
Unscheduled AnytimebNA 2001+ 3
PK samples related to a QTcF ≥ 
501mscNA 2051+ 3
a.Collect Pre -dose PK sample immediately before drug administration (approximately 24 -hrs after the last 
dose and immediately before the next dose)
b.Unscheduled PK blood samples may be collected at any time for measurement of plasma drug 
concentrations if clinically indicated or at the Investigator’s discretion and will be uniquely, sequentially 
numbered 2001, 2002, etc., for ribociclib/placebo
c.Unscheduled PK samples relat ed to a QTcF ≥ 501 ms will be uniquely, sequentially numbered 2051, 2052, 
etc., ribociclib/placebo
d. d.The first DRID No is for the current dose, while the second DRID No is for the last dose the subject 
received prior to the collection of the PK sample

Novartis Confidential Page 109
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Additional guidelines for pharmacokinetic sampling/ECG
On day s with PK sampling and/or ECG testing (collection days are outlined in Table 7 - 1a), the 
following additional guidelines must be followed:
Pre-dose ECGs must be done first, prior to pre -dose PK sampling and prior to dosing .
The time of PK collection and the time the study  medication was taken must be precisel y 
recorded in the eCRF .
Furthermore, the date and time the study  medication was taken on the daybefore the PK 
collection must be precisely  recorded in the eCRF .
Post-dose ECGs and/or PK samples should be collected after dosing of the study  treatment. 
ECGs must be done prior to PK sampling.
ECG and PK sample collection will be performed accord
ing to Section 7.2.3 and 
Table 7-5a andTable 7 -5b, Table 7-6 and Table 7 - 7.
In the case where ribociclib/placebo is being temporaril y interrupted or has been 
permanentl y interrupted, no PK samples will be collected for the corresponding visit.
7.2.3.2 Analytical method
Plasma concentrations of ribociclib (and any relevant metabolite such as LEQ803) will be 
measured using validated liquid chromatography -tandem mass spectrometry  (LC-MS/MS) 
methods with a lower limit of quantification (LLOQ) of approximately  1.0 ng/ml for ribociclib. 
Sample analy sis will be performed by Novartis or a Novartis designated laboratory  using 
validated methods. Any results below the LLOQ and any missing samples will be recorded 
accordingl y.
Leftover plasma from analy sis may be used for  other 
bioanaly tical purposes (e.g., cross check between different sites, stability  assessment).

Novartis Confidential Page 110
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 111
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 112
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 113
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
7.2.6 Patient reported outcomes
The Europ ean Organization for Research and Treatment of Cancer’s core quality  of life 
questionnaire (EORTC -QLQ -C30, version 3.0), the EuroQoL 5-level instrument (EQ -5D- 5L, 
tablet version), and the Brief Pain Inventory -Short form questionnaire (BPI -SF, copyright 1991) 
will be used to evaluate patient -reported outcome measures of health -
related quality -of-life, 
functioning, disease s ymptoms, treatment -related side effects, global health status, and cancer -
related pain. The EORTC QL Q-C30, EQ -5D- 5L, and BPI -SF are recog nized reliable and valid 
measures (Aaronson 1993, Rabin 2001, Cleeland 1994 ) frequentl y used in clinical trials of 
patients with advanc ed or metastatic breast cancer.
All patient -reported outcome (PRO) measures (eg, EORTC QLQ -C30, EQ-5D- 5L, and BPI-SF) 
will be administered before an y study drug administrations at the visits indicated in Table 7 -1a
and Table 7 -9. Collection of PRO measures have a ± 7 day  window unless otherwise indicated.
All PRO data will be collected using an electronic tablet
device and should be administered in 
the patient’s local language at the beginning of the study  visit prior to any  interaction with the 
study  investigator including any tests, treatments or receipt of results from any tests to avoid 
biasing the patient’s perspective. Patients should be given sufficient space and time to complete 
all study  questionnaires and all administered questionnaires should be reviewed for 
completeness. If missing responses are noted, patients should be encouraged to complete any 
missing responses. Attempts should be made to collect responses to all questionnaires for all 
patients, including from those who discontinue prior to the study  evaluation completion visit, 
however, if patients refuse to complete questionnaires, this should be documented in study  
source records. Patient’s refusal to complete stud y questionnaires are not protocol deviations.
The use of electronic data collection of clinical outcome assessments (eCOA), including PROs, 
has been endorsed as standard. The use of both eCOA and paper PRO collect ion of the same 

Novartis Confidential Page 114
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
COA measure in a single study  is not endorsed. However, paper PRO may be utilized as a 
backup shoud there be a failure with the electronic version /system .
Paper should be used as a last resort option. In case of any issues with the device use, which 
cannot be resolved within the visit time window, PRO questionnaires could be completed on 
paper form and transcribed into the tablet at the next possible opportunity .
All questionnaires should be administered in the patient’s local language prior to any 
interaction with the study  investigator. This is to avoid potentially  biasing patients or their 
responses to study  questionnaires.
Completed questionnaires, including both responses to the questions and any unsolicited 
comments written by  the patient, must be reviewed and assessed by  the investigator before the 
clinical examination for responses which may indicate potential AEs or SAEs. This review 
should be documented in study  source records.
If an AE or SAE is confirme d then the physician should record the event as instructed in Section 
8of this protocol. I nvestigators should not encourage the patients to change respons es reported 
in questionnaires.
Following protoc ol amendment 4, no additional PRO measur es should be collected from 
any patients.
Table 7-9 Patient reported outcomes collection plan
Patient 
Questionnaire Cycle Visit Time
EORTC QLQ -C30
EQ-5D-5L
BPI-SFScreening -28to Day -1 Prior to any clinical 
assessments, drug 
dosing or 
diagnostic testingSubsequent 
cyclesEvery 8 weeks after randomization during the 
first 18 months , then every 12 weeks until 36 
months . Thereafter, PRO collection should align 
with periodic efficacy assessments until disease 
progression, death, withdrawal of consent, loss 
to follow -up, or subject/guardian decision
Endof 
treatmentDay of EOT visit
Efficacy follow -
upContinue collection every 8 weeks after 
randomization during the first 18 months and 
every 12 weeks thereafter until 36 months, then 
align with the efficacy assessments only in case 
end of treatment occurs for reasons other than 
death, lost to follow -up, withdrawal of consent, 
or disease progression
7.2.6.1 EORTC QLQ -C30
The EORTC QLQ-C30 contains 30 items and is composed of both multi- item scales and single -
item measures. These include five functional scales (physical, role, emotional, cognitive and 
social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items 
(dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global 
health status/QoL  scale ( Aaronson et al 1993 ).
All of the scales and single -item measures range in score from 0 to 100. A high scale score 
represents a higher response level. Thus a high score for a functional scale represents a high / 

Novartis Confidential Page 115
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
healthy  level of functioning; a high score for the global health status / QoL represents a high 
QoL, but a high score for a symptom scale / item represents a high level of symptomatology  / 
problems. All scoring will follow the scoring procedures defined by the EORTC Scoring 
Manual ( Fayers et al 2001 ).
7.2.6.2 EQ-5D-5L
The EQ-
5D-5L (tablet version) is a standardized measure of health utility  that provides a single 
index value for one’s health status. The EQ -5D- 5L is frequentl y used for economic evaluations 
of health care and has been shown to be a valid and reliable instrume nt (The EuroQol Group 
1990, Rabin 2001). The EQ- 5D- 5L contains one item for each of five dimensions of HRQOL 
(i.e., mobility , self-care, usual activ ities, pain or discomfort, and anxiety  or depression). 
Response options for each item vary from having no problems (e.g., “…no problems walking 
about”), moderate problems (e.g., “…some problems walking about”), or extreme problems 
(e.g., “…unable to walk about”). Patient responses to the five dimensions of HRQOL reflect a 
specific health state that corresponds to a population preference weight for that state on a 
continuous scale of 0 (death) to 1 (perfect health). A visual analog scale (ranging from 0 to 100) 
is also included to capture patient’s rating of their overall health status. Higher scores of the 
EQ-
5D-5L represent better health states. All scoring and handling of data will follow the User’s 
Guide defined b y the EuroQoL  Group ( Oemar and Janssen 2013 ).
7.2.6.3 Brief Pain Inventor y-Short Form
The BPI-SF is a short, self-administered 11-item questionnaire designed to evaluate the 
intensity  of and impairment caused by cancer pain. All questions in the BPI
-SFare scored using 
an 11 -point rating scales. Four questions measure pain intensity (pain now, average pain, worst 
pain, and least pain) using 0 ("no pain") to 10 ("pain as bad as you can imagine") numeric rating 
scales; and seven additional questions measu re the level of interference caused by pain (general 
activity , mood, walking ability , normal work, relations with other persons, sleep, and enjoyment 
of life) using 0 (no interference) to 10 (complete interference) rating scales.
Questions from the BPI -SF are aggregated into a pain severity  index defined based on the sum 
of four items focused on pain intensity , and pain interference indices defined as subscale scores 
of pain interference with activity  (interference with walking, general activity  and work) and 
affect (interference with relations with others, enjoy ment of life and mood) and an overall 
interference score (all seven items) ( Cleeland 1994 ). Missing values will be handled as 
recommended by the developers of the BPI -SF (Cleeland 2009 ). All four severit y items must 
been completed for aggregating a pain severity  index. The pain interference indices are scored 
as the mean of the item scores multi
plied given that more than 50%,of the items have been 
completed.

Novartis Confidential Page 116
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considere d clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s CRF. Adverse event monitoring should 
be continued for at least 30 days following the last dose of study  treatment. Adverse events 
(including lab abnormalities that constitute AEs) should be described using a diagnosis 
whenever possible, rather than individual underly ing signs and symptoms. When a clear 
diagnosis cannot be identified, each sign or s ymptom should be reported as a separate Adverse 
Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adver se 
Events (CTCAE) version 4.03.
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate , severe, 
and life -threatening, corresponding to Grades 1 -4, will be used. CTCAE Grade 5 (death) will 
not be used in this study (‘but is collected as seriousness criteria’) ; rather, information about 
deaths will be collected though a Death form.
The occu rrence of adverse events should be sought by  non-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered bythe patient 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1 -4)
2.Itsduration (Start and end dates)
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No,
Yes, investigational treatment, Yes, the study  treatment (non -investigational), Yes, both 
and/or indistinguishable)
4.Action taken with re spect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therapy )

Novartis Confidential Page 117
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
and which seriousness criteria have been met
If the event worsened the event should be reported a second time in the CRF noting the start 
date when the even worsens in toxicity .  For Grade 3 and 4 adverse events only, if improvement 
to a lower grade is determined a new entry  for this event should be reported in the CRF noting 
the start date when the event improved from having been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by use 
of appropriate 
method (for example, as per RECI ST criteria for solid tumors or as per Cheson's guidelines for 
hematological malignancies), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombos is 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions a nd reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events CRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to norma l or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 
the protocol in which case the lab abnormality  would still, by definition, be an adverse event 
and must be reported as such.

Novartis Confidential Page 118
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
8.2 Serious adverse ev ents
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined a s an event that jeopardizes the patient or may require 
medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospitalization or prolongati on of existing hospitalization,
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
a.Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition.
b.Elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study  and has not worsened sinc e signing the informed consent.
c.Social reasons and respite care in the absence of any deterioration in the patient’s 
general condition.
Note that treatment on an emergency  outpatient basis that does not result in hospital 
admission and involves an event not fulfilling any of the definitions of a SAE given above 
is not a serious adverse event.
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hours of learning of its occurrence.
Any SAEs exper ienced after this 30 days period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study  treatment. Recurrent episodes, 
complications, or progression of the initial SAE must be reported as follow -up to the origin al 
episode within 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously  reported one should be reported separately  as a new event.
Inform ation about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of eac h SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English and submit the completed form within 24 hours to Novartis .Detailed 
instructions regarding the SAE submission process and requireme nts for signatures are to be 
found in the investigator folder provided to each site.
Follow -up information is submitted in the same way the original SAE Report .  Each re-
occurrence, complication, or progression of the original event should be reported as afollow -
up to that event regardless of 
when it occurs. The follow -up information should describe 

Novartis Confidential Page 119
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the Novartis study  treatment, an oncology  Novartis 
Drug Safet y and Epidemiology  (DS&E) departmen t associate may urgently  require further 
information from the investigator for Health Authority  reporting. Novartis may need to issue 
an Investigator Notification (IN), to inform all investigators involved in any study with the same 
drug that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory  requirements 
in particip ating countries.
8.3 Emergency  unblinding of treatment assignment
Following protocol amendment 4, the emergency unblinding procedures are no longer 
applicable as all patients will be unblinded and made aware of their study treatment .
Emergency  unblinding should only be undertaken for safet y reasons when it is essential for 
effective treatment of the patient. Most often, study treatment discontinuation and knowledge 
of the possible treatment assignments are sufficient to treat a study  patient who presents with 
an emergency  condition. Emergency  code breaks are performed using the IRT. When the 
investigator contacts the IRT to unblind a patient, he/she must provide the requested patient 
identify ing information and confirm the necessit y to unblind the patient. The investigator will 
then receive details of the drug treatment for the specified patient and a fax confirming this 
information. The system will automatically  inform the Novartis monitor for the site and the 
Study  Lead that the code has been broken.
It is the investigator’s responsibility  to ensure that there is a procedure in place to allow access 
to the IRT in case of emergency. The investigator will inform the patient how to contact his/her 
backup in cases of emergency  when he/she is unavailable. The protoco l number, study  treatment 
name if available, patient number and instructions for contacting the local Novartis CPO (or 
any entit y to which it has delegated responsibility  for emergency  code breaks) will be provided 
to the patient in case emergency  unblindi ng is required at a time when the investigator and 
backup are unavailable. However, if a mechanism is alread y in place to ensure that the 
investigator and/or back -up can alway s be reached in case of emergency  then the procedure 
above is not required.
Study treatment must be discontinued once emergency  unblinding .
8.4 Pregnancies
To ensure patient safet y, each pregnancy occurring while the patient is on study treatment must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy shou ld be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  Novartis Drug Safety  and Epidemiology  Department (DS&E). 

Novartis Confidential Page 120
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the investigational treatment any  pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropria te, other than those noted in the provided [I nvestigator 
Brochure]. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the study as needed.
8.6 Data monitoring committee
An independent data monitoring committee (IDMC) will be established to assess the safet y 
results of ribociclib in an unblinded manner. The IDMC will be responsible for reviewing the 
safet y results and overseeing the safety  data accruing in the trial at regular intervals of 
approximately  every  six months, provided that sufficient patients have been randomized. Also, 
if requested b y the IDMC Chair, additional safety reviews may  be performed.
The IDMC will consist of at least two oncologists and one biostatist ician and will be formed 
prior to the randomization of the first patient. Detailed recruitment status and interim safety  
reports will be provided to the IDMC on a regular basis. Recruitment will not be interrupted. 
Details will be provided in the IDMC char ter.
8.7 Steering committee
The SC will be established comprising investigators participating in the trial, and Novartis 
representatives from the Clinical Trial Team.
The SC will be an advisory board for the study  according to the protocol through recommending
modifications as circumstances require. The SC will be consulted for protocol amendments as 
appropriate. Together with the clinical trial team, the SC will also develop recommendations 
for publications of study  results. The details of the role of the SC will be defined in a SC charter. 
The SC will not have access to unblinded trial data.
9 Data collection and management
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y

Novartis Confidential Page 121
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new or worsene d AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
Prior to entering key sensitive personally  identifia ble information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, thesystem will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements and 
to enable appropriate age -related normal ranges to be used in assessing l aboratory  test results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the CRF entries. Novartis monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria and documentation 
of SAEs. Additional checks of the consistency  of the source data with the CRFs are performed 
according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 

Novartis Confidential Page 122
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
have been built using fully validated secure web-enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry  and updates are performed in a timely  manner.
Blood and tumor samples for laboratory data, PK  assessments will be collected 
by sites and sent to the Novartis designated central laboratory  for processing. The laboratory 
results and IRT data will be sent electronically  to Novartis. Imaging and ECG data will be 
collected at the sites and the data will be transmitted to a designated CRO for centralized 
analysis, as well as further processing. PRO data will be recorded by patients onto the electronic 
tablet devic e maintained at the study  site. The device will be programmed 
to ensure thatall
relevant observations arerecorded.
As detailed in Section 7.2following Protocol Amendment 4, no additional PK, ePRO data,
central ECGs will be collected for all patients, including 
patients who elect to transition from placebo to LEE011 combination treatment.
9.4 Database management and quality  control
For studies using eCRFs, Novartis personne l will review the data entered by investigational 
staff for completeness and accuracy . Electronic data queries stating the nature of the problem 
and requesting clarification will be created for discrepancies and missing values and sent to the 
investigation al site via the EDC system. Designated investigator site staff is required to respond 
promptly  to queries and to make an y necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data (e.g. PK, ECG, imaging, safety  samples) will be processed 
centrall y and the results will be sent electronically to Novartis. PRO data collected using an 
electronic tablet device will be documented into a separate study -specific database supplied and 
managed by a designated vendor. The PRO database will be accessible to study  sites and 
Novartis personnel (or a designated CRO) for data management. All PRO data will be sent 
electronically  to Novartis personnel (or a designated CRO).
Randomiza tion codes and data about all study  treatments dispensed to the patient and all IRT 
assigned dosage changes will be tracked using an Interactive Response Technology . The system 
will be supplied by a  vendor(s), who will also manage the database. The data will be sent 
electronically  to Novartis personnel.
At the conclusion of the study , the occurrence of any emergency  code breaks will be determined 
after return of all code break reports and unused drug supplies to Novartis personnel (or 
designated CRO). After these actions have been completed and the data has been verified to be 
complete and accurate, the database will be declared locked and the treatment codes will  be 
unblinded and made available for data anal ysis. Authorization is required prior to ma king an y 

Novartis Confidential Page 123
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
database changes to locked data, by joint written agreement between the Global Head of 
Biostatistics and Data Management and the Global Head of Clinical Development.
For EDC studies, after database lock, the investigator will receive a CD -ROM or p aper copies 
of the patient data for archiving at the investigational site.
Following protocol amendment 4, the emergency unblinding procedures are no longer 
applicable as all patients will be unblinded and made aware of their study treatment.
10 Statistical methods and data analy sis
It is planned that the data from all centers participating in the trial will be combined, so that an 
adequate number of patients are available for analy sis. Novartis and/or a designated CRO will 
perform all analyses.. Any data analyses performed independentl y by any investigator should 
be submitted to Novartis before publication or presentation.
10.1 Analysis sets
10.1.1 Full analy sis set
The FAS comprises all randomized patients. Following the ITT principle, patients will be 
analyzed according to the treatment and strata they have been assigned to during the 
randomization procedure.
10.1.2 Safety  set
The Safet y Set includes all patients who received at least one dose of stud y medication defined 
as fulvestrant, or ribociclib/placebo and had at least one post-baseline safet y assessment. 
Patients will be analyzed according to the study  treatment they actually  received. Actual 
treatment refers to the treatment that the patient was randomized to, unless the alternative 
treatment was received throughout the trial. Please note: the statement that a patient had no 
adverse events (on the Adverse Event eCRF) constitutes a valid safet y assessment.
10.1.3 Per-protocol set
The per-protocol set (PPS) will include the subset of the patients in the FAS without major 
protocol deviations. All protocol deviations or conditions leading to exclusion from the PPS 
will be detailed in the data handling plan and analy sis plan. Sensitivity  analy ses of the primary 
endpoint of PFS may be performed using data from the PPS if the FAS and PPS differ and if 
the p
rimary analy sis is significant.
10.1.4 Pharmacokinetic analy sis set
The PK Analy sis Set (PAS) will consist of all patients who receive at least one dose of study  
treatment (ribociclib/placebo or fulvestrant) and have at least one evaluable post-dose 
concentration measurement.

Novartis Confidential Page 124
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.1.5 Cross -over analy sis set
The cross-over analysis setincludes all patients in the placebo arm of the Safety set , ongoing at 
the time of protocol amendment 4,who elected to cross -over toreceive LEE011 combination 
therap yand received at least one dose of LEE011 . This population will be used for the analysis 
of cross -over phase data. The cross -over phase refers to the time from first dose of LEE011
treatment following cross -over until withdrawal from the study  or death .
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristic/prognostic data will be 
summarized descriptively  by treatment group using data from the FAS. Categorical data will 
be presented as freque ncies and percentages. For continuous data, mean, standard deviation, 
median, 25th and 75th percentiles, minimum, and maximum will be presented.
10.3 Treatments (study  treatment, concomitant therapies, 
compliance)
The safet y set will be used for the analy ses be low.
The actual dose and duration of fulvestrant, and ribociclib/placebo treatment, as well as dose 
intensity  (computed as the ratio of actual dose received to actual duration) and the relative dose 
intensity  (computed as the ratio of the dose intensity  toplanned dose received/planned duration), 
will be listed and summarized using descriptive statistics. The total daily doses of fulvestrant 
and ribociclib/placebo for each patient will be summarized using descriptive statistics (e.g. 
mean, median, and mode) .
Concomitant medications and significant non-drug therapies will be listed by patient and 
summarized by ATC (Anatomical Therapeutic Chemical classification system) term for each 
treatment group. These summaries will include medications starting 
on or after the start of study 
treatment or medications starting prior to the start of study  treatment and continuing after the 
start of study  treatment. Any prior concomitant medications or significant non-drug therapies 
starting and ending prior to the start of st udy treatment will be listed.
Compliance to the study drug will be assessed by the number of dose reductions and dose 
interruptions.
The duration of exposure to study  treatment and each 
component of study  treatment will also 
be summarized for the cross- over phase in patients who crossed over to LEE011 combination 
therap y after unblinding (i.e. using the Cross -over anal ysis set).
10.4 Primary  objective
The primary  objective in the study  is to determine whether treatment with fulvestrant +
ribociclib prolongs PFS compared to treatment with fulvestrant + ribociclib placebo in men and 
postmenopausal women with HR+, HER2- advanced breast cancer who received no or only 1 
line of prior hormonal ther apy for advanced breast cancer.

Novartis Confidential Page 125
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.4.1 Variable
The primary  efficacy  endpoin t of the study  is PFS, defined as the time from the date of 
randomization to the date of the first documented progression or death due to any cause. If a 
patient has not had an event, PFS will be censored at the date of the last adequate tumor 
assessment (see RECIST 1.1 in Appendix 2for further details). Clinical deterioration without 
objective radiological evidence will not be considered as documented disease progression. PFS 
will be assessed via a loc al radiology  assessment according to RECI ST 1.1.
10.4.2 Statistical hy pothesis, model, and method of analy sis
The primary efficacy analysis will be the comparison of PFS between the two treatment groups 
using a stratified log -rank test at one -sided 2.5% level of significance.
Assuming proportional hazards model for PFS, the following statistical hypotheses will be 
tested to address the primary  efficacy  objective:
H01: θ1 ≥ 0 vs. Ha1: θ1 < 0
where θ1 is the log-hazard ratio (fulvestrant+ribociclib arm vs. fulvestra nt + placebo arm) of 
PFS.
The primary  efficacy  endpoint PFS will be anal yzed at the interim look/analy sis and final look 
of a group sequential design based on the FAS population according to the treatment group 
patients were randomized to and the strata they were assigned to at randomization (strata formed 
using the randomization factor as obtained via IRT). PFS will be estimated using the Kaplan -
Meier method. The median PFS along with 95% confidence intervals will be presented by 
treatment group.
10.4.3 Handling of missing values/censoring/discontinuations
PFS will be censored if no PFS event is observed before the cut-off date. The censoring date 
will be the date of last adequate tumor assessment before cutoff date. If a PFS event is observed 
after two or more mi ssing or non -adequate tumor assessments, then PFS will be censored at the 
last adequate tumor assessment. If a  PFS event is observed after a single missing or non-
adequate tumor assessment, the actual date of event will be used (see RECI ST 1.1 Appendix 2).
10.4.4 Supportive analy ses
As a sensitivity  analysis, the distribution of PFS will be compared between the treatment groups 
using an unstratified log-rank test and the hazard ratio along with the associated 
95% confidence 
interval resulting from an unstratified Cox model will be presented.
The primary  analysis for PFS may be repeated with data 
based on PPS if the primary  analysis 
is statistically  significant. Other sensitivity  analyses may be performed such as(1) including 
PFS events even if the events are recorded after two or more missed assessments, (2) backdating 
events occurring after missing tumor assessments.
Subgroup analyses will be performed on each level of stratification factors if the primary 
analysis is significant. The analysis will include Kaplan -Meier summaries and estimation of 
hazard ratios from un -stratified Cox regression models. Additional subgroup analyses to assess 
the homogeneit y of treatment effect based on demographic and baseline dis ease characteristics 

Novartis Confidential Page 126
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
may be performed; details about the subgroups to be included will be provided in the study  
analysis plan.
Patterns of censored data will be examined by  the treatment groups using descriptive statistics 
(the numbers of censored patients and reasons for censoring).
PFS assessed by BIRC will serve as supportive evidence of the primary  end point. Two methods 
will be used to summarize the data from the BIRC assessment. The NCI (National Cancer 
Institute) method (Dodd et al. 2011), uses an auxiliary variable estimator of the log-hazard ratio 
that combines information from patient -level investigator assessment from all patients and the 
BIRC assessment of patients randoml y selected for central review. This estimate and its one-
sided 95% CI will be provided.  Details of the audit sample size calculation for the BIRC 
assessment are provided in Section 10.8. The NCI method will be used for audit sample size 
de
termination and summary  of treatment effect (HR, 95% confidence intervals) based on the 
supportive BIRC assessment.
The data from the BIRC assessment generated following the sampling scheme as 
above will 
also be summarized using the method proposed by  Amit et al. 2011, referred to as the PhRMA 
(Pharmaceutical Research and Manufacturers ofAmerica) method. With this approach, the DD 
(differential discordance) of early discrepancy  rate (EDR) and late discrepancy  rate (LDR) 
between the two arms will be estimat ed as the rate on the fulvestrant+ribociclib arm minus the 
rate on the fulvestrant+placebo arm. The EDR and LDR results will also be summarized by 
treatment arm.  
 
Since the primary  endpoint of PFS was met at the time of the primary  analysis, no further formal 
analyses of PFS are planned. 
Note: A descriptive analy sis of PFS was performed at the time of second OS interim analy sis 
with the aim to update the PFS median for the first line patients since the median for that patient 
population was not met in the primary  PFS anal ysis. 
If any descriptive analyses of PFS are performed after allowing patients ongoing on study 
treatment in the placebo arm to cross- over to the LEE011 combination arm (permitted after the 
study  had met its primary  and key secondary  endpoints), appropriate sensitivity  analyses will 
be considered and described in the SAP, for example censoring PFS at the last adequate tumor 
assessment prior to cross -
over for patients in the cross- over anal ysis set.
10.5 Secondary  objectives
The secondary  objectives in this study  are to compare the two treatment groups with respect to 
overall survival (OS), and evaluate  overall response rate (ORR), clinical benefit rate (CBR), 
time to response (TOR), duration of response (DOR) and time to definitive deterioration in the 
quality  of life and ECOG PS, safety. OS between the 2 treatment arms will be statistically  
compared. A hierarchical testing strategy  will be taken to control overall type-I error rate; 
therefore OS will be statistically  evaluated and interpreted only if the primary  efficacy  endpoint 
PFS i s significantly different between the 2 treatment groups.

Novartis Confidential Page 127
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.5.1 Overall Survival
One of the secondary objectives of the study  is to determine whether treatment with fulvestrant 
+ ribociclib prolongs overall survival (OS) compared to treatment with fulvestrant + placebo.
OS is defined as the time from date of randomization to date of death due to any cause. If a 
patient is not known to have died, then OS will be censored at the date of last known date patient 
alive.
Assuming proportional hazards model for OS, the following statistical hypothesis for OS will 
be tested using a stratified log-rank test (stratified according to randomization stratification 
factors) at the one -sided 2.5% level of significance:
H02: θ2 ≥ 0 vs. Ha2: θ2 < 0
where θ2 is the log-hazard ratio (fulvestrant+ribociclib arm vs. fulvestrant+placebo arm) of OS.
The analyses for OS will be based on the FAS. The distribution of OS will be compared between 
the two treatment groups using a stratified log-rank test at one-sided 2.5% level ofsignificance .
The final OS anal ysis will not be performed at the time point of the final PFS analysis, but after 
additional follow -up. Therefore, a four -look design is considered for OS.
1.OS will be hierarchicall y tested (provided the primary  PFS anal ysis is statistica lly 
significant )in the following way .The first potential time point for OS analysis will be at 
the time of the primary PFS  anal ysis at which time approximately  161 death sare 
expected. If PFS is statistically  significant at this stage, OS will also be tes ted. If OS is not 
statistically  significant at this stage, the 2ndOS analy sis isplanned after approximately
263deaths are expected. If OS is not statistically  significant at this stage, the final OS 
analysis will be planned after approximately  351 deaths. 
The type I error probability  for OS tests will be controlled by using a separate Lan-DeMets 
(O’Brien -Fleming) alpha spending function independent of the one used for the primary  
efficacy  anal ysis of PFS at the one
-sided type I error of α=0.025. This guarantees the protection 
of the overall level α = 2.5% across the two hypotheses and the repeated testing of the OS 
hypotheses in the interim and the final analy ses (Glimm 2010 ).
The distribution funct ion of OS will be estimated using the Kaplan -Meier method. The median 
OS along with 95% confidence intervals will be presented by treatment group. The stratified 
Cox regression will be used to estimate the hazard ratio (HR) of OS, along with 95% confidence
interval.
Since the secondary  endpoint of OS was met at the second interim analysis, no further formal 
analyses 
of OS are planned. If any descriptive analy ses of OS are performed after allowing 
patients ongoing on study  treatment in the placebo arm to cross-over to the LEE011 
combination arm (permitted after the study  met its primary  and key secondary  endpoints), 
appropriate sensitivity  analyses will be considered and described in the SAP, for example 
censoring OS at the date of first LEE011 treatment for patients in the crossover anal ysis set. 

Novartis Confidential Page 128
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.5.2 Other secondary  efficacy  objectives
10.5.2.1 Overall response rate
Overall response rate (ORR) is defined as the proportion of patients with best overall response 
(BOR) of complete response (CR) or partial respons e (PR) acco rding to RECI ST 1.1.
ORR will be calculated based on the FAS according to the ITT principle; however patients with 
only non-measurable disease at baseline will be included in the numerator if they achieve a 
complete response. ORR will be presented by treatment group along with approximate 95% 
confidence intervals. The Cochran -Mantel Haenszel chi-square test (stratified by baseline 
stratification factor) will be used to compare the two treatment groups with respect to the ORR 
at one
-sided 2.5% level of significance. As a supportive analy sis, ORR as assessed by the 
blinded independent central review will be calculated by treatment group and presented along 
with the approx imate 95% confidence intervals. As a sensitivity  analysis, ORR for patients with 
meas urable disease at baseline will be calculated and presented by treatment group together
with approximate 95% co nfidence intervals .
10.5.2.2 Clinical benefit rate
Clinical Benefit is defined as CR, PR or SD for 24 weeks or longer. CR, PR and SD are defined 
according to RECI ST 1.1. CBR will be calculated based on the FAS; however patients with 
only non-measurable disease at baseline will be included in the numerator if they achieve a 
complete response. CBR will be summarized for the two treatment groups using descript ive 
statistics. The Cochran -Mantel Haenszel chi-
square test (stratified by baseline stratification 
factor) at 2.5% one-sided level of significance, will be used to compare the two treatment groups 
with respect to the CBR. As a supportive analysis, CBR as a ssessed by the blinded independent 
central review will be summarized for the two treatment group s using descriptive statistics.
10.5.2.3 Time to response
Time to response is the time from the date of randomization to the first documented response 
(CR or PR, which m ust be confirmed subsequently ) according to RECIST 1.1. All patients will 
be included in time to response calculations. Patients who do not achieve a confirmed response 
will be censored at the maximum follow -up time (i.e. first patient first visit to last patient last 
visit used for the anal ysis) for patients who had a PFS event (i.e. either progressed or died due 
to any cause) or at the date of last adequate tumor assessment. Time to response data will be 
listed and summarized by treatment group. The distribution of time to response may be 
summarized through Kaplan -Meier method if sufficient number of events are observed.
10.5.2.4 Duration of response
Duration of Overall Response (DoR) applies only to patients whose best overall response is CR 
or PR according to REC IST 1.1. The start date is the date of first documented response (CR or 
PR) and the end date is the date defined as first documented progression or death due to 
underly ing cancer. In other words, the start date should be determined using the time that the 
response was first determined and not using the time the response was confirmed. If a patient 
had not had an event, duration will be censored at the date of last adequate tumor assessment. 
DoR will be listed and summarized by  treatment arm.

Novartis Confidential Page 129
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.5.2.5 ECOG performanc e status
ECOG PS scale as described in Section 7.2.2.4 will be used to assess physical health of patients. 
An analysis of time to definitive deterioration of the ECOG PS by one category  of the score 
from baseline will be performed. Deterioration is considered definitive if no improvements in 
ECOG PS status is observed at a subsequent time of measurement during the treatment period 
following the time point where the deterioration is observed.
Patients receiving any further therapy  prior to definitive worsening will be censored at their 
date of last assessment prior to start of therap y. Patients that have not worsened at the data cut -
off point will be censored at the date of last assessment prior to start o f therapy . Kaplan -Meier 
method will be used to estimate the distribution of time to definitive worsening and median 
time to definitive worsening will be presented along with a 95% confidence interval. A stratified 
log-rank test at one -sided 2.5% level of significance will be used to compare the distribution of 
time to definitive worsening between the 2 treatment arms.
10.5.3 Safety  objectives
10.5.3.1 Analysis set and grouping for the analy ses
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
treatment group. In addition, for the final study  report, safet y data for patients who crossed over 
to the LEE011 combination arm after the study  had met its primary  and secondary  endpoint of 
OS, will be summarized using the crossover analysis set. The analyses will comprise a subset 
of those described below for the safety set and the details will be specified in the SAP.
The overall observation period will be divided into three mutually  exclusive segments:
1.pre-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
2.
on-treatment period: from day  of first dose of study  medication to 30 day s after last dose 
of study  medication
3.post-treatment period: starting at day  31 after last dose of study medication.
10.5.3.2 Adverse events (A Es)
Summary  tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on
-treatment period, the treatment -emergent AEs. However, all safet y data 
(including those from the pre and post-treatment periods) will be listed and those collected 
during the pre -treatment and post -treatment period are to be flagged.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and or preferre d term, severit y (based on CTCAE grades), 
type of adverse event, relation to study  treatment by  treatment group.
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by patient and 
tabulated b y type of adverse event and treatment g roup.
Specific safet y event categories (SEC) will be considered. Such categories consist of one or 
more well-defined safet y events 
which are similar in nature and for which there is a specific 
clinical interest in connection with the study  treatment(s). SE C will be defined at project level 

Novartis Confidential Page 130
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
and may be regularl y updated. The grouping of AEs in SEC according to project standards will 
be specified in the project level master statistical analy sis and/or the study  statistical analy sis 
plan.
For each specified SEC, number and percentage of patients with at least one event part of the 
SEC will be reported b y treatment group
10.5.3.3 Laboratory  abnormalities
For laboratory  tests covered by the Common Terminology  Criteria for Adverse Events (CTCAE) 
version 4.03, the study ’s biostatistical and reporting team will grade laboratory  data accordingl y. 
For laboratory  tests covered by  CTCAE, a Grade 0 will be assigned for all non -missing values 
not graded as 1 or higher. Grade 5 will not be used.
In some cases (e.g., white blood cell differentials), the lower limits of normal ranges used in 
CTCAE definition have to be replaced by a clinical meaningful limit expressed in absolute 
counts.
For laboratory  tests where grades are not defined by CTCAE, results will be graded by the 
low/normal /high classifications based on laboratory  normal ranges.
The following by-treatment summaries will be generated separately  for hematology , 
biochemistry  and urinary laboratory  tests:
frequency  table for newly  occurring on -treatment grades 3 or 4
shift table s using CTCAE grades to compare baseline to the worst on -treatment value
for laboratory  tests where CTCAE grades are not defined, shift tables using the 
low/normal/high/(low and high)
classification to compare baseline to the worst on-treatment value.
list
ing of all laboratory  data with values flagged to show the corresponding CTCAE 
grades and the classifications relative to the laboratory normal ranges.
In addition to the above mentioned tables and listings,  
 might 
be specified in the anal ysis plan.
10.5.3.4 Other safety  data
10.5.3.4.1 ECG
shift table from baseline to worst on- treatment result for overall assessments
listing of ECG evaluations for al l patients with at least one abnormality .
10.5.3.4.2 Vital signs
shift table from baseline to worst on- treatment result
table with descriptive statistics at baseline, one or several post-baseline time points and 
change from baseline to this/these post -baseline time p oints.

Novartis Confidential Page 131
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.5.3.5 Tolerability
Tolerability  will be studied in terms of dose reductions and drug interruptions due to AE. 
Reasons for dose reductions and interruptions will be listed and summarized by  treatment.
10.5.4 Pharmacokinetics
PK concentrations of ribociclib (and any relevant metabolites such as LEQ803) will be 
summarized by time point using descriptive statistics by treatment only for fulvestrant + 
ribociclib arm. All PK concentration data will be listed as appropriate.
10.5.4.1 Data handling principles
Plasma samples will be assay ed for ribociclib concentrations by Novartis or Novartis designated 
laboratory  using validated LC-MS/MS methods with a LLOQ of approxima tely 1.00 ng/mL for 
ribociclib .
All concentrations below the LLOQ will be displayed in listings as zero with a flag and handled 
as zero in any  calculations of summary  statistics, but handled as missing for the calculation of 
the geometric means and their CV. Any  missing PK parameter data will not to be imputed.
10.5.5 Patient -reported outcomes
The EORTC QLQ-C30 questionna ire and the EuroQol EQ-5D- 5L will be used to collect 
patient’s QoL data. The BPI-SF will be used to assess patient’s subjective assessment of cancer -
related pain. The global health status/QoL scale score of the QLQ -C30 is identified as the 
primary  patient -reported outcome variable of interest. Physical functioning, emotional 
functioning and social functioning scale scores of the QLQ-C30, the health status index score 
and overall health status of the EQ-5D- 5L, and worst pain item (based on question 3), pain 
severit y index, and pain interference indices of the BPI -SF are identified as secondary  patient -
reported QoL variables of interest .
Scoring of PRO data and methods for handling of missing items or missing assessments will be 
handled according to the scorin g manual and user guide for each respective patient 
questionnaire (Fayers 2001 ; Oemar and Janssen 2013 ; Cleeland 2009). No imputation 
procedures will be applied for missing items or missing assessments. Five health states from 
the EQ-
5D-5L will be converted to index values during the data analysis stage and will be 
further defined in the analysis plan. In addition, the visual analog scale (ranging from 0 to 100) 
will be evaluated for patient’s rating of their overall health status.
The number of patients completing the each questionnaire and the number of missing or 
incomplete assessments will be summarized by  treatment group for each scheduled assessment 
time points for each cohort. No formal statistical tests will be performed of PRO data and hence 
no multiplicity  adjustment will be applied. The FAS will be used for analyzing PRO data.
Descriptive statistics will be used to summarize the scored scales of the QLQ -C30; health states, 
overall health status, and index values of the EQ -5D- 5L, and the worst pain item (question 3), 
pain severit y index, and pain interference indices of the BPI-SF at each scheduled assessment 
time point for each cohort. Additionally , change from baseline in the domain scores, health 
states, overall health status, and index values at the time of each assessment will be summarized. 

Novartis Confidential Page 132
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Shift tables will be produced to describe wors ening of pain from baseline based on the worst 
pain item from the BPI -SF. Patients with an evaluable baseline score and at least one evaluable 
post baseline score during the treatment period will be included in the change from baseline 
analyses.
In addition, a repeated measurement anal ysis model may  be used to compare the two treatment 
groups with respect to changes in the domain scores (global health status/QoL  scale score, 
physical functioning, emotional functioning and social functioning scale scores of the QLQ -
C30 index score and overall health status of the EQ-5D- 5L, longitudinally  over time.  
 
Time to definitive 10% deterioration in the global health status/QoL, physical functioning, 
emotional functioning, social functioning will be assessed. The time to definitive 10% 
deterioration is defined as the time from the date of randomization to the date of event, which 
is defined as at least 10% relative to baseline worsening of the corresponding scale score or 
death due to any  cause. If a patient has not had an event, time to deterioration will be censored 
at the date of the last adequate QoL evaluation. The distribution will be presented descriptively 
using Kaplan -Meier curves. Summary  statistics from Kaplan -Meier distributions will be 
determined, including the median time to definitive 10% deterioration along with two -sided 95% 
confidence interval. Additiona lly, time to definitive deterioration with different cutoff 
definitions (e.g. 5%, 15%) may be specified in the RAP as deemed appropriate. A stratified Cox 
regression will be used to estimate the hazard ratio (HR), along with two-sided 95% confidence 
interv
al.

Novartis Confidential Page 133
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 134
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 135
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
10.7 Interim analy sis
10.7.1 Progression free survival
No PFS interim anal ysis is planned in this study . 
10.7.2 Overall survival (OS)
OS will be compared between the two treatment groups, provided the primary  endpoint PFS is 
statistically  significant favoring the test treatment arm (ribociclib + fulvestrant). A gatekeeping 
testing procedure will be adopted in this study  and the OS analy ses will be performed only if 
the primary  efficacy  endpoint PFS is statistica lly significant. A maximum of 3analyses is 
planned for OS; at the time of  the final analysis for PFS (provided PFS is significant), at which 
point approximately 161 deaths are expected, after approximately  263 events have been 

Novartis Confidential Page 136
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
documented), and a final analysis for OS when approximately  351 deaths are expected 
(expected 5 6months from date of f irst patient to be randomized).
An α-spending function according to Lan-DeMets (O’Brien -Fleming) independent of the one 
used for the primary  efficacy  analysis, (as implemented in East 6.3) along with the testing 
strategy  outlined below will be used to maintain the overall type I error probabilit y 
(Lan and DeMets 1983). This guarantees the protection of the 2.5% overall level of significance 
across the two hy potheses and the repeated testing of the OS hy potheses in the interim and the 
final analy sis (Glimm 2010). The trial allows for the stopping of the study  fora superior OS 
result, provided the primary endpoint PFS has already been shown to be statistically significant 
favoring the test treatment arm (ribociclib +fulvestrant). Further, the exact nominal p-values 
that will need to be observed to declare statisti cal significance at the time of these anal yses for 
OS will depend on the number of OS events that have 
been observed at the time of these 
analyses and the α for OS already  spent at the time of earlier anal yses.
The projected timing of interim anal ysis is s ummarized in Table 10-1.
Table 10-1 Estimated timelines for interim and final analyses
Months after 
randomization of 
thefirst patientPFS 
eventsPower (% ) 
against a hazard 
ratio of 0.67OS 
eventsCumulative Conditional 
Power (% )
against hazard ratio of 0.71
26 364 (100%) 90 161(46%) 14
39 -- -- 263(75%) 60
56 -- -- 351(100%) 85
Statistical significance of OS will only be declared if significance for primary PFS anal ysis has 
been declared.
At the time of final PFS anal yses, both PFS and interim OS analy sis will be performed by the 
Sponsor’s clinical team. Investigators and patients will remain blinded to study  treatment and 
all patients will continue to be followed for OS until the final OS analysis (or earlier if OS 
reaches statistical significance at an y of the interim analy ses).
Since the study  has met its primary  endpoint (PFS) and the secondary  endpoint (OS), any 
analysisand update after protocol amendment 4 will be descriptive. 
10.8 Sample size calculation
The median time to progression (TTP) for fulvestrant in first line post-menopausal advanced 
breast cancer patients is estimated to be between 8 month (Howell 2004) and 23 months in 
FIRST trial (Robertson et al 2012). For sample size calculation, the median PFS for 1st line 
patients is assumed to be 18 month. The median PFS for fulvestrant in relapsed advanced breast 
cancer is estimated to be between 4.8 months (SoFEA trial, Johnston et al 2013) and 6.5 months 
(CONFIRM trial, Di Leo et al 2010 ). Since the study  population is closer to the population in 
CONFIRM trial, for sample size calculation, the mPFS for fulvestrant in second line is assumed 
to be 6.5 months. It is assumed that 40% and 60% of the patients will be from first line and 
second line respectivel y. The median PFS in the control arm (fulvestrant + placebo) is estimated 
via simulation to be around 9 months. It is hypothesized that the addition of ribociclib will result 
in a clinically  meaningful 33% reduction in the hazard rate of PFS, corresponding to an increase 

Novartis Confidential Page 137
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
in median PFS to 13.4 months. A maximum of 364 PFS events will be required to detect a 
hazard ratio of 0.67 with 95% power using the log -rank test at one -sided cumulative 2.5% level 
of significance (EAST 6.3) .The increase in power from 90% to 95% while targeting the same 
hazard ratio and the number of events as in the original protocol is primary  due to the 
elimination of the futility  interim analysis. Assuming that enrollmen t will continue for 
approximately  19 months at a uniform rate and 10% dropout rate by the time of PFS final 
analysis, a total of 660 patients should be randomized to the two treatment groups in 2:1 ratio 
to observe 364 events at approximately  7
 months following the randomization of the last patient, 
i.e., 26 months from the randomization date of the first patient in this study . The sample size 
calculation was conducted with software package East 6.3. The sample size calculations are 
based on the estimates from data available from prior studies. A mid-study  sample size re-
assessment based on blinded pooled data may be performed prior to any efficacy  analysis if 
data from the study  indicate substantial deviation from the study  assumptions.A Monte -Carlo 
simulat ion based on 10,000 samples was carried out to characterize the probability  of the stud y 
outcomes under various assumptions of the true hazard ratios (Table 10-2). If the alternative 
hypothesis is true, that is, the true hazard ratio is 0.67, then there is 96% probability  the primary 
analysis will be statistically  significant.
Table 10
-2 Probability  of Study  Outcomes under various true Hazard Ratios
True Hazard Ratio %statistical significa nce*
0.5 100
0.6 99.7
0.67 96
0.7 91
0.8 53
0.9 16
A total of 660 patients will be enrolled with exponential dropout hazard rate 0.0105 (about 10% drop out rate )
*: Based on 10,000 simulations using EAST 6.3
The primary  objective of the study  is to compare investigator assessed PFS between arms in 
the overall population (both 1st line and 2nd line patients). If  the primary  anal ysis is 
statistically  significant, treatment effect will be evaluated in 1st and 2nd line patients 
separately . Based on the estimated median PFS and proportion of patients in 1st line and 2nd 
line respectivel y, it is expected that the accumulation of events in 1st line will be slower than 
2nd line patients. To ensure enough information c oming from 1st line patients, the final 
analysis will be done after approximately  125 events in the first line patients or approximately  
364 events in both arms whichever comes later. 
Audit size for BIRC assessed PFS
The audit size of the sample -based BIRC assessment will be 40% of all randomized patients. 
Based on the audit size calculation approach proposed by Dodd, et. al (2011), assuming 
investigator and BIRC assessments are similar and the estimated log of investigator -based HR 
is -0.40 (i.e., HR=0.67), the audit size of 40% will ensure that the upper bound of a one-sided 
95% CI for BI RC-based log -hazard ratio has 86% probability  of being below 0 (i.e. HR < 1) if 
the correlation between investigator assessment and BIRC assessment is 0.7 (the estimated 

Novartis Confidential Page 138
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
correlation based on data from the BELLE -2 [CBKM120F2302] study  in metastatic breast 
cancer) . 
Power for analy sis of overall survival
OS will be compared between the two treatment arms, provided that the primary  endpoi nt, PFS, 
is statistically  significant. The power statements for overall survival below are therefore 
conditioned on significant primary  PFS result. Estimate of first line median OS with fulvestrant 
alone is not published. However the median OS with fulvest rant alone in first line setting is 
expected to be between 34 months (letrozole alone, Mouridsen 2003 ) and 38 months 
(anastrozole alone, FACT trial, Bergh et 
al 2012 ) based on results from endocrine based 
monotherap y studies. 
For sample size calculation, we assume the median OS for fulvestrant 
alone in first line to be 38 month. Median OS for fulvestrant in 
relapsed post-menopausal 
advanced breast cancer patients is estimated to be between 19 months (SoFEA trial, Johnston 
et al 2013) and 26 months (CONFIRM trial, Di Leo et al 2014). For sample size calculation, 
the mOS for fulvestrant in second line is assumed to be 26 mont
hs. Based on the expected split 
of first line and second line patients mentioned above, the median overall survival of control 
arm is estimated via simulation to be approximatel y 30 months. It is hypothesized that adding 
ribociclib to fulvestrant will result in a 29% reduction in the hazard rate for OS (corresponding 
to an increase in median survival to 42 months). To detect a hazard ratio of 0.71 with 85% 
cumulative power, a max imum of 353deaths need to be observed, (using a log -rank test and a 
3-look [superiority  only] group sequential design at one -sided cumulative 2.5% level of 
significance). The sample size calculation was conducted with software package East 6.3.
Based on the number of patients planned to be randomized and 10% dropout rate by the time 
of OS final anal ysis, it is estimated that these 353deaths will be observed at approximately  56
months after the randomization of the first patient. Therefore the estimated time for the final 
OS evaluation will be 30months after the primary  analysis of the PFS endpoint.
Sample size justification for PK collection
Sparse PK sampling will be performed on approximately 150 patients ( Table 7-6). Assuming a 
2:1 ratio between the ribociclib and placebo arm, sparse plasma concentrations for ribociclib 
will be available in approximately  100 
patients. Trough PK sampling will be performed in all 
remaining patients (Table 7-7). PK data collected from this study  may also be combined with 
data from other studies to support a population PK analysis of ribociclib using non-linear mixed 
effect modeling. The choice of samp
ling time points was selected to ensure capture of Cmax. 
The aim of this analy sis is to analyze the pharmacokinetics of ribociclib in a sample size as 
large as possible. This sample is anticipated to represent the covariate distributions in the 
targeted po pulation. No specific h ypothesis will be tested and therefore no specific sample size 
calculation has been performed. The decisions on number of sparse PK samples and number of 
patients needed are driven by  feasibility .

Novartis Confidential Page 139
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including Euro pean Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature page confirmi ng his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by law or regul ation), IRB/IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally  acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be informe d 
about the study to the extent possible given her understanding. If the patient is capable of doing 
so, he/she should indicate assent b y personally signing and dating the written informed consent 
document or a separate assent form. Informed consent must b e obtained before conducting an y 
study -specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the patient source documents. The date 
when a subject’s Informed Consent wa s actuall y obtained will be captured in their CRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
If there is any question that the patient will not reliably  compl y, they should not be entered in 
the study .
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditi ons for terminating the study are outlined in 
Section 4.4.

Novartis Confidential Page 140
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
11.5 Publication of study  protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessib le database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
11.6 Study documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a Novartis -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by  applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x
-rays, and subject files and recor ds kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study case report form (CRF) is the primary  data collection 
instrument for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on 
the CRF , that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF s hould 
be dated, initialed, and explained (if necessary ) and should not obscure the original entry . For 
electronic CRFs an audit trail will be maintained by  the sy stem. The investigator should retain 
records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.

Novartis Confidential Page 141
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by names 
in any documents submitted to Novartis. Signed informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at th e site - prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the study 
to request approval of a protocol deviation, as no authorized deviations are permitted. If the 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amen dments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
Novartis should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. UK requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working day
s.

Novartis Confidential Page 142
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
13 References (available upon request)
Aaronson NK, Ahmedzai S, Bergma n B, et al (1993) The European Organization for 
Research and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology . J Natl Cancer Inst. Mar 3;85(5):365-76.
Addo S, Yates RA, Laight A .(2002) A phase I trial to assess the pharmacology  of the new 
oestrogen receptor antagonist fulvestrant on the endometrium in healthy  postmenopausal 
volunteers. Br J Cancer. Dec 2;87(12):1354 -9.
Agrawal A, Ay antunde A, Rampaul R et al, 2007. Male breast cancer: a review of clinical
management Breast Cancer Res Treat 103:11
–21
American Cancer Society: Cancer facts and figures 2015. Atlanta, GA: American Cancer 
Society , 2015. Also available online (PDF
-1444 KB).
Amit O, Mannino F, Stone AM, et al (2011) Blinded independent c entral review of 
progression in cancer clinical trials: results from a meta- analysis. European Journal of Cancer 
2011; 47: 1772-1778.
Antoine DJ, Jenkins RE, Dear JW et al (2012) Molecular forms of HMGB1 and keratin- 18 as 
mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen 
hepatotoxicity . J Hepatol .2012 May ;56(5):1070- 9.
ASCO Guidelines 2006 Update of ASCO Practice Guideline Recommendations for the Use of 
White Blood Cell Growth Factors: Guideline Summary  (J Clin Oncol 24:3187 -3205, 2006)
ars.usda.gov/Services/docs.htm?docid=22115
Baselga J, Campone M, Piccart M, Burris HA et al (2012) Everolimus in postmenopausal 
hormone -receptor -positive advanced breast cancer. N Engl J Med. Feb 9;366(6):520-9
Bergh J, Jönsson PE, L idbrink EK,et al (2012) . FACT: an open -label randomized phase III 
study  of fulvestrant and anastrozole in combination compared with anastrozole alone as first -
line therap y for patients with receptor -positive postmenopausal breast cancer. J Clin Oncol .
2012 J un 1;30(16):1919 -25. doi: 10.1200/JCO.2011.38.1095. Epub 2012 Feb 27.
Beroukhim R, Mermel CH, Porter D, et al (2010) The landscape of somatic copy -number 
alteration across human cancers. Nature. 463(7283):899-905.
Beslija S, Bonneterre J, Burstein HJ, et a l (2009). Third consensus on medical treatment of 
metastatic breast cancer. Ann Oncol; 20: 1771-85.
Bosco EE, Wang Y, Xu H, et al (2007) The retinoblastoma tumor suppressor modifies the 
therapeutic response of breast cancer. J Clin I nvest, 117: 218-28
Buzdar AU, J onat W, Howell A, et al (1998) Anastrozole versus megestrol acetate in the 
treatment of postmenopausal women with advanced breast carcinoma: Results of a survival 
update based on a combined anal ysis of data from two mature phase III trials. Arimide x Study  
Group. Cancer 83:1142 -1152, 1998
Caldon CE, Daly  RJ, Sutherland RL, et al (2006) Cell cy cle control in breast cancer cells. J 
Cell Biochem. 2006 Feb 1;97(2):261-74
Ciruelos E, P ascual T, Arroy o Vozmediano ML  et al (2014) Blanco M, Manso L , Parrilla L, 
Muñoz C, Vega E, Calderón MJ, Sancho B, Cortes -Funes H. The therapeutic role of 

Novartis Confidential Page 143
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
fulvestrant in the management of patients with hormone receptor- positive breast cancer.
Breast. 2014 Jun;23(3):201-8. doi: 10.1016/j.breast.2014.01.016. Epub 2014 Mar 1
Cleeland CS (2009) The Brief Pain Inventory . User Guide. Houston, Texas.
Cleeland CS, Ry an KM. (1994) Pain assessment: global use of the Brief Pain I nventory . Ann 
Acad Med Singapore 23(2): 129-138.
Cristofanilli M, Bondarenko I, Ro J, Im S-A, Masuda N, Colleoni M, DeMichele AM, Loi S, 
Verma S, Iwata H, Huang Bartlett C, Zhang K, PuyanaTheall K, Turner NC, Slamon DJ.
PAL OMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre-and postmenopausal 
women with hormone receptor -positive, HER2 -negative metastatic breast cancer that 
progressed on prior endocrine therap y—confirmed efficacy  and safet yposter  P4-13-01 SABC 
Cruz Jurado J, Richart Aznar P, et al (2011) 
Management of patients with metastatic breast 
cancer. Adv Ther. 2011 Sep;28 Suppl 6: 50-65. Epub 2011 Sep 16.
Di Leo, A ; Jerusalem, G ; Petruzelka, L  et al (2014) Final Overall Survival: Fulvestrant 500 
mg vs 250 mg in the Randomized CONFI RM Trial. Jnci
-Journal Of The National Cancer 
Institute, 2014 Jan, Vol.106(1)
Di Leo A , Malorni L. Poly endocrine treatment in estrogen receptor -positive breast cancer: a 
"FACT" yet to be proven. J Clin Oncol . 2012 Jun 1;30(16):1897-900.
Di Leo A, Jerusalem G, Petruzelka L , et al (2010) Results of the CONFIRM phase III trial 
comparing fulvestrant 250 mg wi th fulvestrant 500 mg in postmenopausal women with 
estrogen receptor -positive advanced breast cancer. J.Clin.Oncol .;28 (30):4594
-4600.
Dodd E L , Korn L E, Freidlin B, Gray  R, Bhattachary a S. An audit strategy  for
progression- free survival. Biometrics, Vol 67, Issue 3; 1092-99, 2011.
Dombernowsk y P, Smith I , Falkson G, et al (1998) Letrozole, a new oral aromatase inhibitor 
for advanced breast cancer: double -blind randomized trial showing a dose effect and 
improved efficacy  and tolerability  compared with meg estrol acetate. J Clin Oncol . 1998 
Feb;16(2):453 -61.
Eisenhauer et al (2009) New response evaluation criteria in solid tumours: Revised RECI ST 
guideline (version 1.1). European Journal of Cancer 45(2009)228 -247
Ellis R. E. (1961) The Distribution of Active Bone Marrow in the Adult, Phy . Med. Biol. 
5,255-258
Ellis et al (2015) Fulvestrant 500 mg Versus Anastrozole 1 mg for the First -Line Treatment of 
Advanced Breast Cancer: Overall Survival Anal ysis From the Phase II FIRST Study . 
JCO .2015.61.5831
Ertel A, D ean J L, Rui H, 
et al (2010) RB-pathway  disruption in breast cancer: differential 
association with disease subty pes, disease -specific prognosis and therapeutic response. Cell 
Cycle.2010 Oct 15;9(20):4153- 63. Epub 2010 Oct 27.
 
 
EuroQol Group (1990) EuroQol- a new facility  for the measurement of health- related quality  
of life. Health Policy  1990;16:199 -208.

Novartis Confidential Page 144
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Faslodex US Prescribing Inform ation (2014) available at: 
//azpicentral.com/faslodex /faslodex.pdf#page=1 (last accessed 03 -Mar-2015).
Fayers PM, Aaronson NK, Bjordal K, et al (2001) on behalf of the EORTC Quality  of Life 
Group. The EORTC QLQ- C30 Scoring Manual (3rd Edition). Published by : European 
Organisation for Research and Treatment of Cancer,Brussels 2001.
FDA briefing Document Oncologic Drugs Advisory  Committee Meeting, July  24, 2012, 
Evaluation of ra diologic review of progression -free survival in Non -hematologic 
malignancies.
fda.gov/downloads/advisory committees/committeesmeetingmaterials/drugs/oncologicdrugsad
visory committee/ucm311141.pdf
Finn, Rs, Crown, JP, Lang, I; et al (2015) . The cy clin-depende nt kinase 4/6 inhibitor 
palbociclib in combination with letrozole versus letrozole alone as first -line treatment of 
oestrogen receptor -positive, HER2 -negative, advanced breast cancer (PALOMA -1/TRIO -18): 
a randomised phase 2 study . Lancet Oncology , 2015 Jan , Vol.16(1), pp.25-35
Finn RS, Dering J, Conklin D, et al (2009) PD 0332991, a selective cy clin D kinase 4/6 
inhibitor, preferentially  inhibits proliferation of luminal estrogen receptor- positive human 
breast cancer cell lines i n vitro. Breast Can Res 11:R 77.
Foerster R, Schroeder L, Foerster F, et al (2014). Metastatic male breast cancer: a
retrospective cohort analy sis Breast Care.;9(4):267-71.
Giordano S, Buzdar A, Hortobagy i G, et all 2002 Breast Cancer in Men. Ann I ntern
Med.;137:678-687
Glimm, E., Maurer, W., and Bretz, F. (2010) Hierarchical testing of multiple endpoints in 
group -sequential trials. Statistics in Medicine 29, 219-228
Grunberg SM, Espersen BT, et al (2010) Evaluation of new antiemetic agents and definition 
of antineoplastic agent emetog enicity --state of the art. Support Care Cancer.;19 Suppl 1:S43 -
7.
Holm K, Staaf J, Jönsson G, et al (2012) Characterisation of amplification patterns and target 
genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. 
Breast C ancer Res Treat. 133(2):583 -94.
Howell A, Robertson JF, Abram P, et al (2004) Comparison of fulvestrant versus tamoxifen 
for the treatment of advanced breast cancer in postmenopausal women previously  untreated 
with endocrine therap y: a multinational, double -blind, randomized trial. J Clin Oncol . 2004
May 1;22(9):1605 -
13.
Huang H, Groth J, Sossey- Alaoui K, et al (2005) expression of novel and previously  
described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer 
Res. 2005 Jun 15;11(1 2):4357 -64.
Jeffrey  R. Infante A phase I study of the single -agent CDK4/6 inhibitor LEE011 in pts with 
advanced solid tumors and ly mphomas. ASCO 2014; abstract 2528
Johnston SR, Kilburn L S, Ellis P, et al (2013) ; SoFEA investigators. Fulvestrant plus 
anast rozole or placebo versus exemestane alone after progression on non -steroidal aromatase 
inhibitors in postmenopausal patients with hormone -receptor -positive locally  advanced or 

Novartis Confidential Page 145
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.Lancet 
Oncol . 2013 Sep;14(10):989-98.
Johnston S., Kilburn L.S., Ellis P. et al (2012) Fulvestrant alone or with concomitant 
anastrozole vs Exemestane following progression on non -steroidal aromatase inhibitor: first 
results of the SoFEa trial. EJC Volume 47, Supplement 2.
Knudsen ES, Knudsen KE (2008) Tailoring to RB: tumour suppressor status and therapeutic 
response. Nat Rev Cancer. 2008 Sep;8(9):714
-24.
Lan KK, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika; 70: 
659-63
Lange CA, Yee D (2011) Killing the second messenger: targeting loss of cell cy cle control in 
endocrine -resistant breast cancer. Endocrine -Related Cancer; 18: C19 –C24.
Leung BS, Potter AH (1987) Mode of estrogen action on cell proliferation in CAMA -1 cells: 
II. Sensitivity  of G1 phase population. J Cell Biochem, 34: 213 -25
McMahon C, Suthiphongchai T, DiRenzo J, et al (1999) P/CAF associates with cy clin D1 and 
potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA; 96: 5382-7
Miller TW, Balko JM, Fox EM, et al (2011) ERα -dependent E2F transcription can mediate 
resistance to estrogen deprivation in human breast cancer. Cancer Discov; 1: 338 -51.
Mouridsen H, Gershanovich M, Sun Y, et al (2003) Phase III stud y of letrozole versus 
tamox ifen as first -line therap y of advanced breast cancer in postmenopausal women: anal ysis 
of survival and update of efficacy  from the International L etrozole Breast Cancer Group. J 
Clinl Oncol 2003; 21: 2101-9.
Mouridsen H, Gershanovich M, Sun Y, et al (2001) Superior efficacy  of letrozole versus 
tamoxifen as first- line therap y for postmenopausal women with advanced breast cancer: 
results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol; 
19: 2596-606
Musgrove EA, Caldon CE, Barraclough J, et al (2011) Cyclin D as a therapeutic tar get in 
cancer. Nat Rev Cancer 11:558 -72.
National Cancer Center Network Treatment Guidelines for Breast Can cer, Version 2.2015.
//nccn.org/professional s/phy sician_gls/pdf/breast.pdf.
Neuman E, Ladh a MH, Lin N, et al (1997) C yclin D1 stimulation of estrogen receptor 
transcriptional activity independent of cdk4. Mol Cell Biol; 17: 5338 -47
Nicholson RI , Hutcheson I R, Hiscox SE, et al (2005) Growth factor signalling and resistance 
to selective oestrogen receptor modulators and pure anti- oestrogens: the use of anti -growth 
factor therapies to treat or delay  endocrine resistance in breast cancer. Endocr Relat Cancer . 
Suppl 1:S29 -36. Review.
O'Brien NA, di Tomaso E, Ay ala R, et al (2014) In vivo efficacy  of combined targeting of 
CDK4/6, ER and PI 3K signaling in ER+ breast cancer. In: Proceedings of the 105th Annual 
Meeting of the American Association for Cancer Research; 2014 Apr 5 -9; San Diego, CA. 
Philadelphia (PA): AACR; 2014. Abstract nr 4756
Oemar M, Jan nsen B. (2013) EQ -5D- 5L User Guide: Basic information on how to use the 
EQ-5D- 5L instrument. Version 2.0, October 2013. ©EuroQol Group 2013.

Novartis Confidential Page 146
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Oken MM, Creech RH, Tormey  DC, et al (1982) Toxicity  and response criteria of the Eastern 
Cooperative Oncology  Group. Am J Clin Oncol .5(6):649 - 55
Paridaens RJ, Dirix L Y, Beex LV,et al (2008) Phase III study  comparing exemestane with 
tamoxifen as first
-line hormonal treatment of metastatic breast cancer in postmenopausal 
women: the European Organisation for Research and Treatment of Cancer Breast Cancer 
Cooperative Group. J Clin Oncol. 2008 Oct 20;26(30):4883- 90. doi: 
10.1200/JCO.2007.14.4659. Epub 2008 Sep 15.
Patten D, Sharifi L , Fazel M. (2013) New Approaches in the Management of Male Breast
Cancer Clin Br east Cancer, Vol. 13, No. 5, 309 -14.
Perou CM, Sorlie T, Eisen MB, et al (2000) Molecular portraits of human breast tumours. 
Nature; 406 (6797):747 -752.
Rabin R, de Charro F (2001) EQ- 5D: a measure of health status from the EuroQol Group. 
Ann Med. 33:337 –343
Robertson, Jfr, L indemann, J, Garnett, S et al (2014) A Good Drug Made Better: The 
Fulvestrant Dose
-Response Story . Clinical Breast Cancer, 2014 Dec, Vol.14(6), pp.381-389
[Peer Reviewed Journal]
Robertson JFR, L lombart -Cussac A, Feltl D, et al (2014) Fulvestrant 500 mg versus 
anastrozole as first
-line treatment for advanced breast cancer: Overall survival from the phase 
II “first” stud y. Presented at 2014 San Antonio Breast Cancer S ymposium; December 9-13, 
2014; San Anto nio, Texas. Abstract S6-04.
Robe rtson JFR, L indemann JPO, et al (2012) Fulvestrant 500 mg versus anastrozole 1 mg for 
the first -line treatment of advanced breast cancer: follow- up anal ysis from the randomized 
‘FIRST’ stud y. Breast Cancer Res Treat (2012) 136:503 –511.
Roila F, van der Wete ring M, et al (2016) 2016 MASCC and ESMO guideline update for the 
prevention of chemotherapy -and radiotherap y
-induced nausea and vomiting and of nausea 
and vomiting in advanced cancer patients. Ann Oncol. 27(suppl 5):v119- v133.
Roussel MF, Theodoras AM, P agano M, et al (1995) Rescue of defective mitogenic signaling 
by D-type cy clins. Proc Natl Acad Sci USA; 92: 6837-41Russmann S, Jetter A, Kullak- Ublick 
GA. (2010) Pharmacogenetics of drug- induced liver injury .Hepatology . 2010 Aug;52(2):748 -
61. Sherr CJ, R oberts JM (1995) Inhibitors of mammalian G1 cy clin -dependent kinases. 
Genes Dev; 9: 1149-63
Russmann S, Jetter A, Kullak -Ublick GA (2010) Pharmacogenetics of drug -induced liver 
injury . Hepatology ; 52(2):748 -61.
Sherr CJ, Roberts I M (1999) CDK inhibitors: positive and negative regulators of G1 -phase 
progression. Genes Dev; 13: 1501-12
Sotiriou C, Pusztai L  (2009) Molecular Origins of Cancer Gene -Expression Signatures in 
Breast Cancer. New England Journal of Medicine; 360 (8):790-800.
Thangavel C, Dean J L, Ertel A, et al (2011) Therapeutically  activating RB: reestablishing cell 
cycle control in endocrine therapy -resistant breast cancer. Endocr Relat Cancer. Apr 
28;18(3):333 -45. doi: 10.1530/ERC -10-0262. Print 2011 Jun

Novartis Confidential Page 147
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
The Cancer Genome Atlas Network (2012) Co mprehensive molecular portraits of human 
breast tumours. Nature. 490: 61-70.
Turner N.C. et al (2015) Palbociclib in Hormone- Receptor –Positive Advanced Breast Cancer. 
N Engl J Med 373:209
-219
Wakeling AE. (2000) Similarities and distinctions in the mode of action of different classes of 
antioestrogens. Endocr Relat Cancer .Mar;7(1):17-28.
Weinberg RA (1995) The retinoblastoma protein and cell cy cle control. Cell; 81: 323 -30
Zhang JJ, Chen H, He K, Tang S, Justice R, Keegan P, Pazdur R and Sridhara R. Evalua tion 
of blinded independent central review of tumor progression in oncology clinical trials: a meta -
analysis. Therapeutic innovation & regulatory  science: 2012, 47(2): 167 -174.
Zwijsen RM, Buckle RS, Hijmans EM, et al (1997) CDK- independent activation of e strogen 
receptor b y cyclin D1. Cell; 88: 405 -15
Zwijsen RM, Buckle RS, Hijmans EM, et al (1998) L igand -independent recruitment of steroid 
receptor coactivators to estrogen receptor b y cyclin D1. Genes Dev; 12: 3488-98

Novartis Confidential Page 148
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14 Appendices
14.1 Appendix 1 -Concomitant me dications
In general, the use of any concomitant medication deemed necessary  for the care of the patient 
is permitted in this study , except as specificall y prohibited below. Combination administration 
of study  drugs could result in drug-drug interactions (DDI) that could potentially  lead to reduced 
activity  or enhanced toxicity  of the concomitant medication and/or ribocilcib .
The following lists are not comprehensive and are only meant to be used as a guide. The lists 
are based on the Novartis PK Sciences Memorandum , Drug -Drug Interaction (DDI) and Co-
Medication Considerations for Novartis Clinical Trials (release date: January  2018 ), which was 
compiled from the Indiana Universit y School of Medicine’s P450 Drug Inter action Table 
(http/ /medicine.iupui.edu/clinpharm/ddis/main- table/) and supplemented with the FDA Draft 
Guidance for Industry , Drug Interaction Studies –Study  Design, Data Anal ysis, and 
Implications for Dosing and Labeling (February  2 012) 
(http//wwwfda.gov/downloads/drugs/g uidancecomplianceregulatory information/guidances/uc
m292362.pdf), and the Universit y of Washington’s Drug Interaction Database
(http//wwwdruginteractioninfo.org/). For current lists of medications that may cause QT 
prolongation and/or torsades de pointes (TdP), refer to the CredibleMeds®website 
(wwwqtdrugs.org/). 
Please contact the medical monitor with any  questions.
Table 14
-1 List of prohibited medications during study  drug treatment
Category Drug Name
Strong CYP3A4/5 inhibitors Atazanavir/ritonavir, boceprevir clarithromycin, cobicistat, conivaptan, 
danoprevir/ritonavir , darunavir/ritonavir, elvitegravir /ritonavir , grapefruit 
juice, idelalisib, indinavir, indinavir /ritonavir, itraconazole, ketoconazole, 
lopinavir /ritonavir, mibefradil, nefazodone, nelfinavir, 
ombitasvir/paritaprevir/dasabuvir/ritonavir (VIEKIRA PAK), posaconazole, 
ritonavir, , saquinavir/ritonavir, telaprevir, telithromycin, tipranavir /ritonavir, 
troleandomycin, voriconazole
Strong CYP3A4/5 inducers Apalutamide , carbamazepine3, enzalutamide, lumacaftor, mitotane, 
phenobarbital, phenytoi n3, rifabutin, rifampin (rifampicin)3, St. John's wort 
(hypericum perforatum)2, 3
CYP3A substrates with NTI1Alfentanil, , astemizole, cisapride, cyclosporine, diergotamine 
(dihydroergotamine), ergotamine, fentanyl, lomitapide5, lovastatin, 
nicardipine, nisoldipine , pimozide, quinidine, simvastatin , sirolimus, 
tacrolimus
Medications with a known risk 
for QT prol ongation4Amiodarone, anagrelide, arsenic trioxide, astemizole, azithromycin, bepridil
chloroquine, cocaine , chlorpromazine, cilostazol, ciprofloxacin, cisapride, 
citalopram, clarithromycin, disopyramide, dofetilide, domperidone, donepezil, 
dronedarone, droperidol, erythromycin, escitalopram, flecainide, fluconazole, 
gatifloxacin, grepafloxacin, halofantrine, haloperidol, ibutilide, levofloxacin, 
levomepromazine, levosulpiride, levomethadyl, mesoridazine, methadone, 
moxifloxacin, ondansetron, oxaliplatin, papaverine HCl (intra-coronary), 
pentamidine, pimozide, probucol , , procainamide, propofol, quinidine, 
roxithromycin, sevoflurane, sotalol, sparfloxacin , sulpiride, sultopride, 
terlipressin, terodiline, terfenadine , thioridazine, va ndetanib

Novartis Confidential Page 149
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Category Drug Name
Herbal preparations/ 
medications or dietary 
supplementsHerbal preparations/medications or dietary supplements known as strong 
inducers or inhibitors of CYP3A4/5 or those with a known risk of QT 
prolongation are prohibited throughout the study. These incl ude, but are not 
limited to: St. John’s wort, Kava, ephedra (ma huang), gingko biloba, 
dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, black cohosh, and 
ginseng. Patients should stop using these herbal medications or dietary 
supplements 7 days prior to first dose of study drug.
Other investigational and 
antineoplastic therapiesOther investigational therapies must not be used while the patient is on the 
study. Anticancer therapy (chemotherapy, hormonal therapy, including but 
not limited to all SERMS [including raloxifene ],biologic or radiation therapy   
[except for palliative radiotherapy as outlined in the protocol] , and surgery) 
other than the study treatments must not be given while the patient is on the 
study medication. If such agents are require d,then the patient must 
discontinue the study drug.
1NTI = narrow therapeutic index drugs whose exposure -response indicates that increases in their exposure 
levels by the concomitant use of potent inhibitors may lead to serious safety concerns (e.g., Torsades de 
Pointes) or drugs which have <2 -fold differen ce in the minimum toxic concentrations and minimum effective 
concentrations in the blood.
2Herbal product
3P-gp inducer
4The list provided is as o f December 2019. Check https www crediblemeds.org/healthcare -providers/drug -list 
for the most updated list. 
5Drug has warning for risk of hepatotoxicity.
As far as possible, avoid co -administration of QT prolonging drugs or any other drugs with the potential to 
increase the risk of dr ug-related QT prolongation (e.g., via a potential DDI that increases the exposure of 
ribociclib or the exposure of the QT prolonging drug). A definitive list of drugs with a known risk, possible risk, 
or conditional risk of QT prolongation and/or Torsades de Pointes (TdP) is available online at qtdrugs.org. 
Source: Novartis PK Sciences Memorandum: Drug -Drug Interactions (DDI) and Co -medication Considerations 
for Novartis Clinical Trials (January 2018), which is compiled from Indiana University “Clinically Relevant” 
Flockhart Table™, University of Washington Drug Interaction Database, and FDA Drug Development and Drug 
Interactions: Table of Substrates, Inhibitors and Inducers.

Novartis Confidential Page 150
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Table 14-2 List of medications to be used with caution during study  drug 
treatment
Category Drug Name
Moderate CYP3A4/5 inhibitors Aprepitant , Amprenavir, asafoetida resin (Ferula asaf oetida ),cimetidine, 
crizotinib, diltiazem, faldaprevir ,imatinib, isavuconazole, netupitant, nilotinib , 
tofisopam, Schisandra sphenanthera (nan wu wei zi), verapamil
Moderate CYP3A4/5 inducers Bosentan, dabrafenib , efavirenz, etravirine, genistein, lopinavir5, modafinil, 
nafcillin, telotristat
Sensitive CYP3A4/5 
substrates1Alpha -dihydroergocryptine, apixaban ,aprepitant, atorvastatin, avanafil, 
bosutinib, brotizolam, budesonide, buspirone, cobimetinib, cannabinoids6, 
cannabidiol6,darifenacin,  dasatininb, ebastine, eletriptan, eplerenone, 
everolimus, felodipine, fluticasone, grazoprevir, ibrutnib, isavucon azole, 
ivabradine, ivacaftor , lumefantrine, lurasidone, maraviroc, midazolam, 
midostaurin, naloxegol, neratinib, perospirone, quetiapine, ridaforolimus, 
rivaroxaban , sildenafil, simeprevir, ticagrelor, tilidine, tolvaptan, triazolam, 
ulipristal, vardenafil, venetoclax, vicriviroc , voclosporin
BSEP inhibitors Alectinib, atorvastatin, bromocriptine , candesartan, clobetasol, clofaziminie, 
dabigatran, dipyridamole , glyburide, grazoprevir, ledipasvir, mifepristone,
pioglitazone, reserpine, rifamycin, simeprevir, telmisartan, timcodar, 
troglitazone,  velpatasvir
Medications that carry a 
possible risk for QT 
prolongation2Alfuzosin, apomorphine, aripiprazole, artenimol+piperaquine, asenapine, 
atazanavir, atomoxetine, bedaquiline, bendamustine, bortezomib, bosutinib , 
buprenorphine, cabozantinib, capecitabine, ceritinib, clomipramine, crizotinib, 
clozapine, cyamemazine (cyamepromazine), dabrafenib, dasatinib, degarilix, 
delamanid, desipramine, dexmedetomidine, dolasetron, efavirenz, eliglustat, 
epirubicin, eribulin mesylate , ezogabine (retigabine) , famotidine, felbamate, 
fingolimod, flupentixol, gemifloxacin, granisertron, hydrocodone-ER , 
iloperidone, imipramine (melipramine), isradipine, ketanserin, lapatinib, 
lenvatinib, leuprolide, loperamide , lithium, melperone, midostaurin, 
mifepristone, mirabegron, mirtazapine, moexipril /HCTZ, necit umumab,
nilotinib, , norfloxacin, nortriptyline, nusinersen, ofloxacin, olanzapine ,
osimertinib, oxytocin, paliperidone, palonosetron, panabinostat, pasireotide, 
pazopanib, perflutren lipid microspheres, perphenazine, pilsicainide, 
pimavanserin, pipamperone, promethazine, prothipendyl, quetiapine , 
ranolazine , rilpivirine, risperidone, romidepsin, sertindole, sorafenib, sunitinib, 
tamoxifen , telavancin, tetrabenazine , tipiracil/trifluridine, tizanidine, 
tolterodine, toremifene, trimipramine, tropisetron, vardenafil, vemurafenib, 
venlafaxine, vorinostat , ziprasidone
MATE1/2 substrates3Acyclovir, cephalexin, cimetidine, fexofenadine, ganciclovir, glycopyrronium, 
metformin, pindolol, plisicainide, ranitidine, topotecan, varenicline
OCT 1/2 substrates4Amantadine, carboplatin, cisplatin cephalexin, cephradine , ipratro pium, 
lamivudine, linagliptin, metformin , oxaliplatin, oxybutynin, phenformin, 
picoplatin, pilsicainide, pindolol, ranitidine, sorafenib, tropisetron, trospium, 
umeclidinium and zidovudine
BCRP substrates Daunorubicin, dolutegravir, doxorubicin, hematoporphyrin, imatinib, 
methotrexate, mitoxantrone, pitavastatin, r osuvastatin, irinotecan, ethinyl 
estradiol, sulfasalazine , sofosbuvir, tenofovir, topotecan, venetoclax

Novartis Confidential Page 151
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Category Drug Name
1Sensitive substrates include d rugs whose plasma AUC values have be en shown to increase 5 -fold or higher 
when co -administered with a potent inhibitor.
2The list provided is as o f January 2018. Check https www crediblemeds.org/healthcare -providers/drug -list for 
the most updated list.3MATE1 and MATE2 share considerable sub strate specificity. 
4OCT1 and OCT2 share considerable substrate specificity.
5 Lopinavir and atazanavir is prohibited when combined with ritonavir (see Table 14 -1)
6Based data that,exposure of cannabidiol (CBD), tetrahydrocannabinol (THC), 11 -hydroxy THC ,increased by 
~2-3 folds when co -administered with ketoconazole (CYP3A4 inhibitor); Stott et al, Springerplus. 2013; 2: 236
Source: Novartis PK Sciences Memorandum: Drug -Drug Inter actions (DDI) and Co -medication Considerations 
for Novartis Clinical Trials (January 2018), which is compiled from Indiana University “Clinically Relevant” 
Flockhart Table™, University of W ashington Drug Interaction Database, and FDA Drug Development and Drug 
Interactions: Table of Substrates, Inhibitors and Inducers.

Novartis Confidential Page 152
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.2 Appendix 2 -Guidelines for response, duration of overall 
response, TTF, TTP, progression-free survival and overall 
survival (based on RECIST 1.1)
Harmonization of Efficacy  Analysis of Solid Tumor Studies
Document type: TA Specific Guideline
Document status: Version 3.2: 11-Feb-2016
Version 3.1: 29-Nov-2011
Version 3:0: 19-Oct-2009
Version 2: 0: 18- Jan-2007
Version 1: 0: 13- Dec- 2002
Release date: 11-Feb-2016
Authors (Version 3.2):
Authors (Version 3.1):
Authors (Version 3):
Authors (Version 2):
Authors (Version 1):

Novartis Confidential Page 153
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
GBM Glioblastoma multiforme
MRI Magnetic resonance imaging
LPLV Last patient last visit
OS Overall survival
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown

Novartis Confidential Page 154
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.2.1 Introduction
The purpose of this document is to provide the working definitions and rules necessary  fora 
consistent and efficient analy sis of efficacy  for oncology  studies in solid tumors. This document 
is based on the RECI ST criteria for tumor responses (Therasse et al 2000 ) and the revised 
RECI ST 1.1 guidelines ( Eisenhauer et al 2009 ).
The efficacy  assessments described in Section 14.2.2 and the definition of best response in
Section 
14.2.17 are based on the RECIST 1.1criteria but also give more detailed instructions 
and rules for determination of best response. Section 14.2.18 is summarizing the “time to event” 
variables and rules which are mainl y derived from internal discussions and regulatory 
consultations , as the RECI ST criteria do not define these variables in detail. Section 14.2.29 of 
this guideline describes data handling and programming rules. This section is to be referred to
in the RAP (Reporting and Analy sis Plan) to provide further details needed for programming.
14.2.2 Efficacy  assessments
Tumor evaluations are made based on RECIST criteria ( Therasse et al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-16 and revised RECI ST g uidelines (version 1.1) (Eisenhauer et al 2009 ) European 
Journal of Cancer; 45:228 -247.
14.2.3 Definitions
14.2.4 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in order 
to classify  lesions appropriately  at baseline. In defining measurability , a distinction also needs 
to be made between nodal lesions (pathological l ymph nodes) and non -nodal lesions.
Measurable disease -the presence of a t least one measurable nodal or non -nodal lesion. 
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology .
For patients without measurable disease see Section 14.2.2 7.
Measurable lesions (both nodal and non -nodal)
Measurable non
-nodal -As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm 
whichever is greater -e.g. the minimum non-nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly
mph nodes) -Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Ly mph nodes measuring  10 mm and <15 mm 
are considered non -measurable. Ly mph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not considered indicative of 
disease.

Novartis Confidential Page 155
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Cystic lesions :
Lesions that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no 
septations, and low CT density  [water -like] content) should not be consi dered as 
malignant lesions (neither measurable nor non -measurable) since they  are, by  
definition, simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability  described above. 
However, if noncy stic lesions are present in the same patient, these are preferred for 
selection as target lesions.
Non-measurable lesions - all other lesions are considered non -measurable, including small 
lesions (e.g. longest diameter <10 mm with CT/MRI  or pathological ly mph nodes with 
10 to < 15 mm short axis), as well as trul y non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast 
disease, l ymphangitis cutis/ pulmonis, abdominal masses/abdominal organomegaly 
identified by  physical exam that is not measurable by  reproducible imaging techniques.
14.2.5 Eligibility  based on measurable disease
If no measurable lesions are identified at baseline, the patient may  be allowed to enter the study 
in some situations (e.g. in Phase III studies where PFS is the primary  endpoint). However, it is 
recommended that patients be excluded from trials where the main focus is on the Overall 
Response Rate (ORR). Guidance on how patients with just non -measurable disease at baseline 
will be evaluated for response and also handled in the statistical analy ses is given in Section 
14.2.27.
14.2.6 Methods of tumor measurement -general guidelines
In this document, the term “contrast” refers to intravenous (i.v) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm) , using a ruler or 
calipers. 
All baseline evaluations should be performed as closel y as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.
Imaging- based evaluation is preferred to evaluation by clinical examination when both 
methods have been used to assess the antitumor effect of a treatment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced CT of chest, abdomen and pelvis should preferably be performed 
using a 5 mm slice thickness with a c ontiguous reconstruction algorithm. CT/MRI  scan 
slice thickness should not exceed 8 mm cuts using a contiguous reconstruction algorithm. 
If, at baseline, a patient is known to have a medical contraindication to CT contrast or 
develops a contraindication du ring the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respiratory  artifacts) plus contrast- enhanced MRI of abdomen and pelvis.

Novartis Confidential Page 156
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
A change in methodology  can be defined as either a change in contrast use (e.g. keeping 
the same technique, like CT, but switching from with to without contrast use or vice -versa, 
regardless of the justification for the change) or a major change in technique (e.g. from CT 
to MRI , or vice -versa) , or a change in any  other imaging modalit y.A change from 
conventional to spiral CT or vice versa will not constitute a major “change in method” for 
the purposes of response assessment. A change in methodology  will result by  default in a 
UNK overall lesion response assessment as per Novartis calculated response . However, 
another response assessment than the Novartis calculated UNK response may be accepted 
from the investigator or the central blinded reviewer if a definitive response assessment 
can be just ified, based on the available information.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). New lesions on the basis of FDG- PET imaging can be identified according 
to the following algorithm:
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.
No FDG -PET at baseline with a positive FDG- PET at follow -up:
 If new disease is indicated by a positive PET scan but is not confirmed by  CT (or some 
other conventi onal technique such as MRI) at the same assessment, then follow -up assessments 
by CT will be needed to determine if there is truly progression occurring at that site. In all cases 
PD will be the date of confirmation of new disease by CT (or some other conv entional technique 
such as MRI) rather than the date of the positive PET scan. If there is a positive PET scan 
without any  confirmed progression at that site by  CT, then a PD cannot be assigned.
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by aerated lung. However, CT is preferable.
Physical exams: Evaluation of lesions by  physical examination is accepted when lesions 
are superficial, with at least 10mm size, and can be assessed using calipers. 
Ultrasound : When the primary  endpoint of the study  is objective response evalua tion, 
ultrasound (US) should not be used to measure tumor lesions, unless pre -specified by  the 
protocol . It is, however, a possible alternative to clinical measurements of superficial 
palpable l ymph nodes, subcutaneous lesions and thy roid nodules. US might also be useful 
to confirm the complete disappearance of superficial lesions usually  assessed by  clinical 
examination.
Endoscopy and laparoscopy : The utilization of endoscopy  and laparoscopy  for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may  only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
response should be restricted to vali dation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological response when biopsies are 
obtained.
Tumor markers : Tumor markers alone cannot be used to assess response. However, 
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, 

Novartis Confidential Page 157
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
PSA for prostate cancer, alpha -FP, LDH and Beta- hCG for testicular cancer) can be 
integrated as non -target disease. If markers are initially  above the upper normal limit they  
must normalize for a patient to be considered in complete clinical response when all 
lesions have disappeared.
Cytology and histology: Cy tology  and histology  can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions 
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of neoplastic nature of an y effusion that appears or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation between response and stable disease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the n eoplastic origin of the fluid is confirmed).
Clinical examination : Clinical lesions will only  be considered measurable when they  are 
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions, 
documentation by  color photography , including a ruler to estimate the size of the lesion, is 
recommended.
14.2.7 Baseline documentation of target and non -target lesions
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either targ et or non-target lesions:
Target lesions
: All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitability  for accurate repeated measurements (either by  imaging techniques or 
clinically ). Each target lesion must be uniquely  and sequentially  numbered on the CRF 
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target : Non- nodal target lesions identified by  methods for which slice 
thickness is not applicable (e.g. clinical examin ation, photograph y) should be at least 10 
mm in longest diameter. See Section 14.2.4.
Nodal target : See 
Section 14.2.4 .
A sum of diameters (long axi s for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by which to characterize the objective tumor response. Each 
target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF .
Non-target lesions :All other lesions are considered non-target lesions , i.e. lesions not 
fulfilling the criteria for target lesions at baseline.
Presence or absence or worsening of 
non-target lesions should be assessed throughout the study ; measurements of these lesions
are not required. Multiple non -target lesions involved in the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non -target 

Novartis Confidential Page 158
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF .
14.2.8 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diamete rsfor all target lesions will be calculated (at 
baseline and throughout the study ). At each assessment response is evaluated first separately 
for the target (Table 14-3) and non-target lesions (Table 14-4) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 14 - 5) as well as the presence or absence of new lesions.
14.2.9 Follow -up and recording of lesions
At each visit and for each lesion the actual date of the scan or procedure which was used for the 
evaluation of each specific lesion should be recorded. This applies to target and non-target 
lesions as well as new lesions that are detected. At the assessment visit all of the separate lesion 
evaluation data are examined by the investigator in order to derive the overall visit response. 
Therefore all such data applicable to a particular visit should be associated with the same 
assessment number .
14.2.10 Non
-nodal lesions
Following treatment, lesions may  have longest diameter measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subject to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance of 
the cut from the longest diameter; such lesions may appear to have responded or progressed o n 
subsequent examinations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as 0 mm.
Measurements of non-nodal target lesions that become 5 mm or less in longest diameter are 
likely  to be non -reproducible. Therefore, it is recommended to report a default value of 5 mm, 
instead of the actual measurement. This 
default value is derived from the 5 mm CT slice 
thickness (but should not be changed with varying CT slice thickness). Actual measu rement 
should be given for all lesions larger than 5 mm in longest diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion cannot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confounded by neighboring anatomical structures), no measurement 
should be entered and the lesion cannot be evaluated.
14.2.11 Nodal lesions
A nodal lesion less than 10 mm in size by short axis is considered normal. Lym ph nodes are not 
expected to disapp ear completely , so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become 5 mm or less in short axis are likely  to be
non-reproducible. Therefore, it is recommended to report a default value of 5 mm ,instead of 
the actual measurement. This default value is derived from the 5mm CT slice thickness (but 
should not be changed with varying CT slice thickness). Actual measurement should be given 

Novartis Confidential Page 159
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.
14.2.12 Determination of target lesion response
Table 14-3 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as 
reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, 
taking as reference the smallest sum of diameter of all target lesions recorded at 
or after baseline. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm2.
Stable Diseas e (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions 
which would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions have not 
been assessed or have been assessed using a diffe rent method than baseline.3
1. SOD for CR may not be zero when nodal lesions are part of target lesions
2. Following an initial CR, a PD cannot be assigned if all non -nodal target lesions are still not present and all nodal 
lesions are <10 mm in size. In this case, the target lesion response is CR
3. In exceptional circumstances an UNK response due to change in method could be over -ruled by the 
investigator or central reviewer using expert judgment based on the available information (see Notes 
on target le sion res ponse and methodology change in Section 14.2.6 .)
Notes on target lesion response
Reappearance of lesions: If the lesion appears at the same anatomical location where a target 
lesion had previou sly dis appeared, it is advised that the time point of lesion disappearance (i.e., 
the “0 mm” recording) be re-evaluated to make sure that the lesion was not actually  present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/radiologist has to decide between the following  
possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
on the sum of tumor measurements as presented in Table 14-3 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of allmeasured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at or 
after baseline with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 

Novartis Confidential Page 160
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
have not achieved target response of CR. For patients who have achieved CR, pl ease refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if still small, is considered a PD.
Missing measurements : In cases where mea surements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for 5 target lesions at baseline is 
100 mm at baseline and the sum of diameters for 3 of those lesions at a post -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 
in other cases where a PD cannot definitel y be attributed ,the target lesion response would 
be UNK.
Nodal les ion decrease to normal size : When nodal disease is included in the sum of target 
lesions and the nodes decrease to “normal” size they  should still have a measurement 
recorded on scans. This measurement should be reported even when the nodes are normal 
in order not to overstate progression should it be based on increase in the size of nodes.
Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis - non- nodal lesion, short axis -nodal lesions) of 
the two split lesions should be added together and the sum recorded in the diameter field on 
the case report form under the original lesion number. This va lue will be included in the 
sum of diameters when deriving target lesion response. The individual split lesions will not 
be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced : Conversel y, it is also possible t hat two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such that they 
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On t he case report form, the diameter of the “merged lesion” 
should b
e recorded for the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining lesion numbers which have coalesced.
The measurements for nodal lesions , even if less than 10 mm in size, will contribute to 
the calculation of target lesion response in the usual way  with slight modifications.
Since lesions less than 10 mm are considered normal, a CR for target lesion response 
should be assigned when all nodal targ et lesions shrink to less than 10 mm and all 
non-nodal target lesions have disappeared.
Once a CR target lesion response has been assigned a CR will continue to be 
appropriate (in the absence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non
-nodal target lesion “reappears” or if any  single nodal lesion is at least 10 
mm and there is at least 20% increase in sum of the diameters of all nodal target 
lesions r elative to nadir with at least 5 mm increase in the absolute sum of the 
diameters.

Novartis Confidential Page 161
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
A change in method for the evaluation of one or more lesions will usually lead to an 
UNK target lesion response unless there is progression indicated by  the remaining lesion s 
which have been evaluated by  the same method. In exceptional circumstances an 
investigator or central reviewer might over -rule this assignment to put a non -UNK 
response using expert judgment based on the available information. E.g. a change to a 
more sen sitive method might indicate some tumor shrinkage of target lesions and 
definitely  rule out progression in which case the investigator might assign an SD target 
lesion response; however, this should be done with caution and conservatively  as the 
response c ategories have well defined criteria.
14.2.13 Determination of non -target lesion response
Table 14-4 Response criteria for non-target lesions
Response Criteria Evaluation of non-target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size (< 10 mm short axis)
Progressive Disease (PD): Unequivocal progression of existing non -target lesions.1
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non -target lesions have 
not been assessed or have been assessed using a different method than 
baseline2.
1. The assignment of PD solely based on change in non-target lesions in light of target lesion response of CR, PR 
or SD should be exceptional. Insuch circumstances, the opinion of the investigator o r central reviewer does 
prevail
2  .It is recommended that the investigat or and/or central reviewer should use expert judgment to assign a Non -
UNK response wherever possible (see notes section for more details)
Notes on non -target lesion response
The investigator and/or central reviewer can use expert judgment to assign a non -UNK 
response wherever possible, even where lesions have not been fully  assessed or a different 
method has been used. In many  of these situations it may  still be possible to identify  
equivocal progression (PD) or definitively  rule this out (non- CR/Non -PD) b ased on the 
available information. In the specific case where a more sensitive method has been used 
indicating the absence of any  non-target lesions, a CR response can also be assigned.
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10 mm). If any  of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless there is unequivocal progression of the non-target lesions (in which 
case response is PD)or it is not possible to determine whether there is unequivocal 
progression (in which case response is UNK)
Unequivocal progression :To achieve “unequivocal progression” on the basis of non-
target disease there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of CR, PR or SD in target disease, the o verall tumor burden 
has increased sufficiently to merit discontinuation of therap y. A modest “increase” in the 
size of one or more non- target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progre ssion solely  on the basis of change in 

Novartis Confidential Page 162
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non- target lesions, the increase in the 
extent of the disease must be substantial e ven in cases where there is no measurable 
disease at baseline. If there is unequivocal progression of non -target lesion (s),then at least 
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those described in Section 14.2.12 for assigning PD following a CR for the 
non-target lesion response in the presence of non -target lesions nodal lesions should be 
applied.
14.2.14 New lesions
The a ppea rance of a new lesion is alway s associated with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.
If a new lesion is equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it represents truly  new disease. If repeat scans confirm 
there is definitel y a new lesion, then progression should be declared using the date of the 
first observation of the lesion.
If new disease is observed in a region which was not scanned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. 
The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for an y of this patient's assessment 
(see Section 14.2.15).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to 
10 mm for the first time in the study  plus 5 
mm absolute increase.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See Section 14.2.6 .
14.2.15 Evaluation of overall lesion response
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non-target lesion response and presence of new lesions as shown below in
Table 14
-5.
Table 14-5 Overall lesion response at each assessment
Target lesi ons Non-target lesions New LesionsOverall
lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD

Novartis Confidential Page 163
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Target lesi ons Non-target lesions New LesionsOverall
lesion response
1. This overall lesion response also applies when there are no non -target lesions identified at baseline.
2. Once confirmed PR was achieved, all these assessments are considered PR.
3. As defined in Section 14.2.8 .
If there are no baseline scans available at all ,then the overall lesion response at each assessment 
should be considered Unknown (UNK).
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy ) to confirm the CR.
14.2.16 Efficacy  definition s
The following definitions primarily relate to patients who have measurable disease at baseline. 
Section 14.2.27 outlines the special considerations that need to be given to patients with no 
measurable disease at baseline in order to appl y the same concepts.
14.2.17 Best overall response
The best overall response is the best response recorded 
from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). In general, the patient's best response assignment will depend on 
the achievement of both measurement and confirmation criteria.
The best overall response will usually  be determined from response assessme nts undertaken 
while on treatment. However, if an y assessments occur after treatment withdrawal the protocol 
should specificall y describe if these will be included in the determination of best overall 
response and/or whether these additional assessments will be required for sensitivity  or 
supportive analyses. As a default, any  assessments taken more than 30 day s after the last dose 
of study  treatment will not be included in the best overall response derivation. If any alternative 
cancer therapy  is taken while on study  any subsequent assessments would ordinarily  be 
excluded from the best overall response determination. If response assessments taken after 
withdrawal from study  treatment and/or alternative therap y are to be included in the main 
endpoint determination, then this should be described and justified in the protocol.
Where a study  requires confirmation of response (PR or CR ), changes in tumor measurements 
must be confirmed by  repeat assessments that should be performed not less than 4 weeks after 
the criteria for response are first met.
Longer intervals may  also be appropriate. However, this must be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.
-For non -randomized trials where response is the primary  endpoint, confirmation is 
needed.
-For trials intende d to support accelerated approval, confirmation is needed
For all other trials, confirmation of response may  be considered optional.

Novartis Confidential Page 164
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to progression where confirmation 
not required
PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required
SD = at least one SD assessment (or better) > 6 weeks after randomization/star t of 
treatment (and not qualifying for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after 
more than 6 weeks or early  progression within the first 12 weeks)
The time durations specified in the SD/PD/UNK definitions above are defaults based on a 6 
week tumor assessment frequency . However these may be modified for specific indications 
which are more or less a ggressive. In addition, it is envisaged that the time duration may also 
take into account assessment windows. E.g. if the assessment occurs every 6 weeks with a time 
window of +/ -7 days, a BOR of SD would require a SD or better response longer than 5 week s 
after randomization/start of treatment.
Overall lesion responses of CR must stay the same until progression sets in, with the exception 
of a UNK status. A patient who had a CR cannot subsequently  have a lower status other than a 
PD, e.g. PR or SD, as this would imply  a progression based on one or more lesions reappearing, 
in which case the status would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR (30% reduction of tumor 
burden compared to baseline) at one assessment, f ollowed by a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (orUNK) until progression is documented or the lesions totally  
disappear in which case a CR assignment is applicable. In studies where confirmation of 
response is not required after a single PR the overall lesion response should still be considered 
PR (or UNK) until progression is documented or the lesion totally  disappears in which case a 
CR assignment is applicable.
Example: In a case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be 
PR -SD - PR -PR -PR. The second assessment with 140 mm confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (200 mm to 160 mm) at the following assessments.

Novartis Confidential Page 165
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall response.
Note : these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may  be provided 
from different sources:
Investigator overall lesion response
Central Blinded Review overall lesion response
Novartis calculated overall lesion response (based on measurements from either 
Investigator or Central Review)
The primary  analysis of the best overall response will be based on the sequence of 
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion 
responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in so me protocols or publications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR or 
PR or SD. The objective of this endpoint is to summarize patients with signs of “activit y” 
defined as either shrinkage of tumor (re gardless of duration) or slowing down of tumor growth. 
Clinical benefit rate (CBR) is the proportion of patients with a best overall response of CR or 
PR , or an overall lesion response of  SD or Non -CR/Non -PD which lasts for a minimum time 
duration (with a default of at least 24 weeks in breast cancer studies). This endpoint measures 
signs of activity  taking into account duration of disease stabilization.
Another approach is to summarize the progression rate at a certain time point after baseline. In 
thiscase, the following definition is used:
Early progression rate (EPR) is the proportion of patients with progressive disease within 
8weeks of the start of treatment.
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomial designs of Dent and Zee (2001) and 
counts all patients who at the specified assessment (in this ex
ample the assessment would be at 
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an 
unknown (UNK) assessment at that time point and no PD before, will not be counted as early 
progressors in the anal ysis but may  be included in the denominator of the EPR rate, de pending 
on the analy sis population used. Similarly  when examining overall response and disease control, 
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders” but may be included in the denominator for ORR and DCR calculation depending 
on the anal ysis population (e.g. populations based on an ITT approach).

Novartis Confidential Page 166
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.2.18 Time to event variables
The protocol should state which of the following variables is used in that study.
14.2.19 Progression -free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progress ion or death due to any cause. If a 
patient has not had an event, progression- free survival is censored at the date of last adequate 
tumor assessment.
PFS rate at x weeks is an additional measure used to quantify PFS endpoint. It is recommended 
that a Kapl an Meier estimate is used to assess this endpoint. 
14.2.20 Overall survival
All patients should be followed until death or until patient has had adequate follow -up time as 
specified in the protocol whichever comes first. The follow -up data should contain the date the 
patient was last seen alive / last known date patient alive, the date of death and the reason of 
death (“Stud y indication” or “Other”).
Overall survival (OS) is defined as the time from date of randomization/start of treatment to 
date of death due to an y cause. If a patient is not known to have died, survival will be censored 
at the date of last known date patient alive.
14.2.21 Time to progression
Some studies might consider only death related to underly ing cancer as an event which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underl ying cancer.
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate tumor 
assessment.
14.2.22 Time to treatment failure
This endpoint is often appropriat e in studies of advanced disease where early discontinuation is 
typicall y related to intolerance of the study  drug. In some protocols, time to treatment failure 
may be considered as a sensitivity  analysis for time to progression. The list of discontinuatio n 
reasons to be considered or not as treatment failure may be adapted according to the specificities 
of the study  or the disease.
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progressi on, date of death due to any cause, or date of discontinuation due 

Novartis Confidential Page 167
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment 
failure for patients who did not experience treatment failure will be censored at last adequat e 
tumor assessment.
14.2. 24Duration of response
The analy sis of the following variables should be performed with much caution when restricted 
to responders since treatment bias could have been introduced. There have been repor ts where 
a treatment with a significantly  higher response rate had a significantly shorter duration of 
response but where this probabl y primaril y reflected selection bias which is explained as 
follows: I t is postulated that there are two groups of patients: a good risk group and a poor risk 
group. Good risk patients tend to get into response readily  (and relativel y quickly ) and tend to 
remain in response after they  have a response. Poor risk patients tend to be difficult to achieve 
a response, may have a longer time to respond, and tend to relapse quickly  when they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce a response mainly in good risk patients only. This is described in more detail by Morgan 
(1988)
It is recommended that an analysis of all patients (both responders and non-responders) be 
performed whether or not a “responders onl y” descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide descriptive statistics and even then interpreted 
with caution by evaluating the results in the context of the observed response rates. If an 
inferential comparison between treatments is required this should only be performed on all 
patients (i.e. not restricting to “responders” only ) using appropriate statistical methods such as 
the techniques described in Ellis et al (2008) . It should also be stated in the prot ocol if duration 
of response is to be calculated in addition for unconfirmed res
ponse.
For summary  statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all-patient analysis of these endpoints are not appro priate since the status of 
patients throughout the study  is usuall y taken into account in the anal ysis).

Novartis Confidential Page 168
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Duration of overall response (CR or PR) : For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.
The following two durations might be calculated in addition for a large Phase III study  in which 
a reasonable number of responders is seen.
Duration of ov erall complete response (CR) : For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.
14.2. 25 Time to response
Time to overall response (CR or PR) is the time betwee n date of randomization/start of 
treatment until first documented response (CR or PR). The response may  need to be confirmed 
depending on the ty pe of study  and its importance. Where the response needs to be confirmed 
then time to response is the time to the first CR or PR observed.
Although an analysis on the full 
population is preferred a descriptive analysis may be performed 
on the “responders ” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section 14.2.2 4. It is recommended that an 
analysis of all patients (both responders and non
-responders) be performed whether or not a 
“responders onl y” descriptive analysis is presented. Where an inferential statistical comparison 
is required, then all patients should definitely  be included in the analysis to ensure the statistical 
test is valid. For anal ysis including all patients, patients who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options.
at maximum follow -up (i.e. FPFV to LPLV used for the anal ysis)for patients who had a 
PFS event (i.e. progressed or died due to an y cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently  respond. Since the 
statistical analy sis usually  makes use of the ranking of times to response it is sufficient to 
assign the worst possible censoring time which could be observed in the study  which is 
equal to the maximum follow- up time (i.e. time from FPFV to L PLV)
at last adequate tumor assessment date otherwise . In this case patients have not y et 
progressed so they  theoretically  still have a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis considerations including (if appropriate) 
censoring rules apply  for this endpoint described for the time to overall response endpoint.

Novartis Confidential Page 169
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.2. 26 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest of 
all measurement dates (e.g. X -ray, CT-scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise - if overall lesion response is progression -the assessment date is 
calculated as the earliest date of all measureme nt dates at that evaluation number.
In the calculation of the assessment date for time to event variables, any unscheduled 
assessment should be treated similarly  to other evaluations.
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documented res ponse is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively , when this status is later confirmed.
End dates
The end dates which are used to c alculate ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page or the survival follow -up 
page).
Date of progres sion is the first assessment date at which the overall lesion response was 
recorded as progressive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made before an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that assessment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of treatment is use d.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specified time interval for assessments. This date may  be used if back-dating 
is considered when the event occurred bey ond the acceptable time window f or the next 
tumor a ssessment as per protocol (see Section 14.2.2 7).
Example (if protocol defined 
schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact is defined as the last date the patient was known to be alive. This 
corresponds to the l atest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive from the survival follow- up page is 

Novartis Confidential Page 170
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
used. If no survival follow- up is available, the date of discontinuation is used as last 
contact date.
Date of secondary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therap y or surgery .
14.2. 27 Handling of patients with non -measurable disease only  at baseline
It is possible that patients with only non-measurable disease present at baseline are entered into 
the study , either because of a protocol violation or by design (e.g. in Phase III studies with PFS 
as the primary  endpoint). In such cases the handling of the response data requires special 
consideration with respect to inclusion in any analysis of endpoints based on the overall 
response evaluations.
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoi nts.
Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for patients with measurable 
disease is derived slightly differentl y according to Table 14 -6.
Table 14-6 Overall lesion re sponse at each assessment : patients with non -target 
disease only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 14.2.8 .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non- measurable disease may  be highlighted in an appropriate fashion e.g. in particular by 
display ing the specific numbers with the non- CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression needs to be taken into account.
For ORR it is recommended that the main (I TT) analy sis includes data from patients with only 
non-measurable disease atbaseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all othe r patients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non
-measur able disease at baseline, with possible sensitivity analyses which 
exclude these particular patients. Endpoints such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non-measurable 
disease.

Novartis Confidential Page 171
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.2. 28 Sensitivity analy ses
This section outlines the possible event and censoring dates for progression, as well asaddress es
the issues of missing tumor assessments during the study . For instance, if one or more 
assessment visits are missed prior t o the progression event, to what date should the progression 
event be assigned? And should progression event be ignored if it occurred after a long period 
of a patient being lost to follow -up? It is important that the protocol and RAP specify  the 
primary  analysis in detail with respect to the definition of event and censoring dates and also 
include a description of one or more sensitivity  analy ses to be performed.
Based on definitions outlined in Section 14.2.26, and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005) 
as a reference, the following analy ses can be considered:
Table 14
-7 Options for event dates used in PFS, TTP, duration of response
Situation Options for end -date (progression or 
censoring)1
(1) = default unless specified differently  in 
the protocol or RAPOutcome
A No baseline assessment (1) Date of randomization/start of treatment3Censored
B Progression at or before next scheduled 
assessment(1) Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly  one
missing assessment(1) Date of progression (or death)
(2) Date of next scheduled assessment2Progressed
Progressed
C2 Progression or death after two or more
missing assessments(1) Date of l ast adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression based 
on investigator claim(1) Ignore  clinical progression and follow 
situations above
(2) Date of discontinuation (visit date at which 
clinical progression was determined)As per above 
situations
Progressed
F New anticancer therapy given (1) Ignore the new anticancer therapy and  
follow  situations above (ITT approach) 
(2) Date of last adequate assessment prior to 
new anticancer therapy
(3) Date of secondary anti -cancer therapy
(4) Date of secondary anti- cancer therapyAs per above 
situations
Censored
Censored
Event
G Deaths due to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP and 
duration of 
response)
1.=Definitions can be found in Section 14.2.2 6
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in Section 14.2.26 .
3.=The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and why options (1) are not used for situations C, E and (if applicable) F.

Novartis Confidential Page 172
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Situation s C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using option s(1) for situa tions C1 and C2, i.e.
(C1) taking the actual progression or death date , in the case of only  one missing 
assessment .
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two o r missing assessments (situation C2), option (3) may be considered jointly 
with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression :By default, option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment .However, option (2) may 
be used as sensitivity  analy sis.If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration.
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1) (ITT) is the recommended approach; events 
documented after the initiation of new cancer therap y will be considered for the primary 
analysis i.e. progressions and deaths documented after the initiation of new cancer therapy 
would be included as events. This will require continued follow -up f or progression after the 
start of the new cancer therapy . In such cases, it is recommended that an additional sensitivity  
analysis be performed by censoring at last adequate assessment prior to initiation of new cancer 
therap y.
Option (2), i.e. censoring a t last adequate assessment may  be used as a sensitivity  analy sis. If a 
high censoring rate due to start of new cancer therapy  is expected, a window of approximately 
8 weeks performed after the start of new cancer therap y can be used to calculate the date o f the 
event or censoring. This should be clearl y specified in the anal ysis plan. 
In some specific settings, local treatments (e.g. radiation/surgery ) may not be considered as 
cancer therapies for assessment of event/censoring in PFS/TTP/DoR analysis. For example, 
palliative radiotherap y given in the trial for analgesic purposes or for lytic lesions at risk of 
fracture will not be considered as cancer therap y for the assessment of BOR and PFS analyses. 
The protocol should clearly  state the local treatments which are not considered as antineoplastic 
therapies in the PFS/TTP/DoR analy sis.
The protocol should state that tumor assessments will be performed every  x  w eeks until 
radiological progression irrespective of initiation of new antineoplastic therapy . It is strongl y 
recommended that a tumor assessment is performed before the patient is switched to a new 
cancer therap y..
Additional suggestions for sensitivity analyses
Other suggestions for additional sensitivity  analyses may include analy ses to check for potential 
bias in follow -up schedules for tumor assessments, e.g. by assigning the dates for censoring and 

Novartis Confidential Page 173
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
events only  at scheduled visit dates. The latter could be handled b y replacing in Table 14 -7the
“Date of last adequate assessment” by the “Date of previous scheduled assessment (from 
baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protoc ol assessment scheme was strictly  
followed from baseline, immediately  before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repeated using the Investigators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity  anal yses will depend on the 
individual requirements for the specific study  and disease 
area and have to be specified in the 
protocol or RAP documentation.
14.2. 29 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
14.2. 30 Study/project specific decisions
For each study  (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
14.2. 31 End of treatment phase completion
Patients may voluntarily withdraw from the study  treatment or may be taken off the study 
treatment at the discretion of the investigator at any time. For patients who are lost to follow -
up, the investigator or designee should show "due diligence" by documenting in the source 
documents steps taken to contact the patient, e.g., dates of telephone calls, registered letters, etc.
The end of treatment visit and its associated assessments should occur within 7 days of the last 
study  treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adverse event(s)
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressi ve disease

Novartis Confidential Page 174
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Study  terminated by  the sponsor
Non-compliant with study  treatment
No longer requires treatment
Treatment duration completed as per protocol (optional, to be used if only a fixed number of 
cycles is given)
Death is a reason which “ must ” lead to discontinuation of patient from trial. 
14.2. 32 End of post -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after discontinuation of study  treatment 
and post -treatment evaluations but prior to collecting survival follow-up.
Patients may  provide study  phase completion information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressi ve disease
Study  terminated by  the sponsor
14.2. 33 Medical validation of programmed overall lesion response
In order to be as objective as possible theRECI STprogrammed calculated response assessment 
is very strict regarding measurement methods (i.e. any assessment with more or less sensitive 
method than the one used to assess the lesion at baseline is considered UNK) and not available 
evaluations (i.e. if any target or non-target lesion was not evaluated the whole overall lesion 
response is UNK unless remaining lesions qualified for PD). This 
contrasts with the slightly  
more flexible guidance given to local investigators (and to the central reviewers ) to use expert 
judgment in determining response in these type of situations, and therefore as a consequence 
discrepancies between the different sources of response assessment often arise. To ensure the 
quality  of response assessments from the local site and/or the central reviewer, the responses 
may be re -evaluated by clinicians (based on local investigator data recorded in eCRF or based 
on central reviewer data entered in the database) at Novartis or external experts. In addition, 
data review reports will be available to identify  assessments for which the investigators’ or 
central reader’s opinion does not match the programmed calculated response based on RECIST 
criteria. This may be queried for clarification. However, the investigator or central reader’ s 
response assessment will never be overruled.
If Novartis elect to invalidate an overall lesion response as evaluated by the investigator or 
central reader upon internal or external review of the data, the calculated overall lesion response 

Novartis Confidential Page 175
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
at that specif ic assessment is to be kept in a dataset. This must be clearl y documented in the 
RAP documentation and agreed before database lock. This dataset should be created and stored 
as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ withou t documentation of progression by 
RECI ST criteria should be carefull y reviewed. Only patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.
14.2. 34 Programming rules
The following should be used for programming of efficacy  results:
14.2. 35 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day ) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.
14.2. 36 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.2.26). If all measurement dates have no 
day recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
14.2. 37 Incomplete dates for last kno wn date patient alive or death
All dates must be completed with day, month and year. If the day is missing, the 15thof the 
month will be used for incomplete death dates or dates of last contact.
14.2. 38 Non- target lesion response
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study ), the non-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
14.2. 39 Study/project specific programming
The standard anal ysis programs need to be a dapted for each study /project .

Novartis Confidential Page 176
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.2. 40 Censoring reason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.
For survival the following censoring reasons are possible:
Alive
Lost to follow -up
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:
Ongoing without event
Lost to foll ow-up
Withdrew consent
Adequate assessment no longer available*
Event documented after two or more missing tumor assessments (optional, see Table 14 -7)
Death due to reason other than underl ying cancer (only used for TTP and duration of 
response)
Initiation of new anti
-cancer therapy
*Adequate assessment is defined in Section 14.2.2 6. This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off (or prior to any other 
censoring reason) corresponding to the unavailability  of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason should 
also be not ed:
This may  be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study  evaluation completion page), when patients are not 
followed for progression after treatment completion or when onl y UNK assessments are 
available just prior to data cut- off).
The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therap y) has occurred more than the specified period following the last adequate 
assessment.
This reason will also be used to censor in case of no baseline assessment.
14.2. 41 References (available upon request)
Dent S, Zee (2001) application of a new multinomial phase II stopping rule using response 
and earl y progression, J Clin Oncol; 19: 785-791
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECI ST 
guideline (version 1.1). European Jo urnal of Cancer, Vol.45: 228 -
47
Ellis S, et al (2008) Analysis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465
EMA Guidance: 2012 Guideline on the evaluation of anticancer medicinal products in man

Novartis Confidential Page 177
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May 2007
Morgan TM (1988) Analy sis of duration of response: a problem of oncology trials. Cont Clin 
Trials; 9: 11-18
Therasse P, Arbuck S, Eisenhauer E, et al (2000) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer 
Institute, Vol. 92; 205 -16

Novartis Confidential Page 178
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.3 Appendix 3 -Bone Marrow Reserve in A dults
Adap ted from R.E. ELLIS: The Distribution of Active Bone Marrow in the Adult, Phy.Med. 
Biol. 5, 255 -258, 1961
MARROW DISTRIBUTION OF THE A DULT
SITEMARROW
wt.(g)FRACTION 
RED MARROW 
AGE 40RED MARROW 
wt.(g)
AGE 40%TOTAL RED 
MARROW
CRANIUM AND
MANDIBLEHead:
Cranium
Mandible165.8
16.40.75
0.75136.6
124.3
12.313.1 13.1
HUMERI, 
SCAPULAE, 
CLAVICLESUpper Limb Girdle :
2 Humerus, head & 
neck
2 Scapulae
2 Clavicles26.5
67.4
21.60.75
0.75
0.7586.7
20.0
50.5
16.28.3 8.3
STERNUM AND
RIBSSternum
Ribs:
1pair
2
3
4
5
6
7
8
9
10
11
1239.0
10.2
12.6
16.0
18.6
23.8
23.6
25.0
24.0
21.2
16.0
11.2
4.60.6
All 0.423.4
82.6
4.1
5.0
6.4
7.4
9.5
9.4
10.0
9.6
8.5
6.4
4.5
1.82.3
7.910.2
PELVIC BONES Sacrum
2 os coxae194.0
310.60.75
0.75145.6
233.013.9
22.3 36.2
FEMUR 2 Femoral head
and neck53.0 0.75 40.0 3.8

Novartis Confidential Page 179
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
14.4 Appendix 4 - Patient reported outcomes
Figure 14- 1 EORTC QLQ -C30

Novartis Confidential Page 180
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 181
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Figure 14-2 EQ-5D-5L

Novartis Confidential Page 182
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 183
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301

Novartis Confidential Page 184
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
Figure 14-3 Brief Pain Inventory -Short Form

Novartis Confidential Page 185
Amended Protocol Version 04 (Clean) Protocol No. CLEE011F2301
